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ABSTRACT
THE APPLICATION OF INNOVATIVE HIGH-THROUGHPUT TECHNIQUES TO
SERUM BIOMARKER DISCOVERY
Izabela Debkiewicz Karbassi
Eastern Virginia Medical School and Old Dominion University, 2008
Director: Dr. Richard R. Drake
Time-of-flight mass spectrometry continues to evolve as a promising technique
for serum protein expression profiling and biomarker discovery. As seen in our initial
SELDI-TOF MS and MALDI-TOF MS profiling study of serum for the assessment of
breast cancer risk, many profiling strategies typically employ single chemical affinity
beads or surfaces to decrease sample complexity of dynamic fluids like serum. However,
most proteins, captured on a particular surface or bead, are not resolved in the lower mass
range where mass spectrometers are most effective. To this end we have designed an
expression profiling workflow that utilizes immobilized trypsin paramagnetic beads in
order to reduce large mass proteins into peptides that are in the ideal mass range for
serum expression profiling as well as for direct LIFT-MS/MS sequence determinations.
We demonstrate that this bead-based trypsinization is efficient in digesting large serum
proteins in short incubation times and is highly reproducible and amenable to an
automated platform. Additionally, we show that this workflow may be combined in
tandem with many different types of bead fractionation surfaces. Furthermore, by
utilizing two different pooled human serum sample cohorts as proof-of-concept
experiments, we are able to demonstrate the reproducibility of this method in the
profiling of clinical samples and the ease of differential peptide identity determination.
Overall, this method is an attractive strategy for high-throughput serum profiling with the
goal of detecting and identifying differential peptides.
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CHAPTER I
INTRODUCTION

1.1 History of Proteomics and Evolution of Mass Spectrometry
The term "proteome" was first coined in 1994 at a meeting in Siena, Italy and was
defined as the protein complement to the study of the genome. Thus, the study of the
proteome was termed "proteomics" (1). Currently, proteomics is thought of as the study
of not only all the proteins of a certain system, but also their structure, isoforms,
modifications, interactions with other proteins and almost everything "post-genomic" (2).
The early goal of proteomics was the quick identification of all the proteins expressed by
a cell or tissue. However, this lofty goal has yet to be achieved for any species. Current
research is more varied and focused towards determining systematically the various
properties of proteins (1). Many different technologies have been developed, and are
constantly evolving, to achieve the goals of proteomic researchers.

Two-dimensional electrophoresis
Initial proteomic approaches relied on protein separation by two-dimensional gel
electrophoresis, with identification of protein spots of interest (2). Two-dimensional gel
electrophoresis (2DE) was developed independently by Klose (3) and O'Farrell (4) in the
1970s. This is a gel electrophoresis method that separates proteins at high resolution,
most commonly by first separating the proteins by their charge through isoelectric
focusing in a first dimension, which is then followed by a separation of the proteins by
their size in the second dimension via SDS polyacrylamide gel electrophoresis (SDS-
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PAGE). The separated proteins are then detected by a stain of choosing (i.e. Coomassie
stain, silver stain, or a fluorescent stain) and the staining intensity provides an estimate of
the amount of protein present in each spot. It was recognized that the spot patterns
generated were relatively reproducible and could be overlaid and compared between
samples (5). However, there are many disadvantages to this approach. One issue with
2DE was discovered when upon sequencing of the protein spots it was found that the
incidence of co-migration of proteins was more prevalent than originally thought (6).
This was a draw-back since quantification of 2DE gels relies on the assumption that there
is only one protein present in each spot (1). Another more commonly discussed problem
with 2DE is that this is a very time consuming and labor-intensive process, i.e. as
opposed to a one-dimensional gel only one sample may be run per 2DE gel. This
problem was addressed by 2D-DIGE, or two-dimensional Fluorescence Difference Gel
Electrophoresis. This system uses specially designed CyDye™ fluors, which are
spectrally resolvable and size and charge-matched, to label samples. There are three
fluors: Cy2, Cy3 and Cy5. These fluors have an NHS-ester reactive group, and thus are
able to covalently attach to the amino group of lysine in proteins by an amide linkage.
The lysine amino acid in proteins carries an intrinsic single positive charge at neutral or
acidic pH and the fluors also carry a single positive charge. Therefore, when the fluor is
coupled to the lysine it replaces the lysine's single positive charge with its own, thus not
altering the pi of the labeled protein significantly from the same unlabelled protein. Cy3
and Cy5 are typically used to label independent samples, while Cy2 may be used either as
an internal control between gels or also to label a third independent sample. In this
manner up to three samples may be simultaneously separated on a single 2DE gel and up
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to three separate conditions may be compared in a single 2DE gel. Therefore, this system
is less labor intensive as having to run several separate gels and also helps to remove gelto-gel variability, another common complaint with the 2DE system (7, 8).

Early protein sequencing methods
During the time that 2DE gels were first being implemented, Edman degradation
was the method utilized to sequence the majority of proteins. This method, developed by
Pehr Victor Edman in 1949, is a chemical process that removes amino acids from the Nterminus one at a time (9). The automatic version was later introduced in 1967 by Edman
and Begg (10). The Edman degradation procedure has three steps: coupling, cleavage
and conversion. The coupling reaction consists of phenylisothiocyanate (PITC)
modifying the free-amino terminal alpha-amino of a polypeptide to form a
phenylthiocarbamyl (PTC) polypeptide. The PTC amino-terminal residue is rapidly
cleaved with an anhydrous acid from the polypeptide chain in the cleavage step. This
occurs through the formation of a five-membered heterocyclic derivative,
anilinothiazolinone (ATZ) that is made by the sulfur atom of the derivatized amino
terminus and the carbonyl carbon of the first peptide bond. Thus, the cleavage reaction
yields an ATZ amino acid and a shortened polypeptide. The shortened polypeptide has a
reactive-terminal alpha-amino group and thus can undergo more cycles of coupling and
cleavage. The final conversion step relies on the hydrophobicity of the ATZ amino acid
to separate it and extract it from the hydrophilic polypeptide by a nonpolar solvent. The
unstable ATZ derivative amino acid is then converted to a more stable
phenylthiohydantoin (PTH) derivative via treatment with an aqueous acid. Since this

4
procedure removes the PTH without destroying the remaining peptide, a sequential
degradation of the peptide can be achieved. Each amino acid of the peptide chain may
then be identified through one cycle of the Edman degradation technique followed by one
cycle of high-performance liquid chromatography to analyze the PTH amino acid (11).
The Edman degradation method was not the first and only foray into protein
sequencing. There were several techniques that either came before, or were
contemporaries, of the Edman degradation technique. A method that preceded Edman
degradation, and which the Edman degradation method built upon, was the stepwise
degradation through the use of phenylisocyanate (PIC). This method was developed in
1930 by Abderhalden and Brockmann and was based on the ability of PIC to couple to
amino groups and produce an intermediate that is rearranged under acidic conditions,
thus cleaving the derivatized terminal amino acid from the parent peptide (12). Edman
improved on this method by changing the coupling agent to PITC, which proved to be a
more readily cyclized intermediate and thus a more easily cleaved amino-terminal acid.
However, it was in 1954 that the first complete description of the chemical structure of a
protein was successfully performed. This was done by Frederick Sanger, who was
studying the pancreatic hormone, insulin, which is a low-molecular-weight protein,
composed of fifty-one amino acids. Sanger was able to determine the composition of
insulin by first breaking the two chains of insulin into peptides. The insulin peptides
were sequenced using a DNP (dinitrophenyl)-labeling method which covalently modifies
the end amino acid in a peptide. The DNP group behaves as a chemical marker that stays
attached to the amino group after the peptides are hydrolyzed into their constituent amino
acids. The hydrolyzed, and partially hydrolyzed, peptides are then separated using two-
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dimensional paper chromatography, also called partition chromatography, and the Nterminus is identified by its color. By aligning the peptides a contiguous sequence may
be determined (11). Still, such methods as Edman degradation are time consuming and
require large amounts of sample. Thus, as mass spectrometry based sequencing methods
have emerged over the last 15 years, they have rapidly evolved to replace methods like
Edman degradation as the technique of choice for protein analysis.

The Revolution of "Soft Ionization" Mass spectrometry
Mass spectrometry is an instrumental approach that allows for the mass
measurement of ions generated from molecules and is capable of forming, separating and
detecting ions based on their mass-to-charge ratio (m/z). Mass spectrometers are made up
of several modular sections: The ionization source, the mass analyzer, the detector and
the data recorder/processor. The ionization source converts and transfers molecules into
gas-phase ions, while the mass analyzer is the device that separates gas-phase ions,
usually by electric or magnetic fields. The major types of mass analyzers are quadrupole
(uses oscillating electrical fields to selectively stabilize or destabilize ions), ion-trap (is
typically coupled with the quadrupole mass analyzer, but now allows the ions to be
trapped and sequentially ejected), and time-of-flight (TOF) (uses an electric field to
accelerate ions down a flight tube). The ions from the mass analyzer go on to strike the
detector. Intensity (abundance) and the m/z values of the ions are based on the magnitude
of the current produced at the detector as a function of time. This is collected by the data
recorder and typically displayed as m/z on the x-axis and ion abundances on the y-axis
(11).
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To determine the m/z of a molecule in a mass spectrometer, the analyte is first
ionized and then transferred into a high vacuum system. Traditionally, the ionization of
molecules into the gas phase was accomplished by electron impact (EI) or chemical
ionization (CI) (11). However, peptides and proteins are large molecules and are
consequently difficult to ionize by this manner since it may destroy the molecule through
extensive thermal decomposition. In the early 1980s "soft ionization" techniques were
first discovered and helped revolutionize ionization of peptides and proteins and thus the
detection and sequencing capability of mass spectrometry. "Soft ionization" techniques
are accordingly named because they allow for ionization of large, nonvolatile, polar
compounds such as proteins and peptides at high sensitivity, but without excessive
fragmentation (1, 5, 11). One of the first "soft ionization" techniques was fast atom
bombardment (FAB) developed in the early 1980s (13-15). In FAB, the analyte is
dissolved in a nonvolatile liquid matrix and placed under vacuum. The sample is then
"bombarded" with fast neutral atoms in order to eject analyte ions into the gas phase.
Yet, it wasn't until the late 1980s that two "soft ionization" methods, electrospray
ionization (ESI) and matrix-assisted laser desorption ionization (MALDI), were
introduced commercially and thus made mass spectroscopy more routinely available to
biological researchers (11).
ESI was developed by Fenn et al (16) and is based on the application of a highvoltage potential to a liquid as it passes through a small capillary. The ions are then
desorbed into the gas phase after the evaporation of the droplet as it enters the capillary.
A unique characteristic of ESI is that both singly and multiply charged ions can be
formed from a single precursor. The composition and pH of the electrospray solvent, and
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the chemical nature of the analyte, determine the extent of the multiple charging of an
analyte. Typically peptides (<2000 daltons) yield singly or doubly charged ions, while
proteins (>2000 daltons) give rise to multiply charged species. Multiple charged states
are both a benefit and a drawback to the ESI technique. ESI is typically coupled with
triple-quadrupole or ion-trap instruments (though recently hybrid quadrupole TOF
spectrometers have become available). Thus, the benefit to multiple charging is that even
simple quadrupole instruments, and other types of mass analyzers with limited m/z range,
may be used to detect masses that exceed the m/z maximum of the instrument. The
drawback is that the multiple charging may be very complex with overlapping ions,
especially in the analysis of a mixture. Currently, though, all commercial ESI mass
spectrometers are equipped with a deconvolution algorithm, which processes the charge
state and isotopic envelope in order to provide a statistically averaged molecular mass
(11).
The MALDI platform was first developed by Karas and Hillenkamp (17) and is
based on directing a pulsed laser light onto a matrix-embedded, crystallized sample
(many sample sets may be spotted with matrix on AnchorChip™ plates thus adding to
this method's relative high-throughput and automation capabilities). The interaction of
the laser pulse with the sample results in ionization, typically protonation, of both matrix
and analyte molecules by a transfer of energy from the matrix to the embedded analyte,
instead of by direct laser ionization (11). Unlike ESI, MALDI typically produces singly
charged ions, which are accelerated by an electric field into the analyzer (typically a TOF
for MALDI), which is a chamber under vacuum. The ions drift through the analyzer with
the kinetic energy obtained from the potential energy of the electric field and are
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separated based on their m/z. The relation of m/z is proportional to the square of the
flight time (t) and this information may be used to determine the related mass (their mass
is thus based on the "time of flight" it takes to reach the detector). In addition to this
standard "linear mode", the ions may also be deflected with an electrostatic reflector
which works like an ion mirror. This technique is termed "reflectron mode" and it is
based on the inversion of the ion trajectory in an oppositely polarized electric field. The
reflectron mode thus provides a longer flight path allowing the masses of the ions
reaching the detector to be determined with higher precision. A caveat to the MALDI
platform is that the relative peak intensities may be influenced by ion suppression effects
and in this way may mask peaks or at the least the spectrum may not correctly reflect the
concentration of the detected peptides/proteins (18, 19). However, this may be overcome
by coupling the MALDI platform to a front-end fractionation step such as a High
Performance Liquid Chromatography (HPLC), termed LC-MALDI, or other
chromatography-based fractionation method.

Protein Identification using Mass Spectrometry
There are two main methods that are used for protein sequencing without the need
for de novo sequencing. The first is called peptide mass fingerprinting (PMF) or peptide
mapping. This is the most popular method for the identification of spots from 2DE gels,
since it essentially requires a pure target protein. Typically, PMF is carried out on
MALDI-TOF mass spectrometers (5). In this method, an isolated protein (i.e. from an
excised 2DE spot) is first digested with a protease (typically trypsin). The spectrum from
the resulting peptide fragment masses is then compared against masses calculated from
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the same proteolytic digestion of each entry in a sequence database to obtain the
identification of the target protein (1).
The other method is termed tandem mass spectrometry (MS/MS). Tandem mass
spectrometry occurs when a specific ion (termed parent ion) is selected from a mixture on
the basis of its m/z ratio and then fragmented within the instrument. MS/MS has allowed
the identification of proteins without the need for purification or separating proteins by
SDS-PAGE. The specificity of MS/MS-based protein identification is often times much
higher than that of PMF, because a peptide sequence (thus the MS/MS spectrum of a
peptide) can uniquely identify a protein. Since peptide ions fragment in a sequencedependent manner, the MS/MS spectrum is in theory the amino acid sequence of that
peptide. In certain cases where PMF does not provide sufficient enough information for
protein identification, a peptide from the PMF spectrum may be selected and subjected to
MS/MS for improved protein identification (1, 19). In essence both ESI and MALDI
methodologies have the capability of MS/MS.
In regards to the ESI platform, the method of MS/MS was greatly improved with
the introduction of nanospray-ESI. This technique sprays peptide mixtures into the mass
spectrometer at low flow rates through very narrow capillary columns. The capillary
column serves as the ionization source and the slow flow rate allows generation of
fragment ion spectra of several of the observed precursor ions. This led to peptides being
detected at sensitivities not previously achieved with ESI (11, 20). For ESI, the
fragments from parent ions are generated by Collision Induced Dissociation (CID). CID
involves the activation of selected ions through energetic collisions with a neutral target
gas. This converts translational energy into internal energy and places the targeted ions
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into an activated or excited state, which is followed by the unimolecular dissociation of
the activated ions to yield fragment products (11). In the beginning the selection of
precursor ions was performed by the operator, but most recently software is available for
computer-controlled ion selection thereby automating the MS/MS process (1).
Additionally, the ESI source is typically coupled to a Liquid Chromatography (LC)
system for the improved identification of peptides in mixtures. However, even with
automation, ESI is relatively low throughput as it is time consuming and only one sample
may be run at a time. Furthermore, column contamination is sometimes observed and
overly contaminated instruments are difficult to clean due to the instruments high
sensitivity for certain compounds (11).
MALDI, on the other hand, typically uses a tandem TOF, or TOF/TOF, method
termed LIFT. The LIFT mode of the MALDI instrument (named so because it "lifts" the
potential energy of ions) works by fragmenting a parent ion, re-accelerating the parent
and fragment ions and focusing them on the detector thereby generating a MS/MS
spectrum. The instrument also contains an additional device that suppresses precursor ions. Termed "post lift metastable suppressor", it is located between the LIFT device and
the reflector, where it deflects any remaining intact precursor ions and also prevents
unwanted fragment ion formation after post-acceleration. The MALDI platform may
fragment the parent ion by either LID (Laser-Induced Dissociation) or CID. In terms of
LIFT, LID is fragmentation induced by laser irradiation and it is typically used for
protein identification, while the high-energy CID is typically used for de novo
sequencing (due to its ability of differentiating between leucine and isoleucine) or for
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glycan analysis (19, 21). The LIFT-MALDI-TOF/TOF instrument maybe Mly
automated or may be operator controlled as needed (19).
As ESI and MALDI increased in popularity the size of the sequence library
available has also increased thereby improving the likelihood of a peptide identity match.
Additionally, algorithms that match MS/MS spectra to sequence databases (22,23) have
much improved protein identification by mass spectrometry. MS/MS spectra may also be
used to search translated ESTs, or expressed sequence tags, and other sequence databases
containing incomplete sequences. ESTs libraries were a product of mass DNA
sequencing of cDNAs derived from large pools of mRNA in the early 1990s. A decade
later an ultimate normalized sequence library was available which encompassed the
complete human genomic sequence, and normalized it to account for the dynamic range
of transcript numbers expressed in cells, thus including the low-abundant species as well
(24,25).
There are many search engines available to search these vast libraries. One such
search engine is SEQUEST. SEQUEST, a commercially available product, is the
prototypical algorithmic tool for scanning MS/MS spectra against comprehensive protein
databases. This algorithm finds all peptides in the database that match the input mass and
then theoretically calculates the expected fragment ion masses against the observed
MS/MS spectrum. SEQUEST has been modified several times to include modifications
in searches (22), and to allow searching of DNA databases (26), MALDI fragmentation
data (27) and high-energy CID data (28). Another search engine is Mascot, which is a
free web search service. It allows for uninterrupted MS/MS ion searches of data from
various mass spectrometry instruments. It works by uploading fragment ion masses and
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intensities and then selecting the most intense peaks. Mascot looks for the group that
most clearly differentiates the top score of the matched protein and reports its results
using a probability-based MOWSE (molecular-weight search) score and level of
significance. Several variable modifications, as well as constant modifications, may be
selected for each search. Mascot may also be used for PMF searches (29). In actuality
Mascot is an extension of the original MOWSE search engine, in which the molecular
weight of the protein was taken into account based on a normalized distribution
frequency value calculated for different proteases. The MOWSE scoring system is based
on the principle that larger peptides carry more scoring weight and thus compensates for
the nonrandom distribution of fragment molecular weights in proteins of different sizes
(11,30).

Trypsin digestion in Mass Spectrometry
As mentioned above both PMF and MS/MS are greatly facilitated by digesting
samples with a known protease. This is true for both in-gel digestions (i.e. from onedimension or two-dimensional gels) or for in-solution digestion. The knowledge of the
enzyme that created the peptide in question greatly aids in protein identification through a
sequence database query. In general proteases like trypsin, which produce small
peptides, are beneficial for mass spectrometry because the peptides fall within the
optimal m/z range of most mass spectrometry instruments (11).
One of the most commonly used and best-characterized proteases in proteomics is
trypsin. Trypsin is a serine protease that cleaves at the carboxy side of lysine and
arginine, except if either is followed by a proline. Typically, commercially available
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trypsin is modified to render it resistant to proteolytic digestion, since proteolysis can
generate a version of trypsin that has chymotrypsin specificity. Due to this, extra
precautions are made and most trypsin products available for proteomics are treated with
L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK) to prevent chymotryptic
activity (11).
Traditional tryptic digestions can be tedious and require long incubation times,
since using high concentrations of enzyme will create interfering auto-digestion peaks
and this may also lead to ion suppression. This has led many researchers on a quest to
develop a more efficient trypsin digestion method that will allow for more highthroughput proteomic analysis. In this regard, it has been well documented that
immobilizing enzymes can yield reactions that are faster, more efficient and have highthroughput (31, 32). This is due in part to the increased stability of the immobilized
enzyme and also to the ability of using a higher enzyme-to-substrate ratio. There have
been many approaches to immobilize trypsin onto solid supports to increase its catalytic
ability, thus minimizing the time needed for digestion and streamlining the trypsinization
process. Innovative approaches such as trypsin adsorbed directly onto a metal MALDI
plate (33, 34), linked to copolymer MALDI sample array chips (35) or immobilized onto
different monolithic HPLC columns (32, 36) have been described (monolithic columns
consist of one piece of continuous, porous material that is sealed against the wall of a
tube, so that mobile phase can't bypass any significant length of this porous bed but
instead must permeate through it (37)). Currently, trypsin is also commercially available
bound to agarose beads and immobilized as individual spin columns.

Quantification in Mass Spectrometry
Another important question in proteomics, in addition to the knowledge of a
certain peptide's or protein's identity, is whether, in a particular system being studied,
there are any differentially expressed proteins in the sea of proteins with unchanged
expression. Therefore, quantification is another important issue in mass spectrometry.
However, peptides analyzed in a mass spectrometer will produce different intensities
based on chemical composition, the matrix in which they are present and other poorly
understood variables, thereby hampering quantification (1). Quantification may be
thought of as relative or absolute quantification. Relative quantification looks at the
amounts, or concentrations, of proteins between two conditions that are being compared.
This is the basis for profiling in proteomics (i.e. profiling normal versus cancer).
Profiling typically occurs on the MADLI platform, since, as mentioned above, this
platform has the ability to read more than a hundred samples on a single target plate, thus
using the same laser settings, matrix preparations and other conditions for all sample
comparisons. For relative quantification using a MALDI instrument it is very important
that there is a homogenous distribution of analyte in the cocrystallite composed of matrix
and analyte. Hot-spot formation, the observation that at several points of the sample no
analyte signals can be detected, while at other points strong signals can be seen, must be
avoided. The phenomenon of hot-spot formation is hard to predict and is dependent on
such properties as hydrophobicity, polarity, and H-bond-formation potential of the
analyte, the matrix and the solvent used for the sample preparation. Hot-spots cause
varying ion response on different positions of the sample spots, which leads to poor spot-
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to-spot and shot-to-shot reproducibility and is therefore one of the main reasons
hampering quantitative MALDI-MS (38).
Absolute quantification refers to the amount, or the concentration, of a protein of
interest in a particular system. This type of quantification can be performed on either
MALDI-TOF or ESI instruments using internal standards, or after measurement of a
calibration curve with known amounts of the particular analyte (38). One type of
internal standard techniques that is growing in popularity is the labeling of all proteins in
a solution mixture with stable isotopes. These methods are used for the quantification of
peptides after MS/MS fragmentation. One such method is termed Isotope-Coded Affinity
Tags (ICAT) and it involves labeling the cysteine residues in one sample with dO-ICAT
(polyether mass encoded linker with eight hydrogens) reagent and the cysteine residues in
a second sample with d8-ICAT (polyether mass encoded linker with eight deuteriums)
reagent. Deuterium is a stable isotope of hydrogen that has a neutron and thus is twice as
heavy as hydrogen. This will give the peptides labeled with d8-ICAT reagent a mass
difference compared to the peptides labeled with dO-ICAT reagent. After labeling, the
samples are combined and digested. The biotinylated ICAT-labeled peptides are
enriched on an avidin affinity column and analyzed by LC-MS/MS (1, 39). Another
labeling strategy is termed isotope coded protein label (ICPL), which is based on stable
isotope labeling of free amino groups in intact proteins. This labeling strategy is similar
to ICAT as it also relies on heavy (isotope-encoded) and light (isotope-free) mass tags.
Schmidt et al demonstrated that this approach may be multiplexed by adding different
weighted deuterium atoms (i.e. 7, 3 or 0 deuterium atoms) (40). A slightly different
approach to ICAT and ICPL is termed isobaric Tags for Relative and Absolute
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Quantification (iTRAQ). The iTRAQ method labels peptides on lysine residues and on
the N-terminus with cleavable multiplex isobaric tags to produce MS/MS signature ions
with the relative peak area corresponding to the proportion of labeled peptides. This
technique allows up to 4 samples to be labeled, mixed and analyzed at the same time due
to the availability of 4 mass tags (114,115, 116,117) (41,42). Recently, Applied
Biosystems, the manufacturer of iTRAQ, released an 8 tag version (8-plex with a mass
tag range of 113-121) of this platform, therefore allowing the comparison of up to 8
samples.

SELDI platform
Besides ESI and MALDI, another platform has been described termed Surface
Enhanced Laser Desorption/ Ionization (SELDI) time-of-flight mass spectrometry.
SELDI is essentially the MALDI process but with an incorporated surface capture
chemistry on the spot plate surface, and refined to individual spots on a chip platform.
SELDI-TOF MS technology has helped fuel large-scale clinical proteomic profiling, with
its ability to separate and analyze complex mixtures of proteins in a relatively highthroughput manner (43-45). The SELDI platform uses chips that contain specific
surface-chemistries (with several different chemistries available i.e. ion-exchange,
hydrophobic, normal-phase or metal chelate functional groups) for the affinity capture of
proteins from biological samples. The captured proteins are then analyzed by TOF mass
spectrometry to yield m/z and relative intensities of each ion (46). This technique
garnered much excitement from the research community. However, soon papers
emerged demonstrating the lack of analytical reproducibility of this method from
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different institutions and diminished robustness of discovered biomarkers upon validation
(47-49). Some of these problems have been addressed and shown to be based on study
design bias, chance, overgeneralization of results, and sample processing issues and not
actual problems with the instrument (48). Additionally, it has also been demonstrated
that when careful study design and sample handling is applied along with instrument
calibration, automation of sample preparation and supervised bioinformatics data
analysis, serum expression profiling can be reproducible and portable across multiple
laboratories (47, 50). Still, one of the main concerns with the SELDI platform is that, in
contrast to MALDI-TOF-MS/MS, SELDI-TOF MS has the disadvantage that the peaks
deemed differential can not be subjected to tandem mass spectrometry. Instead,
alternative, and more time-consuming, processes must be utilized to identify the identity
of any peptide or protein of interest (46).

1.2 Profiling for Cancer Biomarkers using Proteomic Technology
Cancer occurs when cells within the body divide aberrantly. These cells may then
become metastatic by dislodging from the primary tumor and the disease may spread
throughout the body via direct organ invasion, the lymphatic system, and/or the
circulatory system (51). At least one in three people will develop cancer, of which one in
four men and one in five women will die from this disease (52).
The method by which cancer develops is a multifactoral process and includes both
endogenous factors, such as genetic predisposition, and exogenous factors, such as
exposure to environmental carcinogens and infectious agents. Another important factor
for the development of cancer is age. There is an age-associated, organ-specific tumor
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incidence. Most cancers maybe divided into three groups: 1) embryonic (i.e.
neuroblastomas, retinoblastomas, and Wilms' tumors); 2) juvenile/young adulthood (i.e.
certain leukemias and testicular cancer); and 3) those that have increasing incidence with
age (i.e. prostate, breast, colon, and bladder cancers). There are several explanations as
to why certain cancers are associated with aging. One such possible factor is the
continuous exposure though-out life to low levels of exogenous carcinogens which would
allow genetic alterations to accumulate over time. There may also be age-associated
changes in some cells (whether caused by exposure to carcinogens or not), such as a
decline in DNA repair capacity, that may lead to mutations that are favorable to tumor
formation. Finally, with age there are alterations to the human body that may create a
more permissive setting for cancer development, such as changes in the immune and
hormonal environment. Typically, cells that divide are at a higher risk of acquiring
mutations than cells that do not divide. Thus, cancer is generally rarer in tissues that do
not divide, such as nerve tissue, but more common in breast, prostate, skin and colon,
which divide frequently (52).
The first large scale technique applied to search for biomarkers in the cancer field
involved the use of DNA microarrays for mRNA expression profiling (53, 54). However,
mRNA levels do not necessarily correlate with corresponding protein abundance.
Additionally, proteins are subjected to post-translational modifications such as
phosphorylation, acetylation, glycosylation and protein cleavages. These posttranslational modifications are not detected at the mRNA level (2). Thus, proteomics for
biomarker discovery gained popularity as a complement to the genomic information
gathered from past microarray data.
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The use of blood for proteomic profiling
Various tissues and biological fluids have been used in proteomic studies for
biomarker discovery. However, plasma and serum have been especially appealing as
sources for cancer biomarkers. This is because blood collection is minimally invasive,
economical to perform, and has the ability to be portable to remote locations (55). In
addition, the "leaky" nature of the newly formed blood vessels of a developing tumor and
the increased hydrostatic pressure within tumor potentially leads to the escape of tumor
molecules into the circulation (56).
Cancer is as much a product of its microenvironment as the microenvironment is
the product of the cancer. This is because the pre-cancerous cells interact with
surrounding epithelial and stromal cells, vascular channels and with the immune system,
which all may be involved in providing a favorable environment for the tumor to flourish.
Conversely, tumors also affect their surroundings by partaking in abnormal cell growth,
angiogenesis and cellular invasion, which are characterized by the release of proteases
that digest normal tissue and blood proteins. Thus, these events may give rise to a unique
cascade of events that will produce distinctive biomarkers (57). It is believed that fulllength cellular or tissue protein may be too large to enter the blood vessel wall passively
and thus biomarkers shed into the circulation from the tumor microenvironment are
predominately peptides and/or cleavage products. This led to the coining of a new
"omics" term, peptidomics. A controversial facet to peptidomics is the knowledge that
peptides are generated both in vivo and ex vivo. Ex vivo peptide production occurs in
serum by undefined collections of proteinases present in the blood that act on degradative
products of the clotting cascade (58). This is a point of contention, because many believe

that ex vivo generation of peptides may falsely bias data, especially if the sample sets are
handled by different individuals or are exposed to other variable conditions. It has even
been demonstrated that the plasma type or type of serum separator used in a study is a
source for profound variability in spectra (59, 60). However, there are also researchers
that argue that the peptides generated ex vivo provide valuable insight into the nature of
the proteinases that generated them. The rationale is that if the proteinases are altered
between disease states, and/or hail from the tumor microenvironment, then the peptide
patterns determined will reflect the activity of resident proteases in a given sample. One
concept that receives universal agreement is that much care must be taken to attain
uniformity in the collection and processing of blood samples (47, 56, 58-62).

Fractionation Techniques
The use of blood for biomarker discovery is hampered by the complexity and dynamic
concentration range of this fluid. The potential biomarkers generated by a tumor are very
dilute in the blood stream. Since, early-stage tumors might arise within a tissue volume
of less than 0.1 mL then the dilution factor of the tumor-generated biomarkers would be
50,000 (assuming that the biomarkers attributed to this tumor are uniformly dispersed in
the 5,000 mL total blood volume) (56). Additionally, the concentration range of
serum/plasma proteins spans about twelve orders of magnitude (63), in which twenty-two
proteins constitute about 99% of the protein content of plasma/serum, with the remaining
1% considered to be at low-abundance levels (Figure 1) (64). There are thought to be
many proteins that are not detected in the convoluted serum proteome because they are
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Figure 1. Pie chart representing relative composition of proteins within plasma. Twenty-two
proteins make up ~ 99% of plasma (adapted from Tirumalai et al, 2003).

overshadowed by high-abundant proteins, such as serum albumin.
The current methods for evaluating the blood proteome, which includes twodimensional gel electrophoresis-based techniques and mass spectrometry-based
techniques, are only capable of examining about three orders of magnitude (64, 65).
Therefore, it appears to be highly unlikely that current proteomic approaches may be able
to identify molecules in the concentration range of common tumor markers (ng/mL
range) without first reducing the complexity of the plasma/serum proteome (63).
One avenue for simplifying the proteome is the targeted capture of specific
proteins. This capture may be for the purpose of depletion, for example the depletion of
top-abundant proteins like albumin or immunoglobulins, so that the lower abundant
proteins may be more readily accessible for analysis. However, the targeted capture may
also be to study the captured proteins themselves. For example, one theory exists that
biomarkers may be enriched in the circulatory system by accumulating on highconcentration resident proteins (i.e. albumin), thus being protected from clearance by the
kidneys (56). This has led to the study of the "albuminome" were albumin is captured
(i.e. targeted capture via albumin antibodies) and the proteins bound to albumin are
analyzed via mass spectroscopy (64, 66).
The most common approach to reducing sample complexity is through the use of
affinity-based chromatography columns (commonly used on the front-end of LC-MS/MS
instrument). However, these columns are not ideal for large sample numbers and are not
suited for automation. An alternative chromatography-based fractionation method that is
more suited for high throughput analysis is SELDI-TOF MS, which as discussed
previously, uses chips coated with different surface chemistries to fractionate samples.
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However, because the surface area of the chips is small, this leads to a diminished
binding capacity and thus competition among proteins. This greatly influences the
spectrum of peptides and proteins detected (67-70). Chromatography columns or
magnetic particles with higher surface area and binding capacities provide fractionation
with less influence from competition over binding sites (70).
MALDI-TOF MS analysis typically takes advantage of these higher surface area
affinity-coated magnetic beads, which may be interfaced with robotic instruments (i.e.
ClinProt robot from Bruker Daltonics) that utilize magnets to automate the front-end
manipulation of samples. There are various magnetic bead types available that may be
combined with the ClinProt robot and the MALDI-TOF/TOF instrument from Bruker
Daltonics to produce an automated method that is high-throughput, reproducible, limits
operator error and consumes small amounts of the patient's sample (Figure 2) (43, 62, 71,
72). This leads not only to more significant results due to the increase in sample
numbers, but may also provide an ideal technique that translates effectively into clinical,
diagnostic laboratories.

1.3 Breast Cancer
Breast cancer is the most common cancer among women, and is the second
leading cause of cancer mortality in women after lung cancer. According to the
American Cancer Society, approximately 178,480 women in the United States were
estimated to be diagnosed with invasive breast cancer and around 40,460 women were
expected to die from the disease in 2007. Though predominately a female disease, breast
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Figure 2. MALDI-TOF scheme with magnetic beads for automation. Serum proteins are first
bound to magnetic beads that may be either chemically altered (such as cation/anion exchange)
or conjugated to a protein (i.e. lectin or antibody). After incubation the unbound fraction is
removed and the beads are washed to remove non-specifically bound proteins. The bound
proteins are removed, diluted with matrix (i.e. CHCA), and spotted on a target plate. This entire
process may be performed manually or robotically using a platform like the ClinProt robot from
Bruker. The spotted samples are analyzed using the MALDI-TOF instrument. Adapted from
Semmes et al, 2006.
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cancer also affects men. In 2007 2,030 men were projected to de diagnosed with invasive
breast cancer and 480 men were estimated to die from the disease (73).
The breast is composed of several lobes separated by septa of connective tissue.
Each lobe consists of several lobules. These lobules are made of connective tissues and
contain clusters of alveoli (secreting cells of the gland) that surround small ducts called
ductules. The ductules stem into ducts and then these ducts from the various lobules
come together to form a single lactiferous (milk-carrying), duct for each lobe (15-20 for
each breast). Each of these main ducts terminates in a tiny opening on the surface of the
nipple. A comparatively large amount of adipose tissue is deposited around the surface
of the gland and between the lobes. Breast size is determined mainly by this fat
surrounding the glandular tissue and not by the glandular tissue itself. The glandular and
connective tissues are supported by suspensory ligaments that help anchor the breast to
the underlying fascia of the pectoral muscles (74).
Estrogen and progesterone control breast development during puberty, with
estrogen stimulating growth of the ducts of the mammary glands, while progesterone
stimulates development of the alveoli (74). Initially, terminal ductal lobular units are
formed. These are the most actively growing terminal ductal structures and are believed
to contain stem cells that potentially give rise to breast cancer. Terminal ductal lobular
units grow until they either regress to terminal ducts, or differentiate to aveolar buds and
later to lobules during pregnancy's high branching period. The differentiated lobular
structures rarely give rise to malignant tumors, thus partly explaining the protective
effects of pregnancy against breast cancer (75, 76).

There are several pathological types of breast cancers demonstrating the
heterogeneity of this disease. Ductal carcinoma in situ (DCIS) is the most common type
of noninvasive breast cancer, and is considered a precursor of breast cancer, potentially
leading to invasive disease. DCIS is confined to the ducts and does not spread into the
tissue of the breast. This type of breast cancer is best detected with a mammography and
almost all women with cancer at this stage are cured. Lobular carcinoma in situ (LCIS),
begins in the milk-producing glands, but does not infiltrate beyond the wall of the
lobules. Having LCIS increases a woman's risk for being diagnosed with more invasive
breast cancer later in life and thus women with LCIS are closely monitored. The most
common invasive breast cancer, accounting for 80% of invasive breast cancers, is
invasive (infiltrating) ductal carcinoma (IDC). IDC starts in a milk duct, metastasizes
beyond the confines of the duct into the breast tissue from where it. can spread to other
parts of the body. A less common invasive breast cancer is invasive (infiltrating) lobular
carcinoma (ILC) and it accounts for about 10% of invasive breast cancers. This type of
breast cancer starts in the milk glands, or lobules, and can metastasize to other parts of
the body. Finally, the rarest, but also the breast cancer with the worst prognosis, is
inflammatory breast cancer. Women presenting with this type of breast cancer have
reddened-swollen breasts, due to the presence of cancer cells in the lymphatics of the
skin, in addition to the presence of cancer cells in the ducts and lobules (77).
Pain is typically the most frequent breast complaint that brings a patient to a
doctor's office, yet this is an uncommon risk factor since breast cancer, especially in its
early stages, is usually painless. Thus, in the past, the primary symptom of breast cancer
was a palpable mass and was typically first detected by the patient. However, today there

is an increased use of mammography, especially in screening programs, which has
resulted in many cancers being found at a preclinical stage (78).

Risk assessment models for breast cancer
There are many factors that can put you at risk for developing breast cancer, some
more significantly than others. Typically these risk factor are thought of as a culmination
of risk up to a certain point in time, instead of one specific risk factor dictating whether a
woman develops breast cancer or not. Some common risk factors are discussed below.
As mentioned previously, age is a common risk factor for breast cancer, with
breast cancer being more common in older women. Race is another risk factor, as
African American and Hispanic women are more prone to present with advanced breast
cancer than Caucasian women. However, though biological differences do play a part, it
is also thought that this may also be based on certain socioeconomic conditions, such as
access to the same quality health care and screening (79). Another risk factor is early
menarche and/or late menopause as it appears that the number of ovulatory menstrual
cycles a woman experiences correlates with breast cancer risk. This is supported by the
finding that oophorectomy before the age of menopause lowers the risk of breast cancer
by two thirds (80, 81). Other risk factors are benign breast lesions (i.e. atypical
hyperplasia is associated with the most risk, resulting in a four to five fold increase in
breast cancer, while non-proliferative lesions do not pose any risk for further breast
cancer development), the aforementioned LCIS and DCIS, and prior history of invasive
breast cancers (81).
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A protective factor against breast cancer is pregnancy. Pregnancy at a young age,
especially before the age of twenty, is associated with a striking reduction on breast
cancer risk. However, being over thirty years old at first live birth or nulliparity (no
pregnancy) are associated with a greater than two fold risk for developing breast cancer.
Additionally, the "protective" effect of pregnancy is only seen in the birth of a viable
fetus (80-82). This may be because the shedding of the placenta after delivery cuts off a
major source of estrogen. This drastic drop in estrogen then stimulates the secretion of
prolactin, which in turn stimulates alveoli to secrete milk. Additionally, the suckling
movements of the baby stimulate the secretion of oxytocin, which stimulates the alveoli
to eject milk into the ducts (74). The actions of these various hormones and also the
differentiation of the branched breast structure are thought to add to the protective effect
of pregnancy and breast feeding.
Finally, another risk factor is familial or hereditary risk. Familial breast cancer
risk occurs when one or more first- or second- degree relatives have breast cancer. On the
other hand, hereditary breast cancer is a subset of familial breast cancers in which the
incidence of breast cancer is related to an autosomal dominant susceptibility trait (81).
The majority of hereditary cancers can be attributed to mutations in the BRCA1 gene
(breast cancer predisposition gene 1), which was discovered in 1990 by Hall et al on
chromosome 17q21 (83) and the BRCA2 gene which was mapped to chromosome 13ql213 in 1994 (84). Subsequently, others found that germ line BRCA1 mutations
substantially increase the risk not only of breast cancer but also of ovarian cancer, while
BRCA2 mutations increase the likelihood of breast cancer development in females as well
as in males (78). BRCA1 and BRCA2 are nuclear proteins that function in DNA repair
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pathways. Loss of BRCA1 and/or BRCA2 function leads to the inability to repair
damaged DNA. When damage occurs to critical checkpoint genes, such as p53,
checkpoints such as p21 cannot be activated and cells proliferate (85).
Based on this knowledge risk assessment models that determine the probability
of developing breast cancer help health care providers determine an individual's best
options for cancer screening, follow-up, and the use of risk management therapies. The
most popular statistical model used is the Gail model which takes into account such risk
factors as age, race, age at menarche, age at first live birth, the number of first-degree
relatives with breast cancer, the number of previous breast biopsy examinations, and
presence of atypical hyperplasia (81). However, this model has been shown to perform
poorly on an individual basis and incorporating more epidemiological risk factors only
modestly improves its discriminatory accuracy (86, 87). There are other models available
that mainly look at heredity, i.e. models such BRCAPRO (88) are designed to predict
who is a BRCA1 or BRCA2 gene mutation carrier. However, the use of such models is
restricted to a small subset of the population as it is predicted that at most 5-10% of
diagnosed breast cancers have BRCA1 or BRCA2 mutations (89).
Intervention for people that are deemed at a high risk for breast cancer is very
physically and emotionally draining. Current risk-reducing options include lifestyle
modifications, chemoprevention with tamoxifen, prophylactic surgery and ovarian
suppression. Prophylactic mastectomies provide the most breast cancer risk reduction
(decreases the woman's breast cancer risk to 10% of the original risk). However, this
radical option is very unattractive and very traumatic to women even with the current
improvements in reconstructive options (89). This is also the case for prophylactic

oophorectomies, which if performed on women in their thirties, can reduce their breast
cancer risk by 60% (90). A less invasive therapy is the use of tamoxifen, a selective
estrogen receptor modulator (SERJVI), which competitively binds estrogen receptors (ER)
and is therefore prescribed to patients with ER+ breast cancers. However, as with most
hormonally responsive cancers, they may develop hormone resistance (or independence)
and thus will no longer respond to this type of treatment. Additionally, tamoxifen carries
with it certain serious potential side effects such as development of endometrial cancer,
stroke, and pulmonary embolism (which is more age dependent and seen typically in
older women) (89). Since current therapies for risk-reduction carry heavy health and
well-being burdens there is a need for complementary analysis tools, such as breast
cancer associated biomarkers, that will aid in improving the current breast cancer risk
assessment models.

Biomarkers in Breast Cancer
Recently, the American Society of Clinical Oncology released their 2O07
recommendations for the use of tumor markers in breast cancer (91). CA 15-3 and CA
27.29, which are well-characterized assays for screening MUC-1 antigen in peripheral
blood, were approved for monitoring of patients with metastatic disease during therapy,
but in conjunction with physical examinations and diagnostic imaging. MUC-1 is a type
of mucin protein. Mucins are high molecular weight glycoproteins that provide a
protective layer on epithelial surfaces and are involved in cell-cell interactions, signaling,
and metastasis (92). Rising levels of MUC-1 as seen by CA 15-3 and CA 27.29, in the
absence of measurable disease, would indicate treatment failure. The same is true for
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another approved biomarker, carcinoembryonic antigen or CEA, though it is less
sensitive than the MUC-1 test for detecting metastatic disease. Current established
biomarkers that are used to initially screen breast cancers to aid in the determination of
treatment options are the ER, progesterone receptor (PgR) and HER2/neu (c-erb-B2). ER
and PgR content are associated with favorable prognosis and would benefit from
hormonal treatments such as tamoxifen or hormone ablation therapy. HER2 is a member
of the epidermal growth factor receptor family (93) and is amplified and overexpressed in
15-30% of newly diagnosed breast cancers and is linked with more aggressive breast
cancers (94). Additionally, circulating HER2 extracellular domain (ECD) levels, which
can be detected in plasma or serum and are elevated in about 30% of metastatic breast
cancer cases (91, 95, 96), have been proposed for the monitoring of patient response to
certain therapies (91). An assay recently approved for the prediction of breast cancer
recurrence in patients diagnosed with node-negative, ER positive breast cancer and
treated with tamoxifen is the Onco^pe DX assay (from Genomic Health Inc, Redwood
City, CA). Oncotype DX is a reverse transcriptase (RT)-PCR assay that measures the
expression of 21 genes (16 cancer related genes and five reference genes). This
information is then processed by an empirically derived algorithm to categorize patients
into 3 risk groups of distant recurrence: low, intermediate and high. Thus, this assay is
used to identify patients that would obtain the most therapeutic benefit from adjuvant
tamoxifen and thus may not require adjuvant chemotherapy. However, patients with
high-recurrence score would be best treated with chemotherapy rather than tamoxifen
(91, 97). Finally, there are many biomarkers and novel techniques that are reported, but
yet to be successfully validated and recommended for use on patients. One example is

the use of circulating tumor cells (CTCs) as markers for breast cancer. CTCs are cells
within blood that possess antigenic or genetic characteristics of a specific tumor type.
Thus, the presence of CTCs in a breast cancer patient may predict the presence of an
aggressive primary tumor or potentially micrometastasis. CTCs may be detected by
positive cell selection using immunocapture (using imrnunomagnetic beads conjugated
with an antibody specific for a cell surface, epithelial or cancer related antigen) and
immunocytochemistry or by gene expression analysis for the presence of cytokeratins
and rumor antigens. A reverse methodology is to first remove the leukocytes and then
interrogate the remaining cells by immunocytochemistry or RT-PCR. Recently the US
Food and Drug Administration approved a test for CTCs called CellSearch Assay
(Veridex, Warren, NJ). However, this assay still needs to undergo additional validation
to confirm clinical value of this test for use in patients (91).

1.4 Prostate Cancer
Prostate cancer (PCa) remains the most common malignancy and second-leading
cause of cancer deaths among males in the United States, with an estimated 218,890 new
cases in 2007, accounting for 29% of new male cancers (98). Early prostate cancers
demonstrate few signs and symptoms and the presence of symptoms such as hematuria,
obstructive voiding symptoms, and bone pain generally indicate advanced prostate
cancer.
Disorders of the prostate can be divided into three main categories: benign
prostatic hyperplasia (BPH), prostate cancer (prostatic adenocarcinoma), and prostatitis
(bacterial infections of the prostate). The prostate, a small glandular organ in men that is
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located in front of the rectum and beneath the urinary bladder, has three distinct zones:
transitional, central and peripheral. These zones have different histology, embryonic
origins and give rise to different pathologic entities. The central zone extends from the
bladder base and encircles the ejaculatory ducts. It contains roughly 25% of prostatic
glandular elements and only 1-5% of prostate cancers stem from there. The transitional
zone surrounds the proximal urethra and, in youth, contains 5-10% of the prostatic
glandular tissue. BPH arises from the transitional zone, as well as 20% of prostate
cancers. The peripheral zone comes from the mesoderm and accounts for the majority of
the glandular tissue. This zone gives rise to about 70% of prostate cancers and is also the
site of most prostatic infections (Figure 3) (99).
Risk factors for developing prostate cancer include a family history of prostate
cancer (which increases with the number of first-degree relatives affected), age (since 7080% of patients who have prostate cancer are 65 years old or older), and race (i.e.
African-American men have the highest incidence of prostate cancer in the United
States). Interestingly, African American men have higher levels of endogenous androgen
than Caucasians, and it is these higher levels that are thought to play a role in the
development of prostate cancer. The prostate is a hormone responsive glandular organ,
similar to the breast, and therefore a typical treatment for advanced stage prostate cancer
is androgen ablation. Androgen ablation may be performed through surgical or medical
(chemical) castration. However, the use of androgen ablation, termed androgen
deprivation therapy (ADT), leads to androgen-independent or hormone-refractory
prostate cancer. Thus, most patients with metastatic prostate cancer will respond initially
to this therapy, but eventually these patients will develop progressive disease despite
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Figure 3. Schematic depicting the zones of the prostate. The central zone extends from the
bladder base and encircles the ejaculatory ducts accounts for only 1-5% of prostate cancers
cases. The transitional zone surrounds the proximal urethra and gives rise to BPH as well as
20% of prostate cancers. The peripheral zone, which contains the majority of the glandular
tissue, gives rise to about 70% of prostate cancers and is also the site of most prostatic
infections.
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continued androgen suppression. Unfortunately, advanced prostate cancer patients on
ADT have an average survival of twenty-four months and the five year survival is only
20% (100). Additionally, ADT therapy has been linked with an increased risk of heart
disease and diabetes (101). However, if the disease is caught early on it is far more
manageable. Treatment for localized prostate cancer is either watchful waiting or
surgery. Current surgical methods, such as laproscopic radical prostectomy, have
improved in terms of becoming less invasive and the five year survival rates of men after
radical prostectomy are around 80% (99).

PSA as a Biomarker for Prostate Cancer
Currently, one of the main pretreatment diagnostic screens used in the detection
of prostate cancer is the presence of the biomarker Prostate Specific Antigen (PSA).
PSA, a 240 amino acid serine protease, is a member of the human kallikrein gene family
(102). The functional role of PSA is not entirely understood, but it is known that it is
secreted in high concentrations in the seminal fluid where it acts to liquefy the semen.
PSA is found in much lower concentrations in the serum (103). The elevation of this
marker in blood, usually in conjunction with an abnormal digital rectal exam (DRE) will
lead to a biopsy of the prostate for a definitive diagnosis (104).
There is still a debate over the exact value that should serve as the threshold
between normal and abnormal serum levels of PSA. Traditionally, the normal serum
value for PSA was accepted to be 4.0 ng/mL or less. However, more recently, it has been
suggested that men sixty years old and younger should not have a PSA value of 2.5
ng/mL or higher (104, 105). This change was brought about by the Prostate Cancer

Prevention Trial (PCPT), which was a randomized clinical trial to test the hypothesis that
blockade of 5-alpha reductase activity with finasteride could prevent prostate cancer. The
criteria for patient enrollment in this study were PSA levels of less than 3 ng/mL, normal
results of a DRE and being at least fifty-five years of age. The patients were then
randomly assigned to finasteride or placebo for seven years. At the end of the study all
participants, regardless of PSA value, underwent an end-of-study biopsy. When the
prevalence of prostate cancer among men in the placebo group was evaluated it was
found that even in this very-low-risk group of men, the incidence of prostate cancer on
sextant biopsy was 15.2%. Ultimately, it was determined that there is no single PSA
value that will provide assurance that a man does not have prostate cancer (106).
However, this study also found that as the PSA value increases, the likelihood that there
is a detectable prostate cancer and more specifically a high-grade prostate cancer
significantly increases (107).

Ability of PSA to differentiate between BPH and Prostate Cancer
Unfortunately, PSA is not a specific biomarker for prostate cancer since its serum
level increases with BPH, and can also be affected by many other factors such as
inflammation, prostatitis and even ejaculation. It has been estimated that two out of three
men with abnormal results on routine PSA screening will not have prostate cancer (108).
It is therefore critical to be able to distinguish between prostate cancer and BPH, since
BPH is highly prevalent amongst older men. Histologically, 50% of men in the fifth
decade of life demonstrate evidence of BPH at the time of their autopsies. In addition, it
has been estimated that 18% of men in their forties, 29% of men in their fifties, 40% of

men in their sixties, and 56% of men in their seventies have signs of BPH, such as
decreased force of stream, nocturia, straining, urinary frequency, and urinary urgency.
This data is based on the study of 7,588 men from nine Asian countries and these rates
have been shown to be similar in Australia, America, and Europe (99,105).
A step forward in improving the specificity of the PSA test for prostate cancer
screening came about in the form of free PSA (fPSA). In serum, PSA exists in bound
and unbound forms, with the bound form being more prevalent. Generally, the bound
form consists of PSA being complexed to the anti-proteases, alpha-1-antichymotrypsin or
alpha-2-macroglobulin. However, it is the fPSA that has been found to be lower in
patients with cancer and seems to be less affected by benign hyperplasia than total PSA.
The risk of cancer is high for those who have a free/total PSA (f/tPSA) of less than 15%,
whereas BPH is more likely when f/tPSA is more than 25%. Unfortunately, for most
patients, f/tPSA falls between these two values and is mainly used to evaluate the need
for repeat biopsies when negative (105). Another method of improving the accuracy of
PSA may be to not rely on an isolated PSA value, but rather study PSA trends. For
example, many studies suggest that if a patient's serum PSA increases more than 0.75
ng/mL per year, then there is an elevated risk for prostate cancer regardless of the
absolute serum PSA value (99). A new diagnostic tool that is currently being evaluated is
a test for the inactive precursor form of PSA (proPSA). The native form of PSA is
designated as (-7), which is proPSA without 7 amino acids, while the proPSA form
includes the truncated products of PSA, (-5), (-4), (-2) and (-1) forms (109, 110).
ProPSA has been shown to increase the sensitivity of PSA and specificity of PSA in
differentiating between PCa and BPH. The (-2)proPSA has been found to have the most

significant correlation and is seen elevated in serum of PCa patients compared with
serum of BPH patients. Further validation of this assay needs to be performed before it
clinical utility is determined (111-113).
The road to prostate cancer diagnosis is still very much littered with unnecessary
biopsies and this leads to needless anxiety, in addition to expensive follow-up testing and
procedures that carry further health risks (55). It is becoming very clear that PSA alone
will not accurately predict the development and progression of this complex disease.
Hence, the pursuit of new biomarkers that will complement and improve the current
diagnostic tools continues.

CHAPTER II
DISSERTATION RATIONALE AND SUMMARY OF AIMS

The goal of this research project is to develop techniques to address the
requirements of serum protein expression profiling of cancer cohorts for the purpose of
early detection and the prediction of cancer risk. To effectively profile serum for cancer
biomarkers one must preserve the integrity of the proteome, have the capacity to
reproducibly process many samples simultaneously for statistical validity, allow for
several fractionation techniques to simplify the serum proteome and also possess the
ability to determine the identity of differential peaks.
MALDI-TOF MS is currently the platform of choice for expression profiling, due
to its high-throughput nature and its capability to identify peaks of interest directly with
the LIFT-MS/MS platform. Additionally, the MALDI instrument may be integrated with
front-end automated fractionation processing of samples. However, the effective range
for most MS instruments, including the MALDI platform, is in the low molecular weight
range (less than 20kDa) and thus higher molecular weight proteins are typically excluded
from high-throughput profiling studies. Hence, in addition to profiling these lowmolecular weight endogenous peptides and proteins, one may increase the mass range of
the MALDI platform by trypsinizing fractionated serum and profiling the resulting tryptic
peptides. Thus, the specific hypothesis of this dissertation is that development of
integrated fractionation and digestion techniques will allow for more effective
detection and identification of differential cancer biomarkers secreted or shed into
the blood from the growing tumor or from the interaction of the cancer with the

surrounding microenvironment. Different front-end fractionation schemes will be
considered for their ability to increase the scope of the proteome under investigation and
for their compatibility with the developed digestion protocol. Additionally, we will also
investigate sample sparing techniques that will allow continued use of precious, limited
samples, while preserving the quality of the proteome under investigation.
During the course of this project we will use two model serum cancer cohorts to
gauge the validity of the techniques laid out in this thesis dissertation. The first serum
cohort is a group of patients that will or will not develop breast cancer within the next 5
years. Biomarkers from such a study would be ideal for use in conjunction with current
breast cancer risk assessment models such as the Gail method. The second serum cohort
is a group of men that either have been diagnosed with either BPH or PCa, but have PSA
levels in the non-discriminatory zone of 2-10 ng/mL. Results from this type of sample
set would be instrumental in assessing the possibility for the development of early
detection screens that would compliment the current PSA diagnostic tool in the
differentiation between BPH and PCa afflicted males.
The hypothesis of this dissertation was evaluated by addressing the following
specific aims:
Aim I: Development of precious sample sparing techniques for mass spectrometry
analysis. This aim entails:
A. Validating a "scrape" technique for the use of sparing precious samples unnecessary
freeze-thaw cycles.
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B. Application of the scrape technique to a large cohort of valuable serum samples that
are in limited quantity and need to be preserved for further experiments. The cases in this
sample cohort are of women who developed invasive breast cancer during the first 10
years of follow-up and who had stored serum available that had been drawn between 1
and 5 years prior to the diagnosis of breast cancer. The controls are matched to the cases
on age and length of follow-up, who were not diagnosed with breast cancer during the
first 10 years of follow-up.

C. Utilization of SELDI-TOF MS and MALDI-TOF MS to investigate this cohort for the
purpose of differentiating between women that will develop invasive breast cancer 1-5
years into the future from women that will not develop breast cancer in that same time
frame. IMAC (immobilized metal affinity capture) chips will be used prior to SELDITOF/MS and magnetic bead (MB)-IMAC and MB-WCX (weak cation exchange) will be
used prior to MALDI-TOF MS.

D. Generating algorithm models, using Biomarker patterns software for SELDI-TOF
data analysis or ClinProTools software for MALDI-TOF data analysis, for identification
of differential peaks and assessing their ability to segregate the two groups.

E. Validation of models using larger serum sample sets that are processed as described in
B and C. The validation sample sets are both unblinded and blinded thus allowing for the
alteration of models and the determination of the ability of these models to correctly
classify samples groups.
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Aim II. Increasing the effectiveness of the MALDI-TOF/TOF for analysis of large
molecular weight proteins. This aim entails:
A. Integrating a trypsin digestion step following standard chemical affinity fractionation
of serum samples. The effect of buffer pH and protein concentration on digestion
efficiency and sample clean-up prior to MALDI-TOF analysis will be evaluated. The
protocol will take advantage of paramagnetic bead technology and will strive to make
each aspect of the workflow compatible with future automation.

B. Comparing the efficiency of the trypsin magnetic bead digestion of serum proteins
with a standard soluble trypsin protocol.

C. Assessing reproducibility of the trypsin bead digestion workflow, using MB-WCX as
a representative initial serum fractionation step.

D. Investigating a MB-WAX (magnetic bead weak anionic exchange) front-end
fractionation step for its adaptability to the typsinization workflow.

E. Performing and comparing sequence identifications of selected m/z peaks from the
WCX and WAX fractionation/ trypsin bead digestion workflows using the LIFTMALDI-TOF/TOF. Additionally, tryptic peptide workflows will be compared against
endogenous peptide results in terms of profiling and ability of peptide identification
efficiency.
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F. Performing proof-of-concept trypsin bead workflows on clinical samples in order to
determine the ability of this method to detect and identify differential peptides in a
reproducible manner. The two serum cohorts used in this effort will either investigate the
ability to predict occurrence of breast cancer in the future (using the samples from Aim I)
or will attempt to differentiate between BPH and PCa patients.

Aim III. Development of integrated fractionation protocols for in-depth and automated
MALDI-TOF/TOF analysis. This aim entails:
A. Investigating whether workflows designed in Aim II (MB-WCX and MB-WAX initial
fractionation followed by immobilized-trypsin digestion and MB-C18 capture) may be
compatible if performed in tandem for the purpose of sample preservation and for further
mining of the serum proteome.

B. Determining if lectins immobilized on magnetic or agarose bead supports may be
incorporated in the immobilized-trypsin bead workflow for the purpose of automated
protocols. These protocols may be used to profile the serum proteome for differences in
glycan moieties between captured glycoproteins.

C. Designing schemes for the ClinProt robot to determine if the protocols developed in
this dissertation may be automated in an effective and reproducible manner.

CHAPTER III

AIM I: DEVELOPMENT OF PRECIOUS SAMPLE SPARING TECHNIQUES
FOR MASS SPECTROMETRY ANALYSIS

3.1 Introduction
Breast cancer is the most common malignancy in women and the second most
common cause of cancer-related death according to the 2007 American Cancer Society
report (73, 77). When treated early breast cancer is a manageable disease i.e. women
presenting with localized disease have a greater likelihood of remaining disease-free after
five years than women presenting with regional disease or metastatic disease (114).
Thus, detecting a malignancy before its clinical appearance is the goal of cancer
diagnosis and treatment (77). In response to this, risk assessment models that determine
the probability of developing breast cancer have been developed to help health care
providers determine an individual's best options for cancer screening, follow-up, and the
use of risk management therapies such as chemoprevention with tamoxifen or surgical
intervention.
The most popular statistical model used is the Gail model which takes into
account such risk factors as age, race, age at menarche, age at first live birth, the number
of first-degree relatives with breast cancer, the number of previous breast biopsy
examinations, and presence of atypical hyperplasia (81). However, this model has been
shown to perform poorly on an individual basis and incorporating more epidemiological
risk factors only modestly improves its discriminatory accuracy (86, 87). Therefore,
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there is a need for complementary analysis tools that will aid in improving the current
breast cancer risk assessment models.
To this end, using proteomic technology, such as the surface-enhanced laser
desorption/ionization time-of-flight (SELDI-TOF) and matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) instrument, allows for the profiling of
patient serum in a reproducible manner (18, 50, 115) with the potential to identify serum
biomarkers that may differentiate between women who in the future will develop breast
cancer and those who will not.
Serum samples are collected and processed in specialized tubes, which allow for
the clotting of the blood and the removal of blood cells and resulting fibrin clots from the
fluid portion of the blood. If the serum samples are destined for a particular study then
they will typically be aliquoted from these larger sample collection/serum storage tubes
into smaller tubes and stored until the experiment is about to be performed. In this way
the aliquots may be used for the study on an "as needed" basis, thus minimizing freezethaw cycles. However, more often then not, studies are performed on samples that were
collected and frozen for storage. This may be due to lack of freezer space or that the
samples may be needed for another retrospective study down the line, beyond the goals
of the original study design plan.
Excess freeze-thaw cycles have been shown to effect the dynamic alterations of
the serum proteome in the mass range of most mass spectrometry instruments (18).
Additionally, adding extra freeze-thaw cycles allows for more sample handling and may
introduce variability into the sample set. It has been found that the length of time that
samples are left on ice or on the bench-top greatly influenced the peptide profile by mass

spectrometry (18, 116). One reason for this may be the fact that there are still proteases
in the serum that may lead to the production of ex-vivo peptides. Ex vivo generation of
peptides may falsely bias data, especially if the sample sets are handled by different
individuals or are exposed to other variable conditions.
In Aim 1 we thus present a sample cohort utilized for the goal of predicting a
women's chance of developing breast cancer within the next five years. This sample
cohort was originally destined for a women's osteoporosis study in the San Francisco
Bay area. During the course of this large study many women developed breast cancer,
thus the serum cohorts were selected to compare samples from women who were going to
develop breast cancer versus age-matched women who will not. Since, these samples are
precious and repeated freeze-thaw will damage the quality of the proteome for future
studies, we scraped the serum samples, while they were still frozen, with a sterile, blunt
needle. This technique negated a freeze-thaw cycle for both the stock samples and
aliquots to be analyzed. The scrape method is shown to be comparable in spectra quality
to spectra generated from samples that are completely thawed before processing for mass
spectrometry analysis. Additionally, SELDI-TOF MS and MALDI-TOF MS data of
scraped samples, after weak cationic exchange (WCX) and immobilized metal affinity
chromatography (IMAC) fractionation to reduce serum proteome complexity, is
presented with the goal of finding discriminatory peaks that will aid in the prediction of
breast cancer risk in the future. The discriminatory biomarkers for breast cancer risk can
be developed into simple blood tests that can be combined with current statistical
methods to improve risk assessment for breast cancer.

3.2 Materials and Methods
Sample Selection and Processing
Serum samples were selected by Jeffrey Tice, M.D., from participants in the
Study of Osteoporotic Fractures (SOF), which is a population based cohort study of risk
factors for the development of osteoporotic fractures in postmenopausal women. Dr.
Tice is a coordinator of the SOF study and an epidemiologist and breast cancer clinician
from the University of California San Francisco. The original osteoporosis study had
9704 women enrolled from four geographic regions (Baltimore, MD; Pittsburgh, PA;
Minneapolis, MN; Portland, OR) between September 1986 and October 1988.

African

American women were excluded at baseline because of their low risk of hip fracture. For
our breast cancer study, "cases" of women were selected at random who developed
invasive breast cancer during the first 10 years of follow-up and who had stored serum
drawn between 1 and 5 years prior to the diagnosis of breast cancer. "Controls" were
chosen randomly which were matched to cases on age and length of follow-up, from the
remaining participants in the SOF cohort who were not diagnosed with breast cancer
during the first 10 years of follow-up. For the pilot study, 42 cases and 42 controls were
selected. For the validation study, an additional 104 cases and 104 controls were
selected. All serum samples selected came from post-menopausal women who were not
using hormone replacement therapy. Institutional Review Boards at the four clinical sites
and the coordinating center approved the study protocol and all participants signed
informed consent at enrollment. The selected serum cases and controls were scraped
without thawing and processed with IMAC chip surfaces for SELDI-TOF MS analysis
and with MB-WCX (weak cationic exchange magnetic beads) and MB-IMAC

(immobilized metal affinity chromatography magnetic beads) on the Bruker ClmProt
robot for MALDI-TOF MS analysis.

Scraping vs. Thawing serum processing techniques
A traditional "thaw" technique was compared to a "scraping" technique. Initially,
100 (iL was scraped from the top of each frozen sample (samples had been frozen at 80°C) with a steel nail. The same frozen samples were then allowed to thaw to
completion and 100 /xL of each sample was collected to compare against the "scrape"
technique. For the large cohort processing, the steel nail was replaced with a sterile,
blunted, thick steel needle.

SELDI-TOF MS and data analysis
Twenty microliters of each serum samples was diluted in a 1M urea, 0.125%
CHAPS and phosphate-buffer saline buffer. These diluted samples were then robotically
processed onto eight-spot copper activated immobilized metal affinity chromatography
(IMAC-Cu or IMAC3) chip arrays (Ciphergen Biosystems, Freemont, CA) with a
Biomek 2000 liquid handling system (Beckman Coulter, Fullerton, CA). The IMAC3
chip arrays were air dried and overlaid with a saturated matrix solution containing
sinapinic acid in 50-% (v/v) acetonitrile and 0.5% (vol/vol) trifluoroacetic acid.
The IMAC3 chips with sample and matrix were run on a SELDI ProteinChip
System (PBS-II, Ciphergen Biosystems). The mass spectrometer was externally
calibrated using a mixture of known peptides. Blinded serum samples were randomized
in blocks of seven to ensure that each chip included at least three cases and three controls.
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Each sample was run in duplicate on separate chips and the results were averaged.
Additionally, a standard serum sample (QC) was applied to one of the eight spots on each
chip for quality control. Spectra generated were subjected to pattern recognition and
sample classification analysis performed with the Biomarker Pattern Software (Ciphergen
Biosystems).

MALDI-TOF MS and data processing
Samples were randomized (QC samples were included) and processed using the
ClinProt robot (Bruker Daltonics, Bremen, Germany) using both MB-WCX and MBIMAC independently as per manufacturer's instructions (10 /iL magnetic beads incubated
with 20 fxL serum sample). The eluted samples were mixed 1:10 with R-cyano-4hydroxycinnamic acid (CHCA) matrix solution (0.008 g CHCA prepared in 2mLs
acetone and 2mL ethanol) and 0.8 fiL was spotted in duplicate robotically on an
AnchorChip plate. The fractionated endogenous peptide profiles were generated from an
average of four hundred laser shots in the linear mode by the MALDI-TOF Ultraflex I
mass spectrometer (Bruker Daltonics) and analyzed with ClinProTools 2.0 (Bruker
Daltonics). ClinProt software baseline subtracted and normalized the spectra (using total
ion current). A k-nearest neighbor genetic algorithm contained in this software suite was
used to generate prediction models to classify the groups analyzed. Twenty percent of
the samples were left out of the model generation process and used to cross-validate the
model within the software.

50
3.3 Results
"Scrape" vs. traditional "Thaw" method
The SOF study cohort is made up of 9,704 participants, thus making aliquoting
these samples into multiple tubes not feasible at the main storage site. Additionally, each
of these participants only has one available sample drawn at a given date. In order to
utilize this expansive in participants, yet limited in individual sample quantity, serum
cohort that would give us the potential of predicting whether a woman will develop breast
cancer within the next five years, we had to evaluate a method to process the samples
without thawing whole stock/storage vials. The method we developed in lieu of a freezethaw cycle was a simple scraping of the frozen sample from the top of the vial. We
determined the validity of this scrape method by comparing a traditional total thaw
technique to a scraping technique. Initially, 100 [JL was scraped from the top of each
frozen sample with a steel nail (later this was adapted to the utilization of a blunt sterile
needle). The same frozen samples were then allowed to thaw to completion and 100 juL
of each sample was collected to compare against the "scrape" technique. Samples were
processed on IMAC chips and analyzed with SELDI-TOF MS. Spectra patterns and
intensities were compared between the thawed and scraped samples and standard
deviations were calculated for ten representative peaks. Since no difference in intensities
and standard deviations was observed between scraped or thawed samples (Figure 4), we
deemed that this scrape technique was compelling enough to continue and process the
remainder of the cohort samples.
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Figure 4. Comparison of scraped and thaw techniques on frozen serum samples. Intensities and
standard deviations often representative peaks are shown, with no significant differences seen
between the techniques. Spectra were generated using the SELDI-TOF MS platform after
processing on IMAC chips.
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Analysis of samples processed with scrape method using SELDI-TOF MS
We compared 84 samples (42 cases and 42 controls) using IMAC chips and the
SELDI-TOF MS platform as described in Materials and Methods. In a classification and
regression tree analysis using Biomarker patterns software (Ciphergen Biosystems), we
generated a tree with a recognition capability of 85.7% of cases and 78.6% of controls of
the test set. After cross-validation of the generated tree we could correctly classify 31 of
the 42 cases (74% cases correctly classified) and 30 of the 42 controls (71% of controls
correctly classified) (Table 1). Of the 11 peaks that were predictor variables used in the
generation of the classification and regression trees, only the tree containing 4 terminal
nodes was deemed optimal and thus was used for the analysis. Seven peaks were used in
the generation of this tree with only 3 peaks used as splitting factors in this tree analysis.
These peaks were m/z 7850.989, 9303.888, and 9190.488, with peak m/z 7850.989 being
the most significant in differentiating between the two groups (p-value of 0.039). A list
of peaks with significant p-values is provided in Table 2. Overall, sensitivity (correctly
classified cases) and specificity (correctly classified controls) were similar and
moderately impressive in predicting future breast cancer risk. Unfortunately, this
SELDI-TOF MS data was re-analyzed by an independent institution with blinded-serum
samples and was not found to have statistically relevant sensitivity and specificity. A
peak probability contrast (PPC) procedure was utilized for this analysis (117).
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Table 1. Classification and regression tree analysis of 84 serum samples processed
on IMAC chips.

N
N
Cases Misclassified
42
11
Case
42
12
Control
Class

N Correctly
classified
31
30

Table 2. Significant peaks (p-value < 0.05)
differentiating between cases and controls
after SELDI-TOF MS analysis.

m/z

p-value

3992.462

0.003

4184.852

0.003

7850.941

0.039

8157.624

0.050

9190.488

0.005

9303.888

0.009

9439.381

0.031

% Correctly
classified
73.8%
71.3%
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Analysis of samples processed with scrape method using MALDI-TOF MS
The 84 samples were also processed using the ClinProt robot with MB-WCX
(found previously by our lab to yield the most robust peaks within the MALDI-TOF MS
mass range) and robotically spotted on an AnchorChip plate with CHCA matrix. The
resulting spectra were imported into ClinProTools 2.0 software and genetic algorithm
models were generated. These models were then used to externally validate a set of 112
samples (56 controls and 56 cases) run in duplicate. Though increasing the number of
peaks in the genetic algorithm model beyond 5 peaks improved the internal crossvalidation, it resulted in lower sensitivity and specificity of the external validation (Table
3). Additionally, the models that had less than 5 peaks also had decreased sensitivity and
specificity compared to the 5 peak model. Thus, the genetic algorithm model containing
5 peaks was deemed the most ideal and models containing more than 5 peaks were
probably over-fitted to the sample set of 84. The genetic algorithm model containing 5
peaks had a 100% recognition capability of the test set and yielded an overall 63.64%
cross-validation with 59.87% correctly classified cases and 67.42% correctly classified
controls. Additionally, of the 112 (224 total when in duplicate) samples used for external
validation of this model, 60.7% were classified correctly as cases and 61.6% were
correctly classified as controls using this 5 peak genetic algorithm model. Table 4 shows
the peaks utilized in the genetic algorithm model and Table 5 shows the top significant
peaks as determined by T-test/ANOVA. Figure 5 shows the cluster plot for the set of 84
samples using the two peaks with the most significant p-values as determined by Ttest/ANOVA. Additionally, a set of 96 blinded samples was run through the genetic
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Table 3. Cross-validation and External Validation of genetic
algorithm models
3 a. 5 peak genetic algorithm model
Class

Correct Classified
(cross-validation)

Correct Classified
(external validation)

Cases

59.9 %

60.7 %

Controls

67.4 %

61.6%

3b. 6 peak genetic algorithm model
Correct Classified
Class
(cross-validation)

Correct Classified
(external validation)

Cases

64.5 %

62.5%

Controls

67.4%

45.5 %

3 c. 7 peak genetic algorithm model
Class

Correct Classified
(cross-validation)

Correct Classified
(external validation)

Cases

73.68 %

53.6 %

Controls

68.54 %

42.9 %

Table 4. Masses used for the classification of 84 WCX fractionated serum samples
using the 5 peak genetic algorithm model

Mass (m/z)
2139.38
2675.72
3542.28
1781.11
1501.3

Weight (importance given in model)
0.25
0.09
0.04
0.13
0.1

Table 5. Significant peaks as determined by T-test/ANOVA (p-value < 0.05) for the
84 serum sample set

Mass (m/z)
2178.28
•2511.78
7342.55
2975.96
3706.07
3276.18
•1716.00
5700.62
4742.36
3366.19
6524.28
7117.81
1911.81
5262.98
3839.32
3492.29
5247.62
6906.83
3352.33
4350.35
2578.2
1487.85
3120.22
4370.59
1377.35
7055.13
.1138.63

P-value
0.043
0.043
0.043
0.043
0.043
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
0.046
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Figure 5. Cluster plot for the set of 84 WCX fractionated serum samples. The cluster
plot was generated by the ClinProTools 2.0 software. The intensities of 2 peaks with
the most significant p-values (as determined by T-test/ANOVA) are plotted on 2 axes.
The more clustered the points are in relation to their group and the more separated the
clusters are from each other then the more significantly distinct the 2 groups are in
relation to each other. In this cluster plot the intensities of peak m/z 2178.28 are found
along the "x" axis, while the intensities of peak m/z 2511.78 along the "y" axis. The
control sample peaks are designated by "o" and the case sample peaks are designated by
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algorithm model generated from the 84 samples. Of the 96 blinded samples, 52.1% were
classified correctly with 51.0% of the cases correctly classified and 53.1% of the controls
correctly classified.
In order to evaluate if the classification of the unknowns may be improved, an
additional model was generated using the 84 samples with the 112 samples (n=196 run in
duplicate). The set of 96 blinded samples was run through the various genetic algorithm
models generated from the 196 samples and the 5 peak model was found to have the best
classification ability. The genetic algorithm model containing 5 peaks had a 100%
recognition capability of the test set and the cross-validation yielded an overall 57.34%
correct classification with 58.2% sensitivity and 56.4% specificity. Table 6 shows the
peaks utilized in the genetic algorithm model (the top significant peaks as determined by
T-test/ANOVA was m/z 7341.66 with a p-value of 0.04). Figure 6 shows the cluster plot
for the set of 196 samples using the two peaks with the most significant p-values as
determined by T-test/ANOVA. Of the 96 blinded samples, 52.1% were classified
correctly with 58.3% of the cases correctly classified and 45.8% of the controls correctly
classified. Thus, the sensitivity was slightly improved in the classification of the
unknowns as compared to the genetic algorithm model generated from the 84 samples;
however the specificity was slightly decreased.
The 112 samples were also analyzed using MB-IMAC beads as a comparison to
the IMAC chip SELDI data. A genetic algorithm model containing 5 peaks was found to
have a 100% recognition capability of the test set and the best cross-validation with
60.8% correctly classified cases and 61.8% correctly classified controls. However, the
classification results of the 96 independently run blinded samples was disappointing. Of
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Table 6. Masses used for the classification of 196 WCX fractionated serum samples
using the 5 peak genetic algorithm model

Mass (m/z)
2757.08
6056.85
1733.82
4144.51
4642.61

Weight (importance given in model)
0.05
0.03
0.06
0.01
0.04

Idi 116ft-§CB1 m/z

4.0'

3.5

3.0

2.54

2.0'

>

^-.^

1-+

,

v

/>
N

'\£

X

-^ ^

„

A

,„

x

\

xx

s

-x

0.5-

0.0-1
0.0

'

'

I

0.2

'

'

'

'

I

0.4

'

'

'

'

I '

OS

'

'

'

I

0.8

'

'

'

'

I

1.0

'

'

'

'

I

'

'

1.2
Idx 230,7342 mix

'

'

I

1.4

'

'

'

'

I

1.6

'

'

'

'

I

1.8

'

'

'

' I

2.0

'—'

'

'

I

'

2.2

Figure 6. Cluster plot for the set of 196 WCX fractionated serum samples. The cluster
plot was generated hy the ClinProTools 2.0 software. The intensities of 2 peaks with
the most significant p-values (as determined by T-test/ANOVA) are plotted on 2 axes.
The more clustered the points are in relation to their group and the more separated the
clusters are from each other then the more significantly distinct the 2 groups are in
relation to each other. In this cluster plot the intensities of peak m/z 7341.66 are found
along the "x" axis, while the intensities of peak m/z 3051.22 along the "y" axis. The
control sample peaks are designated by "o" and the case sample peaks are designated by
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the 96 blinded samples, 43.3% were classified correctly with 40.6% of the cases correctly
classified and 45.8% of the controls correctly classified. The cross-validation of the
MAC sample set appeared to have a comparable sensitivity and specificity as the crossvalidation of the models from WCX samples; however this was not true for the
classification of the blinded sample sets. Table 7 shows the peaks utilized in the 5 peak
genetic algorithm model used for unknown classification (there were no significant
peaks, p-value <0.05, as determined by T-test/ANOVA). There appeared to be no
similarities between the peaks used for the tree analysis of the SELDI-TOF MS data and
the peaks used for the genetic algorithm analysis of the MALDI-TOF MS data. Figure 7
shows the cluster plot for the set of 112 samples using the two peaks with the most
significant p-values as determined by T-test/ANOVA.

3.4 Discussion
We have demonstrated a profiling scheme on an interesting and novel sample set,
which may prove helpful in finding biomarkers to predict a woman's risk of developing
breast cancer. The cases in this sample cohort were randomly chosen from a group of
women who developed invasive breast cancer during the first 10 years of follow-up and
who had stored serum available that had been drawn between 1 and 5 years prior to the
diagnosis of breast cancer. The controls were randomly selected, matched to cases on
age and length of follow-up, from the remaining participants in the SOF cohort who were
not diagnosed with breast cancer during the first 10 years of follow-up. Thus, this serum
cohort contains proteomic information of women that will develop invasive breast cancer
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Table 7. Masses used for the classification of 112 IMAC fractionated serum samples
using the 5 peak genetic algorithm model.

Mass (m/z)
5916.51
2549.66
2606.95
5336.53
1548.85

Weight (importance given in model)
0.13
0.14
0.12
0.07
0.01
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Figure 7. Cluster plot for the set of 112IMAC fractionated serum samples. The cluster
plot was generated by the ClinProTools 2.0 software. The intensities of 2 peaks with the
most significant p-values (as determined by T-test/ANOVA) are plotted on 2 axes. The
more clustered the points are in relation to their group and the more separated the clusters
are from each other then the more significantly distinct the 2 groups are in relation to each
other. In this cluster plot the intensities of peak m/z 6560.83 are found along the "x" axis,
while the intensities of peak m/z 1468.88 along the "y" axis. The control sample peaks are
designated by "o" and the case sample peaks are designated by "x".
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1-5 years into the future and how they may differ from women that will not develop
breast cancer in that same time frame.
The main success from Aim 1 is the validation of the scrape technique for the use
of sparing precious samples unnecessary freeze-thaw cycles. The results showed that
there was no significant difference in quality of data between scraping a frozen sample
and thawing the whole sample. A main concern for the scrape technique would be the
unequal distribution of proteins throughout the frozen sample, with a fractionation of
proteins based on biochemical properties and/or with a predominance of ice crystals at
the top of the frozen sample. The unequal distribution of proteins throughout the frozen
sample and the predominance of ice crystals on the top of the sample are especially
concerning for samples that are allowed to freeze slowly. Generally, slow freezing
causes large, non-uniform ice crystals to form and freeze concentrations to occur, where
solutes and protein molecules are pushed into non-frozen regions, producing a large
increase of solute and protein concentrations. The faster the freezing process the more
nucleation is promoted and the greater the number of ice crystals of smaller size that will
result, thus making the frozen sample more uniform (118). However, we seemed to have
avoided the problem of unequal distribution of proteins and solutes within the sample. If
the top of the tube to be scraped mainly contained "sample" that was composed of ice
crystals then we would have seen a very dilute amount of peptide/proteins in our SELDITOF MS spectra, if we saw anything at all. Additionally, as stated before there seemed
to be no significant changes between the spectra from the samples that were scraped first
and the same samples that were subsequently thawed and mixed. This technique also
illustrates the importance of storage and sample handling during the collection of
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samples. MALDI-TOF MS (18, 115) and SELDI-TOF MS are reproducible (50) as far as
instrumentation performance, however much thought into the standardization of protocols
must occur for this to be correct for the true comparison of sample groups. McLerran et
al found that initial discrimination, as seen by SELDI-TOF MS, between serum from
patients that have been diagnosed with benign prostatic hyperplasia and those diagnosed
prostate cancer may have been due to storage time variability between the two groups,
thus leading to a general bias in the sample analysis process (119).
In our study the initial modeling results from the scraped serum sample cohort
were promising; with MALDI-TOF MS ClinProTools 2.0 software generating models
with 100% recognition capability of the test set groups, cases and controls. SELDI-TOF
MS had an overall 82.15% recognition capability of the test set groups. However, the
cross-validation was less than ideal with the best SELDI-TOF MS regression tree
algorithm having an overall 74.6% recognition capability between groups. The best
MALDI-TOF MS genetic algorithm model was generated using the WCX fractionation
scheme with the initial 84 sample set and yielded an overall 71.1% recognition capability
between groups. This 7 peak genetic algorithm model proved to be over-fitted with the
84 sample set and yielded low external validation sensitivity and specificity. The genetic
algorithm model that performed the best in the external validation, with an overall
recognition capability of 61.2% between cases and controls, was the 5 peak model
generated from the 84 serum sample set. However, this model performed poorly when
used again to identify case and control status of 96 blinded samples (overall recognition
capability of 52.1%). Additionally, the SELDI-TOF MS data set was unable to correctly
classify the majority of the blinded sample set as determined by an independent lab.
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Interestingly, this epidemiology group also found that that the MALDI-TOF MS data was
more reproducible between duplicate samples than the SELDI-TOF MS data. This
analysis was performed using the peak finding and alignment algorithm from the PPC
procedure. Briefly, for each pair of replicates, the peaks were aligned and deemed
discordant or concordant peaks. If both spectra possess a peak at a specific point, then
that site has a concordant peak. However, if only one spectrum has a peak at a particular
sites and the other does not, then that site has a discordant peak. Thus, MALDI-TOF MS
data was found to have a lower percentage of discordant peaks than SELDI-TOF MS
data.
Overall, this is a very difficult sample set since we are asking the peptide/protein
profiles in the serum to predict the future, not the current state of the women at blood
draw. Breast cancer is a clinically heterogeneous disease with histological type, grade,
tumor size, lymph node involvement, ER and HER-2 receptor status all influencing
prognosis and response to available therapies (120). Thus, to provide better risk
assessment models we may need to interrogate the sample sets with more specific
guidelines. In this study age was controlled for as all patients were age-matched and
postmenopausal, both characteristics which are risk factors for breast cancer.
Additionally, two other main variables were already taken out of the equation. AfricanAmerican women were excluded during the osteoporotic fracture study and thus were
unavailable for our cohort. Additionally, women that were on hormone replacement
therapies (HRT) were excluded from the selection process for the breast cancer prediction
study. Race is a known risk factor for developing breast cancer, as African American and
Hispanic women are more prone to present with advanced breast cancer than Caucasian
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women. This is a complex issue involving both biological differences and certain
socioeconomic conditions, such as access to the same quality health care and screening
(79). HRT, especially in the long term, has also been recently implicated as a risk factor
for breast cancer (121). Additionally, women that are postmenopausal and on HRT
would more than likely have distinct peptide/protein secretion patterns compared to
women that are postmenopausal and do not have stimulation of estrogen signaling
pathways through HRT. Other variables that may be minimized to increase sensitivity
and specificity of detecting a particular woman's risk of developing breast cancer is
stratifying samples based on their BRCA and HER2 status. As discussed in Chapter I,
mutations in the BRCA genes are known risk factors for breast cancer development and
the presence of HER2 receptor fragments in serum has been shown to directly correlate to
the aggressive nature of the breast cancer and its subsequent treatment. By stratifying
samples according to these and other variables (which will be further discussed in the
future directions section of Chapter VI) we may begin to focus more on biomarkers
related to breast cancer risk then on biological variables compounded between various
patients.
One facet hampering the discovery of breast cancer biomarkers is the overall
complexity and large dynamic range of the blood proteome and the relatively low
abundance of these cancer biomarkers in the blood as compared to other proteins. For
example, early-stage tumors might arise within a tissue volume of less than 0.1 mL, thus
making the dilution factor of the tumor-generated biomarkers about 50,000 (assuming
that the biomarkers attributed to this tumor are uniformly dispersed in the 5,000mL total
blood volume) (56). In this study there may not even be an early-stage tumor in the

classical sense, but rather a condition within the breast tissue that will promote the
growth of said tumor. One approach that other researchers have taken is to work with
proximal fluids that are regionally closer to the tumor such as nipple aspirate fluid (NAF)
and proximal or tumor breast tissue (91, 122) in hopes of later being able to detect, or
correlate, the discovered biomarkers in the blood for patient screening. However, for our
study, in which a valuable and interesting cohort of serum is already available, and for
individuals that are interested in discovery of biomarkers in the same fluid type as will
later be used for patient screening, reducing the complexity of the serum proteome using
various fractionation techniques is a pre-requisite. There are several fractionation
techniques available to further dissect the proteome such as the depletion of the top most
abundant proteins, lectin-capture strategies for the targeted capture of glycoproteins
(since glycan changes in proteins have been linked to cancer disease states (71, 123,
124)) and tandem fractionation techniques. These extensive fractionation techniques are
more readily adaptable to the MALDI platform, which typically employs front-end
fractionation with paramagnetic beads conjugated to various chromatography chemistries
(either chemical or biological) and would allow in-tandem use of these bead types in an
automated manner. However, as discussed in Chapter I, the SELDI-TOF MS utilizes flat
chips coated with different surface chemistries that have smaller surface areas than the
paramagnetic particles and thus lead to less efficient fractionation.
Another problem facing researchers profiling for breast cancer biomarkers is that
differential spectra patterns are not complete for validation purposes without the
knowledge of the identity of the peptides/proteins behind the peaks. As discussed in
Chapter I, the linear TOF mode typically utilized with the SELDI and MALDI platforms

(as it was in this Aim), does not yield information about the identity of peptides/protems.
Thus, profiling in the range of reflectron mode, which has the capability on the MALDITOF/TOF for tandem-MS identification of peaks, may prove useful to ascertain
additional, complementary information of a specific sample set. A caveat to this
complementary technique is that endogenous peptides/proteins found in the range of the
reflectron mode are sparse and not robust enough for useful, informative profiling. Thus,
this problem will be addressed in the next Aim.
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CHAPTER IV
AIM II. INCREASING THE EFFECTIVENESS OF THE MALDI-TOF/TOF FOR
ANALYSIS OF LARGE MOLECULAR WEIGHT PROTEINS

4.1 Introduction
Biomarker discovery is an ever evolving research area spurred by advances in
technology and improvements in clinical study design and bioinforrnatics strategies
(125). Typically, in order to reduce the sample complexity of high protein concentration
fluids like serum and plasma, chemical affinity capture using beads or chip surfaces has
been employed along with time-of-flight mass spectrometry to generate comparative
spectral peak profiles. These approaches, also termed expression profiling, can be
automated for relatively high throughput and generally consume small amounts of
clinical sample (44, 45). Additionally, expression profiling can be reproducible and
portable across multiple laboratories, especially when rigorous study design and sample
handling are combined with carefully controlled instrument calibration, automated
sample preparation, and supervised bioinformatic data analysis (47, 50, 62, 126).
Nevertheless, the difficulty in determining the protein identities of potential biomarker
peaks, and a concern that the sensitivity and dynamic range of prevalent proteins in
serum or plasma prohibits identification of proteins associated with disease continues to
hamper these expression profiling approaches (48, 49,127). Recently, however, the
development of TOF/TOF technology has brought with it the capability of protein
identification (4,000 m/z or less) through the generation of fragment ions and subsequent
homology searching (19).
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Most MALDI-TOF based expression profiling studies only examine endogenous
low molecular mass constituents (1-20 kDa) of serum or plasma. Yet most proteins
captured on a particular surface or bead are not effectively resolved in the MALDI
instruments used due to their larger sizes (>20 kDa). In this regards, we report a workflow of magnetic bead-based chromatography surfaces and immobilized trypsin to
generate peptide profiles reflective of the broader range of proteins captured in front-end
purification and fractionation strategies applied to complex clinical fluids like serum or
plasma. This is essentially a "bottom-up" approach (43), but tailored for the MALDITOF as the generation of tryptic peptides increases the breadth of proteins detected and
provides peak masses ideal for LIFT-MALDI-TOF/TOF sequencing identification.
Using pooled human serum samples, two different workflow combinations of
chromatography beads with the immobilized trypsin beads are described. We found that
the bead-based trypsinization method was highly reproducible and efficient in digesting
large serum protein fractions at short incubation times, and that the resulting peptides
were readily able to be identified by LIFT-MALDI-TOF/TOF. Representative lists of
proteins present in a pooled healthy serum sample are presented. Additionally, as a
proof-of-concept for clinical application, the method was used in two serum profiling
studies. One such study utilizes the aforementioned SOF sample cohort from Aim I. A
separate serum study has the goal of detecting differences between individuals diagnosed
with benign prostatic hyperplasia (BPH) and individuals diagnosed with prostate cancer
(PCa). Similar to the SOF samples, which are designed to assist in the prediction of a
woman's breast cancer risk years into the future, the question posed by the BPH/PCa
sample set is also very difficult to answer. As discussed in more detail in the first
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chapter, prostate specific antigen (PSA) is the current biomarker used in the diagnosis of
PCa. Unfortunately, it is not a specific biomarker for prostate cancer since its serum
level is affected by many other factors such as inflammation, ejaculation and'BPH. It has
been estimated that two out of three men with abnormal results on routine PSA screening
will not have prostate cancer (108). Thus, a diagnosis of BPH or PCa is often mistaken
for the other, resulting in men being exposed to unnecessary medical intervention and
anxiety. The PSA levels of the men in this study fall between 2 and 10 ng/mL, which is a
particularly grey area for doctors, as these levels are considered elevated by today's
standards, but are not high enough to for a confident PCa diagnosis. Using these two
sample cohorts we demonstrate the reproducibility of the trypsin bead method with
clinical samples and showcase typical workflow strategies that may be applied for the
purpose of biomarker identification.

4.2 Materials and Methods
Serum Samples
A pooled human serum sample collected from over 360 donors (50) was used for
method development procedures.
For the proof-of-concept tryptic analysis of clinical serum samples, pools of each
group were generated. For the prostate cancer study, BPH and PCa confirmed-diagnosis
patients with elevated levels of PSA (range 2-10 ng/mL) were pooled in the following
manner: 10 pools for BPH and 10 pools for PCA with each pool containing 6 samples.
For the SOF samples, the samples were pooled in the following manner: 12 pools for
control and 12 pools for cancer with each pool containing 8 samples.
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Magnetic bead-based fractionation
Initial fractionation of serum was done with either MB-WCX (weak cationic
exchange) or MB-WAX (weak anionic exchange) paramagnetic beads essentially as
described by the manufacturer's protocols (Bruker Daltonics, Bremen, Germany).
Briefly, 20 uL of serum was mixed with 40 uL of binding solution (the WAX protocol
utilized a pH 5 binding solution) supplied with the beads and 20 uL MB-WCX or MBWAX beads (note that the WAX beads were equilibrated with activation solution prior to
this step) for 15 minutes (mixing every 5 minutes). A magnetic bead separator was used
to concentrate the beads and for the wash/rinse processes. Unbound serum proteins were
removed and the beads were washed 3 times with 100 \xL of MB-WCX or MB-WAX
wash solution. Bound serum proteins were eluted with 10 uL of MB-WCX or MB-WAX
elution solution supplied by the manufacturer. Finally, 8 uL of HPLC water and 1 uL of
MB-WCX stabilization solution were added to the WCX eluate (this step was added
during method development and it is stated in the Results when it was incorporated into
the protocol), and 11 uL of MB-WCX elution was added to the WAX eluate, to give a
final sample pH of 7.5-8.5.
For reduction and alkylation, 8 ug of the fractionated samples were reduced with
8 mM DTT in 25 mM ammonium bicarbonate (pH 7.8) at 56 °C for one hour (24 uL total
volume). The reduced samples were then alkylated with 17 mM iodoacetamide in 20
mM ammonium bicarbonate total solution (29 uL total volume).

Liquid and magnetic bead-based trypsinization
Sequencing grade trypsin (Roche, Basel, Switzerland) was re-suspended in 50
mM ammonium bicarbonate / 4% acetonitrile (ACN) to a final concentration of 40
ng/uL. For each reaction in the comparative soluble trypsin study, 200 ng of trypsin was
added to the reduced and alkylated samples yielding a 40:1 serum protein to trypsin ratio
(other ratios were utilized and are indicated in the figure legends) and incubated for 30
minutes and overnight at 37°C. Paramagnetic immobilized trypsin, EnzyBeads™
Trypsine (Agro-Bio, La Ferte Saint Aubin, France), were initially washed with 25 mM
ammonium bicarbonate (pH 7.8). Twenty microliters of reduced/alkylated samples were
trypsinized with 25 uL beads as described by the manufacturer for 30 min. at 37 °C. This
is the equivalent of 3 units of enzyme activity per reaction, with one unit defined as the
amount of EnzyBeads Trypsine required to hydrolyze lumole of chromogenic substrate
in one minute at 25°C. Digested peptides were removed from the beads that were held in
place by a magnetic separator.

Sample clean-up and concentration
Initially, ZipTipC18 cartridges (Millipore, Billerica, MA) were used to clean-up
and concentrate the digested sample. The 10 uL of trypsinized sample was acidified with
1 u.L of 1% TFA and allowed to bind to the CI8 cartridge. The CI8 cartridge was
washed with 0.1% TFA and the sample was eluted in 5 uL of 50% ACN. Later, this
method was adapted so that tryptic peptides were re-captured and concentrated with
Hydrophobic Interaction Chromatography (HIC)-C18 paramagnetic beads (Bruker
Daltonics, Bremen, Germany) as follows. Twenty microliters of the tryptic digest was
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incubated with 10 uL HIC-C18 beads and 40 uL HIC-C18 binding buffer (or were noted
with HIC-C8 beads and binding buffer). Bound peptides were washed with the
manufacturer's wash solution and eluted in 10 \\L of 50% ACN as per the manufacturer's
specifications.

MALDI-TOF/TOF
Two microliters of the tryptic peptide sample after HIC-C18 clean-up was mixed
with 4 |iL of CHCA matrix solution (4 mL ethanol, 2 mL acetone, 0.008 g CHCA and
0.1% TFA) and 1 uL of the mixture was manually spotted (or robotically spotted by the
ClinProt robot where indicated) onto an AnchorChip plate using a dried droplet spotting
technique. Also, where noted, a reverse thin-layer spotting technique was used where 1
uL of the tryptic peptide sample was overlaid with 2 uL of CHCA matrix. The spotting
techniques found ideal for untrypsinized samples were as follows: For untrypsinized
WCX fractionated samples, the samples were mixed 1:15 with matrix and for
untrypsinized WAX fractionated samples, the samples were spotted using the thin-layer
method (1 uL sample overlaid with 2 uL matrix). Additionally, where noted, a matrix
formulation (ACN, Acetone, 0.1% TFA, CHCA) was used for LIFT-MALDI-TOF/TOF
analysis.
UltraFlexI and UltraFlex III MALDI-TOF/TOF instruments (Bruker Daltonics)
were used to analyze peptides in linear and reflectron modes. The resulting spectra were
processed using FlexAnalysis and ClinProTools 2.0 software (Bruker Daltonics). The
ClinProt software baseline subtracted and normalized the spectra using total ion current
and an m/z starting point of 800. A k-nearest neighbor genetic algorithm contained in

76
this software suite was used to generate prediction models to classify the groups
analyzed. Twenty percent of the samples were left out of the model generation process
and used to cross-validate the model within the software. Peaks of interest were further
analyzed on a separate platform using the LIFT function of a MALDI-TOF/TOF
Ultraflex III instrument. The BioTools software and the MASCOT search engine
(www.matrixscience.com) were used to compare the TOF/TOF spectra against primary
sequence databases (SwissProt) to determine peptide sequence identities (unless
otherwise noted the search criteria is as follows: carbamidomethyl and oxidation
modifications; 100 ppm mass tolerance MS; 0.5 Da MS/MS tolerance).

4.3 Results
Integrating trypsin digestion into a bead-based affinity fractionation workflow
The initial goal of this study was to integrate a trypsin digestion step following
standard chemical affinity fractionation of serum samples, the latter being a common
(off-line) first step in many serum/plasma proteomic profiling studies (50, 62, 125, 128,
129). We hypothesized that inclusion of the trypsin digestion would facilitate more direct
protein identifications of high mass novel proteins by generating peptides in an optimal
mass range for detection and sequence identification by MALDI-TOF instruments (<
4000 m/z). This approach could also broaden the dynamic concentration and mass range
of detected proteins.
The common approach to digestion of complex protein samples like serum is to
perform an in-solution digest with added, soluble trypsin. A shortcoming of trypsin insolution protocols is long reaction times (4-16 hours) and the autocatalytic activity of the
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trypsin may create contaminating trypsin cleavage products. One solution to this has
been to use trypsin immobilized on a solid support, which acts to stabilize the trypsin and
greatly increase the concentration of trypsin that can interact with substrate leading to a
more rapid digestion (31). For these studies, we utilized a newly developed trypsin
product immobilized on paramagnetic beads, EnzyBeads™ Trypsine, which can quickly
and efficiently remove the trypsin from the digestion reaction by placing the reaction tube
against a magnet.
We first assessed the importance of initially reducing and alkylating the sample
before the trypsinization step. We used the reducing agent DTT (dithiothreitol) and the
alkylating agent iodoacetamide. DTT reduces disulfide bonds and maintains monothiols
in a reduced state. After reduction, the sulfhydryls are then reacted with iodoacetamide
to prevent reformation of disulfide linkages in a random manner (130). Figure 8 clearly
shows that for these secreted proteins, which have disulfide bonds, reduction and
alkylation improves the digestion efficiency. Thus, the reduction/alkylation step was
included in the trypsin digestion protocol.
Another observation that was made during the development phase of the trypsin
digestion workflow pertained to the MALDI-TOF spectra. It was noted that the signal
intensity was weak and that the matrix/sample spots on the target plate were not uniform
(i.e. there was a propensity towards "hot-spot" formation), regardless of the spotting
technique (i.e. dried droplet or reverse thin-layer technique). It is known that certain
reagents negatively effect matrix crystallization and hinder ionization of the sample (11).
Thus, we first investigated whether ZipTipsCl 8 would improve the spectra and the
uniformity of the spot on the MALDI AnchorChip plate. These ZipTips have CI 8 (18
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Undigested
Control

40ng/uL
Trypsin

10ng/uL
Trypsin

40ng/uL
Trypsin

10ng/uL
Trypsin

Figure 8. Improved trypsinization efficiency of WCX fractionated serum proteins
after reduction and alkylation. A Biorad Criterion Tris-HCl 8-16% is shown. The
lanes labeled 40 ng/uL of trypsin utilized a 1:30 soluble trypsin to protein ratio,
while the lanes labeled 10 ng/uL of trypsin utilized a 1:120 soluble trypsin to
protein ratio. Three micrograms of protein from each condition was loaded on the
gel. The gel was silver stained using a Biorad reagent.
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carbons) derivatized surfaces that bind peptides in aqueous solutions through
hydrophobic interactions, allowing small interfering molecules (i.e.salts, buffers, and
chaotropes) to be washed off. The peptides are then eluted with various organic solvents
that are compatible with the MALDI-TOF technique (11). In Figure 9 the improvement
in spectra quality in a sample with clean-up as compared to a sample without clean-up is
shown. Hence, a final clean-up and concentration step was added into the trypsin digest
workflow.
Since, ZipTips are labor-intensive and would later be difficult to accommodate to
an automated workflow, we investigated whether magnetic beads with immobilized
carbons could substitute. We found no significant difference between the ZipTipC18 and
the CI 8 treated magnetic beads (Bruker Daltonics). However, there are other
hydrophobic interaction chromatography (HIC) magnetic beads available as well. In fact,
various papers published by Bruker utilize the C8 magnetic bead-type for capture of
peptides (131). Thus, we compared which bead type yielded the best results in terms of
the capture and concentration of our trypsinized peptides. Simultaneously, we also
assessed whether we would gain more peptide information through the sequential elution
of the HIC-magnetic beads. Figure 10 shows the sequential elutions off of the CI 8 HICmagnetic bead versus the sequential elutions off of the C8 HIC-magnetic bead. When
comparing the initial elution (which yielded the most robust spectra), using the
FlexAnalysis software, for both bead types, the spectra of tryptic peptides after CI 8
purification yielded 41 peaks between m/z 1000 and 4000, while the spectra of tryptic
peptides after C8 purification yielded only 20 peaks between m/z 1000 and 4000. This
mass range is most ideal for sequence identification using LIFT-MALDI-TOF/TOF and
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Figure 9. Effect of ZipTipC 18 clean-up on MALDI-TOF spectra of WCX
fractionated samples tryspinized with immobilized trypsin beads. The top panel
showcases a sample that was concentrated and cleaned-up using ZipTipC 18, while
the bottom panel shows the same tryptic digest not processed with ZipTipC 18.
Samples were processed using MB-WCX fractionation and immobilized-bead
trypsinization, spotted on an AnchorChip plate using a reverse thin-layer method
and analyzed on the MALDI-TOF Ultraflex I in reflectron mode as stated in
Materials and Methods.
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2500
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Figure 10. Comparison C8 and CI 8 HIC-magnetic bead sequential elutions. The panel on the
left shows sequential elutions (15, 30 and 70% of ACN) off of the MB-C8 bead of tryptic
peptides after MB-WCX fractionation and immobilized-trypsin bead digestion. The panel on
the right shows sequential elutions off of the MB-C18 bead of tryptic peptides derived by the
same protocol. Samples were analyzed on the MALDI-TOF Ultrafiex III in reflectron mode
after being spotted (1:5 ratio of sample to CHCA matrix) by the ClinProt robot on an
AnchorChip plate as described in Material and Methods.
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Figure 11. Comparison of CI 8 and C8 HIC bead 15% acetonitrile elutions. (A) The top
panel shows a 15% ACN elution off of MB-C18 beads, while the bottom panel shows a
15% ACN elution off of MB-C8. (B) Peptides in the lower mass range (1000 - 1400 m/z)
are seen captured by the CI8 bead type (denoted by arrows in the top panel), but are lost
by the C8 bead type (bottom panel). Samples were analyzed on the MALDI-TOF
Ultraflex III in reflectron mode as stated in Figure 9 and Materials and Methods.
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also discounts most matrix peaks. As shown in Figure 11, it is clear that there are certain
peptides that are not captured by the C8 bead, but are captured by the CI 8 bead. This is
expected as peptides are small and polar and thus need more carbons for successful
binding, while larger proteins have more hydrophobic areas and thus will bind
tenaciously to the available carbons (i.e. C4 or C8) (11). Therefore, we decided that we
would continue on with the CI 8-HIC magnetic bead type. Additionally, during the
course of this comparison, we found that the reverse thin-layer method, which we had
utilized after the ZipTipC18 purification, would be impractical for an automated
approach and also yielded less compact and uniform spots when compared to the dried
droplet method (as is performed by the ClinProt robot). The dried droplet method also
yielded more resilient spots that could withstand larger quantities of laser shots, which is
advantageous for both profiling and LIFT identification.
During the optimization of the immobilized-trypsin bead method, we also
determined the necessary protein concentration and pH of the fractionated sample for
ideal trypsin efficiency and spectra quality. The SDS gel and spectra in Figure 12
illustrates that 8 ug is an optimal concentration for efficient trypsin digestion with
immobilized-trypsin beads. Additionally, we found that digesting 20 uL of the digested
sample and diluting this sample 1:3 with matrix minimized contaminating matrix peaks,
while still producing robust tryptic spectra on the MALDI-TOF instrument. Using these
specifications, 82 peaks were counted, when excluding matrix peaks. This approach
works well with the CI 8 beads since, unlike ZipTipsC18, which concentrate 10 uL of
digested sample into 5 uL of eluted sample; CI8 HIC-magnetic beads concentrate 20 \iL
of digested sample into 10 uL of eluted sample. The elution buffer is a volatile 50%
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Figure 12. Concentration determination for ideal trypsinization using immobilized-trypsin
beads. The gel shown is a NuPage 4-12% Bis-Tris with MES from Invitrogen. WCX
fractionated sample was added varying amounts into reduction/alkylation and
trypsinization reactions to generate the most efficient digestion. Lane 1: Undigested serum
sample after WCX fractionation. Lane 2: 15.5 ug of sample reduced/alkylated and 5.2 ug
was digested with immobilized-trypsin beads. Lane 3: 15.5 ug of sample
reduced/alkylated and 10.4 ug was digested with immobilized-trypsin beads. Lane 4: 8 ug
of sample reduced/alkylated and 5.5 ug (20 uL of reduced/alkylated sample) was digested
with immobilized-trypsin beads. Lane 5: 24 ug of sample reduced/alkylated and 15.5 ug
was digested with immobilized-trypsin beads. Equivalent to 5 ug of protein is loaded in
each well. Gel was stained with a silver stain from Biorad. The lower panel shows the
distribution of peaks from the best digest (Lane 4) and the worst digest (Lane 5).
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acetonitrile solution, thus an elution with more volume allows for easier and more
efficient handling that may be adapted to an automated workflow.
Trypsin works optimally at a pH between 7 and 9, however Figure 13 also shows
that adjusting the pH to ~8 prior to reduction and alkylation (not just at the point of
trypsin digestion) improves the digestion efficiency. This is important to know because
each WCX fractionation preparation may vary slightly in terms of protein concentration,
thus one would be adding more of the basic elution buffer (pH ~11) into the reduction
reaction if the preparation had a lower protein concentration. These small variations turn
out to be enough to alter the reduction reaction solution pH so that it affects digestion
efficiency. Using the specification listed thus far (Figure 14), we found that this trypsin
bead based method yielded on average a total of 85 peaks, discounting the matrix peaks.
This is compared to 20 peaks that are seen on average with undigested WCX fractionated
serum in the ideal range of reflectron mode for peptide identification. This clearly shows
that trypsinizing the sample prior to MS analysis yields more peptides in the range of
optimal MALDI-TOF/TOF analysis and thus may lead to direct identification of peptides
via LIFT.

Comparison of free trypsin and immobilized trypsin digestions
We then compared the efficiency of the trypsin bead digestion of serum proteins
with a standard soluble trypsin protocol as described in Materials and Methods. Pooled
healthy serum was incubated with MB-WCX paramagnetic beads to reduce sample
complexity, and the eluate proteins were used in subsequent digestions using either
immobilized-trypsin beads or soluble trypsin. These tryptic eluates were applied to CI8,
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Figure 13. Effect of pH on ideal trypsinization using immobilized-trypsin beads. The
gel shown is a NuPage 4-12% Bis-Tris with MES from Invitrogen. Lane 1: Undigested
serum sample after WCX fractionation. Lane 2: 8 fig digested of serum sample after
WCX fractionation and 20 uL (~5.5ug) digested with immobilized-trypsin beads. Lane
3: Same as Lane 2 with the exception that after WCX fractionation the pH of the
sample was adjusted to ~8. Lane 4: Increasing the amount of trypsin beads (from 25 uL
to 35 uL) to improve digestion efficiency. Lane 5: Digesting less reduced/alkylated
sample (-2.75 ug) to improve digestion efficiency.
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Figure 14. Workflow designed for immobilized-trypsin beads for peptide
profiling using MALDI-TOF/TOF. Serum/Plasma samples are first fractionated
by a chromatography-based magnetic bead (i.e. WCX or WAX). The pH of the
sample is adjusted to ~ 8 and 8 (xg of the fractionated sample is reduced and
alkylated (final reaction volume is 29 uL). Twenty microliters of the
reduced/alkylated sample is added to 25uL of immobilized-trypsin beads and
allowed to incubate at 37°C for 30 minutes. The total tryptic digest is then
removed from the beads and added directly to a MB-C18 cleanup/concentration reaction. Two microliters of the CI 8 captured sample is then
mixed with 4 uL CHCA matrix of which 1 uL is spotted on an AnchorChip
plate and analyzed in reflectron mode of the MALDI-TOF/TOF Ultraflex III.
Peaks of interest are subjected to MS/MS directly off of the profiled spot via the
LIFT mode of the MALDI-TOF/TOF Ultrafelx HI. MS/MS is spectra is
analyzed and identified using the BioTools software from Bruker along with the
MASCOT search engine.
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and then spotted 1:3 with CHCA matrix for MALDI-TOF analysis. Representative
spectra from the three tryptic digests (digested with trypsin beads for 30 minutes and
digested with soluble trypsin for 30 min and overnight) along with the undigested MBWCX eluate are shown in reflectron mode in Figure 15 and in linear mode in Figure 16.
The trypsin beads were clearly more efficient for the conditions utilized and produced a
greater number of lower mass peptides as compared to the standard soluble trypsin.
However, the drawback with the trypsin-bound beads is that, as with most
chromatography-based procedures, there is some extent of sample binding to the solidsupport (it is estimated that -1/6 of the sample binds to the solid-support). In terms of
the soluble trypsin, it was noted that there were minimal differences between a 4 hour
incubation time and an overnight incubation with the soluble trypsin. This is consistent
with some trypsin digest protocols calling for the addition of more trypsin into the
digestion reaction after the 4 hour mark or adding a higher starting concentration of
trypsin to increase digestion efficiency (132, 133). As seen in Figure 17, there is already
a certain level of contamination by trypsin peaks in the spectra and thus adding more
trypsin to improve digestion efficiency would exacerbate this problem.

Reproducibility of immobilized trypsin protocol
The reproducibility of the MB-WCX and trypsin bead digest workflow described
in Materials and Methods was applied to multiple aliquots of serum to determine the
reproducibility of the technique. Six aliquots of the same serum samples were
independently processed and spotted in triplicate for MALDI-TOF profiling. As shown
in Figure 18, there was a high degree of reproducibility across the spectra, which is also
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Figure 15. Reflectron mode MALDI-TOF comparison of WCX fractionated samples
untrypsinized and trypsinized by either soluble trypsin or immobilized-trypsin.
Samples were processed with 25 uL of trypsin beads for 30 minutes or with soluble
trypsin (1:40 sample-to-trypsin ratio) for 30 minutes or overnight as described in
Materials and Methods. The tryptic peptides were captured by MB-C18 beads from
Bruker and the eluted peptides were mixed 1:3 with CHCA matrix. One microliter of
the sample/matrix mixture was spotted on an AnchorChip plate and analyzed using
the reflectron mode of the MALDI-TOF UltraFlex EL The spectra were compared
using the FlexAnalysis 2.0 software from Bruker.
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Figure 16. Linear mode MALDI-TOF comparison of WCX fractionated
samples untrypsinized and trypsinized by either soluble trypsin or immobilizedtrypsin. Samples were processed with 25 uL of trypsin beads for 30 minutes or
with soluble trypsin (1:40 sample-to-trypsin ratio) for 30 minutes or overnight
as described in Materials and Methods. The tryptic peptides were captured by
MB-C18 beads from Bruker and the eluted peptides were mixed 1:3 with
CHCA matrix. One microliter of the sample/matrix mixture was spotted on an
AnchorChip plate and analyzed using the linear mode of the MALDI-TOF
UltraFlex III. The spectra were compared using the FlexAnalysis 2.0 software
from Bruker.
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Figure 17. Example of trypsin contaminant peaks in soluble trypsin digests. The
top panel shows representative peaks seen when the Roche trypsin is spotted on an
AnchorChip plate with CHCA matrix. The bottom panel is a soluble, overnight
trypsin digest of WCX fractionated serum. The arrows point to peaks found in the
trypsin only spectra that are contaminating the soluble trypsin digest spectra.
Samples were analyzed using the refiectron mode of the MALDI-TOF UltraFlex III
and the resulting spectra were compared using the FlexAnalysis 2.0 software from
Bruker.
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Figure 18. Reproducibility of immobilized trypsin bead method. Six aliquots of the same
pooled serum sample were processed using the WCX fractionation and immobilized-trypsin
digestion method as described in Figure 14 and Materials and Methods. Two microliters of
each of the digested samples was mixed with 4 uL CHCA matrix and 1 \xL of this mixture
was spotted on an AnchorChip plate in triplicate. Spectra were generated in reflectron mode
of the MALDI-TOF UltraFlex III and analyzed using ClinProTools 2.0. The top panel
shows a heat map of all the samples in triplicate in the 900-3500 m/z range. The bottom
panel shows the peak distribution of each individual sample in triplicate in the 900-3500 m/z
range.

Table 8. Reproducibility of immobilized trypsin bead method as seen by the
coefficient of variance (CV) of twelve representative peaks.
Manual run
Mass

Intensity

CV (%)

1124.81

5.33

8.41

1585.99

10.15

7.14

1667.97

8.32

4.96

1670.92

19.48

11.02

1694.93

6.75

13.65

1717.04

10.8

9.30

1885.02

39.18

8.88

1932.26

13.92

5.60

2017.31

154.16

11.34

2383.24

28.00

11.18

2425.80

46.22

11.49

2636.63

16.65

7.49
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illustrated by the low coefficient of variance seen with twelve representative peak
intensities (Table 8).

Bead-based Workflow with MALDI-TOF/TOF Identification of Tryptic Peptides
The WCX fractionation workflow was used in combination with trypsin beads for
LIFT-MALDI-TOF/TOF sequencing identification of selected m/z peaks. Identified
peptides are summarized in Table 9 and Figure 19 shows LIFT analysis for a
representative peak. As expected, the protein identities represent common serum protein
components from across all native mass ranges. Peaks with relatively low signal-to-noise
ratio (S/N) values could be identified, in general, depending on whether any prevalent
adjacent or co-migrating peaks were present to confound the LIFT fragmentation spectra.
During this time we also examined two matrix formulations (a CHCA formulation in an
EtOH/acetone solution and a CHCA formulation in an acetonitrile solution) and their
effectiveness during the LIFT technique. Although both of these matrix formulations did
not differ in spectra quality and LIFT results, it was found that the CHCA formulation in
an acetonitrile solution was more resilient to the high laser energy needed for parent ion
fragmentation and thus more shots per spot were able to be collected. However, this
matrix would be difficult for large-scale spotting, either performed manually or
robotically, due to the high content of acetonitrile, which is difficult to handle. Thus, the
CHCA formulation used for the reproducibility study (EtOH/acetone based) was retained
in the workflow for profiling and for direct LIFT application from the original spots used
in profiling. Conversely, if sample quantities are limited and the LIFT procedure needs
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Table 9. Peptides from immobilized-trypsin digest of WCX fractionated workflow
identified by LIFT-MALDI-TOF/TOF.
1003.66
1030.63
1088.62

Accession
#
P01042
P01042
P00747

1124.71

P04196

1158.71

P01042

1184.70

P02775

1215.76

P06727

1283.69

P02647

1301.77

P02647

1314.81

P04004

1342.77

P02768

1352.79

P06727

1561.87

P00734

1623.83

P02768

1640.09

P02768

1724.99

P02775

1875.05
1884.06

P01042
P00734

1898.12

P02775

2012.17

P00734

2016.24

P02765

2042.09

P02671

2081.20

P02765

2126.16

P00747

2381.39

000512

2441.32

P01042

2585.33

P02768

2599.38

P02768

2778.59

P02768

2815.52

P00751

Mass

Peptide
Identity
Kininogen-1
Kininogen-1
Plasminogen
Histidine-rich
glycoprotein
Kininogen-1
Platelet basic
protein
Apolipoprotein
A-IV.
Apolipoprotein
A-I
Apolipoprotein
A-I
Vitronectin
Serum
albumin
Apolipoprotein
A-IV
Prothrombin
Serum
albumin
Serum
albumin
Platelet basic
protein
Kininogen-1
Prothrombin
Platelet basic
protein
Prothrombin
Alpha-2-HSglycoprotein
Fibrinogen
alpha chain
Alpha-2-HSglycoprotein
Plasminogen
B-cell
lymphoma 9
protein
Kininogen-1
Serum
albumin
Serum
albumin
Serum
albumin
Complement
factor B

27
44
32

Expect
value
0.02
0.0014
0.029

R.QWAGLNFR.I
K.YFIDFVAR.E
R.WELCDIPR.C

42

0.0011

R.DGYLFQLLR.I

44

0.0012

K.KYFIDFVAR.E

49

0.00037

R.KICLDPDAPR.I

62

1.6e-05

K.ALVQQMEQLR.Q

34

0.014

K.WQEEMELYR.Q

33

0.015

R.THLAPYSDELR.Q

50

0.00023

R.RVDTVDPPYPR.S

67

6.2e-06

K.AVMDDFAAFVEK.C

32

0.015

R.RVEPYGENFNK.A

68

4.8e-06

R.TATSEYQTFFNPR.T

46

0.00084

K.DVFLGMFLYEYAR.R

66

6.9e-07

K.KVPQVSTPTLVEVSR.N

105

7.5e-10

K.GKEESLDSDLYAELR.C

76
83

6.8e-07
1.2e-07

K.YNSQNQSNNQFVLYR.I
R.TFGSGEADCGLRPLFEK.K

99

2.4e-09

K.GTHCNQVEVIATLKDGR.K

63

9.8e-06

R.TFGSGEADCGLRPLFEKK.S

115

2.5e-ll

R.TWQPSVGAAAGPWPPCPGR.I

92

1.7e-08

K.QFTSSTSYNRGDSTFESK.S

83

le-07

R.HTFMGWSLGSPSGEVSHPR.K

74

8.6e-07

R.ATTVTGTPCQDWAAQEPHR.H

34

0.005

K.KPEGPIQAMMAQSQSLGKGPGP
R.T + Oxidation (M)

93

l.le-08

75

6. le-07

72

1.2e-06

32

0.0085

71

l.le-06

Score

Peptide

K.SLWNGDTGECTDNAYIDIQLR.I
K.VHTECCHGDLLECADDRADLAK
.Y
K.QNCELFEQLGEYKFQNALLVR.Y
R.LVRPEVDVMCTAFHDNEETFLK
K.Y
R.LLQEGQALEYVCPSGFYPYPVQT
R.T
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Figure 19. LIFT analysis of representative peak m/z 2016.24. The top panel shows the
fragmented spectrum as is it is seen using FlexAnalysis. This MS/MS spectrum is then
imported into the BioTools software program and MASCOT is used to search a selected
database (SwissProt in this case) with the following criteria: carbamidomethyl and
oxidation modifications; 100 ppm mass tolerance MS; 0.5 Da MS/MS tolerance.
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to be repeated or performed on re-spotted sample, we recommend using the acetronitrilebased CHCA matrix.
The front-end bead fractionation may be varied for a more comprehensive sample
analysis. Another front-end fractionation step easily adapted to this typsinization
technique utilizes MB-WAX beads. Examples of the types of tryptic peptides generated
from MB-WAX fractionated samples are listed in Table 10. There are some shared
commonalities (i.e. apolipoprotein AIV, prothrombin, vitronectin and alpha-2HSglycoprotein), and there are also several differences between these WAX front-end
fractionated tryptic peptides identified by LIFT-MALDI-TOF/TOF and those that were
generated from WCX fractionated serum. For instance, the WCX fractionation workflow
has such proteins as kininogen, histidine-rich glycoprotein, platelet-basic protein and Bcell lymphoma 9 protein that among others are not seen in the WAX fractionation
workflow spectra. Vice versa, haptoglobin, ceruloplasmin, apolipoprotein CIII, and
complement C4-A are amongst the proteins represented in the WAX workflow protocol
that are not seen in the WCX workflow spectra. Additionally, the predominant protein in
the WCX workflow is serum albumin, while the predominant protein in the WAX
fractionated sample is inter-alpha-trypsin inhibitor. This is one reason why the pH 5.0
WAX binding buffer was utilized as specified in Materials and Methods. The average
serum albumin pi is ~5.2 (main pi isoforms range from 4.7 to 5.6) (134), thus at the pH
of the binding step the negatively charged (at neutral pH) serum albumin takes on an
overall neutral charge and thus does not bind to the WAX bead. However, the other pH
binding solutions (pH 7.4 and pH 9) would have made serum albumin negatively charged
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Table 10. Examples c>f top peptides seen in the immobilized-trypsin digestion of
WAX fractionationalted serum.
Expect
Accession
Peptide
Mass
Peptide Identity
Score
value
#
980.61
34
0.01
R.VGYVSGWGR.N
P00738
Haptoglobin
Fanconi anemia
1182.69
0.0062
Q9HB96
37
R.EEPWQGPDGR.L
group E protein
Apolipoprotein
K.ALVQQMEQLR.Q
1215.79
P06727
35
0.0064
A-IV
Inter-alpha1337.84
trypsin inhibitor
44
0.00064
P19823
K.FYNQVSTPLLR.N
heavy chain H2
1401.82
Fibronectin
32
0.021
K.HYQINQQWER.T
P02751
Inter-alpha1470.62
trypsin inhibitor
K.QYYEGSEIVVAGR.I
P19827
80
2.3e-07
heavy chain HI
1561.88
P00734
Prothrombin
79
3.5e-07
R.TATSEYQTFFNPR.T
R.DVWGIEGPIDAAFT
1647.00
P04004
Vitronectin
70
2.2e-06
R.I
R.DWHGVPGQVDAA
1666.62
P04004
Vitronectin
9.1e-07
69
MAGR.I
Apolipoprotein
K.DALSSVQESQVAQQ
1717.04
62
P02656
1.3e-05
AR.G
C-III
Ig alpha-1 chain
R.QEPSQGTTTFAVTSI
1836.12
P01876
42
0.00071
LR.V
C region
Apolipoprotein
K.TAKDALSSVQESQV
2017.25
P02656
73
5e-07
AQQAR.G
c-m
Alpha-2-HSR.HTFMGWSLGSPSG
2081.22
P02765
102
l.le-09
glycoprotein
EVSHPR.K
R.FNKNNEGTYYSPNY
2293.26
Ceruloplasmin
0.0011
P00450
43
NPQSR.S
Complement
R.TLEIPGNSDPNMrPD
2551.46
P0C0L4
102
1.2e-09
C4-A
GDFNSYVR.V
R.EGVQKEDIPPADLS
2755.57
P01024
114
Complement C3
6.6e-ll
DQVPDTESETR.I
Inter-alphaR.GMADQDGLKPTIDK
2994.16
P19827
trypsin inhibitor
67
1.3e-06
PSEDSPPLEMLGPR.R
heavy chain HI

and thus most amenable to binding to the WAX bead type. In addition to this
observation, we also saw that compared to the other binding solution, pH 5.0 yielded
the highest protein concentration, thus allowing the fractionated sample to be applied
easily to the immobilized-trypsin workflow.
Additionally, we attempted a LIFT of an untrypsinized sample of both WCX
fractionated samples and WAX fractionated samples. Table 11 shows the identified
peptides from both the WCX and the WAX untrypsinized samples. As discussed above
for the WCX fractionated samples, the spectra of untrypsinized samples are sparse as
compared to the spectra generated immobilized trypsin samples. This is also true for
WAX fractionated samples (on average there are 55 peaks for trypsinized samples versus
18 peaks for untrypsinized samples). Additionally, using WCX as an example, the peaks
that qualify as good candidates for LIFT (i.e. good S/N ratio and not in the midst of a
peak patch) are on average ~ 45 for the trypsinized samples as compared to ~12 for the
untrypsinized samples. Furthermore, the lack of knowledge as to the identity of the
enzyme that created the peptide of interest adds to the difficulty of identifying the
endogenous peptide peaks in the untrypsinized samples. Of the 45 peaks that were
subjected to LIFT-MS/MS from the serum samples processed with the
WCX/immobilized-trypsin bead workflow, 30 peaks were successfully identified.
However, of the 12 peaks that were subjected to LIFT-MS/MS from the untrypsinized
WCX fractionated serum samples, only 5 peaks were successfully identified. This is true
for the WAX workflow as well i.e. LIFT-MS/MS performed on 25 peaks from the
trypsinized sample with 17 identified, while only 4 peaks were identified from the 10
peaks fragmented by LIFT-MS/MS from the untrypsinized sample. Thus, it is easier to
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Table 11. Peptides identified from untrypsinized WCX and WAX fractionated
serum.
WCX fractionated serum
Enzyme
Expect
Accession
Mass
Peptide Identity
Peptide
denotation
#
value
1060.66
2.8e-05
K.RPPGFSPFR.S
Trypsin*
P01042
Kininogen-1
0.014
R.RHDWGHEKQ.R
No enzyme
1192.66
P01042
Kininogen-1
Inter-alphaR.MNFRPGVLSSR.L
1263.80
Q14624
trypsin inhibitor
0.0059
Trypsin*
H4
R.TATSEYQTFFNPR.T
1561.82
P00734
Prothrombin
9.1e-06
Trypsin
A.KVEQAVETEPEPEL
1753.98
1.8e-05
No enzyme
P02649
Apolipoprotein E
R.Q
WAX fractionated serum
Accession
Expect
Enzyme
Mass
Peptide Identity
Peptide
#
value
denotation
Semi1206.72
G.EGDFLAEGGGVR.G
P02671
Fibrinogen alpha
0.0015
trypsin
A.DSGEGDFLAEGGGV
Semi1465.82
Fibrinogen alpha
l.le-10
P02671
R.G
trypsin
T.ADSGEGDFLAEGGG
Semi1616.84
Fibrinogen alpha
2.4e-08
P02671
VR.G + Phospho (ST)
trypsin
G.SPMYSHTPNILRLES
2193.34
P01024
0.012
No enzyme
Complement C3
EET.M

f

SwissProt database searched with the following criteria: oxidation modifications; 120 ppm mass
tolerance MS; 0.5 Da MS/MS tolerance. * Indicates that without enzyme selection the peptide
identification would not be significant.

identify a peptide from the immobilized-trypsin workflow, (where we know that the
enzyme that created that peptide is trypsin), than from the untrypsinized sample.

Trypsin-bead workflow on clinical samples: SOF study revisited
We next performed proof-of-concept trypsin bead workflows on clinical samples
as described in Figure 14. The first set of samples utilized consisted of the scraped SOF
serum samples from Aim 1. We processed these samples with the WCX fractionation
and immobilized-trypsin digestion workflow as discussed in Materials and Methods in
order to examine the reproducibility of this workflow with clinical samples and also to
investigate whether there are any differential peptides that can be identified between the
two sample sets (cases and controls). We made 24 pools (12 pools per group) with 8
samples per pool. Two peaks that were deemed most significant using the ClinProTools
software, m/z 2017 and m/z 2383 were included in the generation of a genetic algorithm
model, along with another significantly differential peak, m/z 1030 (it should be noted
that the values we list in the text are average of isotopic values generated by
ClinProTools, but the values used for the LIFT identification are of the 1st isotopic peak).
Figure 20 shows the cluster plot of peaks m/z 2017 and m/z 2383. These peaks were
identified as alpha-2HS-glycoprotein (m/z 2017), B-cell lymphoma 9 protein (Bcl-9) (m/z
2383), and kininogen (m/z 1031), which were all increased in patients that were going to
develop breast cancer (cases). The genetic algorithm model had 100% recognition
capability of the test set and the cross-validation yielded a sensitivity of 87.23% and a
specificity of 77.36%.
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Figure 20. Cluster plot of relative intensity distributions of peaks m/z 2017 and 2383 in
the initial run of the SOF cohort. The cluster plot was generated by the ClinProTools 2.0
software. The intensities of the 2 peaks, m/z 2017 and 2383, are plotted on 2 axes. The
more clustered the points are in relation to their group and the more separated the clusters
are from each other then the more significantly distinct the 2 groups are in relation to each
other. In this cluster plot the intensities of peak m/z 2017 are found along the "x" axis,
while the intensities of peak m/z 2383 along the "y" axis. The control sample peaks are
designated by "o" and the case sample peaks are designated by "x".
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We re-processed the 24 samples and analyzed them again in duplicate on the
MALDI-TOF/TOF instrument. A genetic algorithm model was generated using the same
peaks (m/z 1031, 2017, and 2383) as for the previous ran and was found to have a
recognition capability of 100% of the test samples, with a cross-validation yielding a
sensitivity of 70.83% and a specificity of 70.83%. A cluster plot using the peaks m/z
2017 and m/z 2383 is shown in Figure 21. We then used this newly generated model to
see if it could properly externally validate the samples analyzed in the original run. The
genetic algorithm model that was designed specifically for the repeated sample set was
able to validate the 1st group of samples with a sensitivity of 70.83% (17/24 correctly
classified) and a specificity of 83.3% (20/24 correctly classified). The combined peak
intensity distributions for these SOF runs and the respective p-values are shown for
kininogen (Figure 22), alpha-2HS-glycoprotein (Figure 23) and Bcl-9 protein (Figure 24).
Interestingly, an independent iTRAQ analysis that was performed in our lab using lectin
capture and different SOF sample pools showed that there was a 2.33-fold increase of
alpha-2HS-glycoprotein in cases as compared to controls (1.0 to 0.43 iTRAQ ratio of
case to control).
The results shown here are very promising in terms of the reproducibility of this
method over time since there was a lengthy lapse between the analyses of these two SOF
runs on the MALDI-TOF/TOF, during which time the instrument had been serviced by
Bruker engineers. Yet the intensity and distribution patterns of the peaks used to
construct our genetic algorithm models are still comparable enough to produce similar
cross-validations between the two runs and also to allow for a good external validation of
the first run by the genetic algorithm criteria set forth by the repeat run.

Figure 21. Cluster plot of relative intensity distributions of peaks 2017 and 2383 in the
repeat run of the SOF cohort. The cluster plot was generated by the ClinProTools 2.0
software. The intensities of the 2 peaks, m/z 2017 and 2383, are plotted on 2 axes. The
more clustered the points are in relation to their group and the more separated the
clusters are from each other then the more significantly distinct the 2 groups are in
relation to each other. In this cluster plot the intensities of peak m/z 2017 are found
along the "x" axis, while the intensities of peak m/z 2383 along the "y" axis. The
control sample peaks are designated by "o" and the case sample peaks are designated by
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Figure 22. Box plot of relative intensity distributions of peak m/z 1031 in the SOF
cohort. Relative intensities were plotted from both runs. The two runs were processed
by the ClinProTools software independently with a 0.1% maximum peak shift
tolerance and a beginning m/z cut-off of 800. The box denotes where the intensities of
the majority of samples lie and the whiskers of the box plot demonstrate range of
intensities of all samples that are not deemed outliers. All outliers are shown as
individual points. The mean is depicted as a dotted line and the median is depicted as
a solid line. For m/z 1031, the mean was 9.25 for cases and 7.67 for controls, while
the median was 8.08 for cases and 7.63 for controls. Using a student t-test, the Pvalue for this peak was determined to be 0.0064. Significance is < 0.05.
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Figure 23. Box plot of relative intensity distributions of peak 2017 in the SOF cohort.
Relative intensities were plotted from both runs. The two runs were processed by the
ClinProTools software independently with a 0.1% maximum peak shift tolerance and
a beginning m/z cut-off of 800. The box denotes where the intensities of the majority
of samples lie and the whiskers of the box plot demonstrate range of intensities of all
samples that are not deemed outliers. All outliers are shown as individual points. The
mean is depicted as a dotted line and the median is depicted as a solid line. For m/z
2017, the mean was 112.88 for cases and 94.36 for controls, while the median was
108.81 for cases and 98.14 for controls. Using a student t-test, the P-value for this
peak was determined to be 0.00095. Significance is < 0.05.
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Figure 24. Box plot of relative intensity distributions of peak 2383 in the SOF cohort.
Relative intensities were plotted from both runs. The two runs were processed by the
ClinProTools software independently with a 0.1% maximum peak shift tolerance and
a beginning m/z cut-off of 800. The box denotes where the intensities of the majority
of samples lie and the whiskers of the box plot demonstrate range of intensities of all
samples that are not deemed outliers. All outliers are shown as individual points. The
mean is depicted as a dotted line and the median is depicted as a solid line. For m/z
2383, the mean was 18.59 for cases and 14.19 for controls, while the median was
17.03 for cases and 13.57 for controls. Using a student t-test, the P-value for this peak
was determined to be 0.0046. Significance is < 0.05.

Trypsin-bead workflow on clinical samples: Serum from patients diagnosed with
Benign Prostatic Hyperplasia and Prostate Cancer
In addition to the SOF sample cohort we also processed a set of serum samples
through the workflow described in Figure 14 from individuals diagnosed with BPH and
those diagnosed with prostate cancer (PCa) (all the patients had PSA levels between 2
and 10 ng/mL). Twenty pooled samples (10 pooled samples per group) were run in
duplicate as described in the Materials and Methods. We found that two peptides
identified as Apolipoprotein AIV (ApoAIV) (m/z 1216 and 1353) were increased in
patients that were diagnosed with BPH. In addition, a kininogen peptide (m/z 1031) was
also noticeably increased in patients that had PCa. ClinProTools was used to generate a
genetic algorithm model using these three peaks and this model was able to differentiate
100% between the two test groups. Upon cross-validation this model was able to
distinguish between sample groups with a sensitivity of 84.11% (correctly classified
cases i.e. PCa) and specificity of 75% (correctly classified controls i.e. BPH).
To determine the reproducibility of this method using clinical samples we
randomly re-processed 12 of the samples (6 samples per group) with the front-end MBWCX fractionation and trypsinization scheme. These samples were blinded and analyzed
in duplicate by the MALDI-TOF using the exact specification and setting used for the
initial run. We utilized the model generated from the original 20 samples to classify the
blinded samples. In this manner we were able to classify 10/12 correctly as BPH and
10/12 correctly as PCa, giving us a specificity and sensitivity of 83.3%. A cluster plot
was created using the ApoAIV m/z 1216 peptide and the kininogen peptide intensity
distributions from both runs (Figure 25). Figure 26 is a box plot of the combined
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Figure 25. Cluster plot of relative intensity distributions of peaks 1031 and 1216 in
the PCa vs. BPH cohort. The cluster plot was generated by the ClinProTools 2.0
software. The intensities of the 2 peaks, m/z 1031 and 1216, are plotted on 2 axes.
The more clustered the points are in relation to their group and the more separated
the clusters are from each other then the more significantly distinct the 2 groups are
in relation to each other. In this cluster plot the intensities of peak m/z 1216 are
found along the "x" axis, while the intensities of peak m/z 1031 along the "y" axis.
The control sample peaks are designated by "o" and the case sample peaks are
designated by "x".

•
•

T

•

+
•41

PCa

BPH

Figure 26. Box plot of relative intensity distributions of peak 1031 in the PCa vs.
BPH cohort after WCX fractionation. Relative intensities were plotted from both
runs. The two runs were processed by the ClinProTools software independently with
a 0.1% maximum peak shift tolerance and a beginning m/z cut-off of 800. The box
denotes where the intensities of the majority of samples lie and the whiskers of the
box plot demonstrate range of intensities of all samples that are not deemed outliers.
All outliers are shown as individual points. The mean is depicted as a dotted line and
the median is depicted as a solid line. For m/z 1031, the mean was 8.14 for PCa and
6.34 for BPH, while the median was 8.32 for PCa and 6.61 for BPH. Using a student
t-test, the P-value for this peak was determined to be 0.00024. Significance is < 0.05.
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intensity distributions of kininogen and Figure 27 is the box plot of the combined
intensity distributions of the two ApoAIV peaks between BPH and PCa using the WCX
fractionation/immobilized-trypsin bead workflow
Additionally, we knew that an ApoAIV peak is also found in the WAX
fractionation workflow, we thus processed the 20 samples by that workflow and found
that the peptide for ApoAIV (m/z 1216) was also increased in the BPH sample set using
this fractionation scheme. Figure 28 shows the intensity distribution of the ApoAIV peak
between BPH and PCa in the WAX scheme.
We also compared the raw values of peak intensities between the first group of
WCX processed and immobilized-trypsin bead digested samples and their repeated
counterparts. These workflows are reproducible with clinical samples over-time when
specific instrumental settings are utilized, since the intensities did not vary much between
the same samples which were processed and analyzed weeks apart. For example, two
BPH samples had an intensity (duplicates averaged) of 11.48 and 7.36, respectively at
m/z 1216. The same samples re-processed and re-analyzed weeks later, had an intensity
of 12.29 and 7.47, respectively at m/z 1216. On the PCa side, two PCa samples had peak
intensities of 4.52 and 3.34 at m/z 1216. These same PCa samples were re-processed and
re-analyzed weeks later and had intensities of 4.57 and 3.75 at m/z 1216.

4.4 Discussion
The development of new instrument configurations and continued improvement in
existing proteomic mass spectrometry technologies has allowed for unprecedented
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Figure 27. Box plot of relative intensity distributions of the ApoAIV peaks in the PCa vs. BPH cohort after WCX
fractionation. Relative intensities were plotted from both runs. The two runs were processed by the ClinProTools software
independently with a 0.1% maximum peak shift tolerance and a beginning m/z cut-off of 800. The box denotes where the
intensities of the majority of samples lie and the whiskers of the box plot demonstrate range of intensities of all samples that
are not deemed outliers. All outliers are shown as individual points. The mean is depicted as a dotted line and the median is
depicted as a solid line. For m/z 1216, the mean was 4.47 for PCa and 6.52 for BPH, while the median was 4.35 for PCa and
5.78 for BPH. Using a student t-test, the P-value for this peak was determined to be 0.00025. For m/z 1353, the mean was
5.29 for PCa and 7.9 for BPH, while the median was 5.15 for PCa and 6.83 for BPH. Using a student t-test, the P-value for
this peak was determined to be 0.00096. Significance is < 0.05.
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Figure 28. Box plot of relative intensity distributions of peak 1216 in the PCa vs.
BPH cohort after WAX fractionation. Relative intensities were plotted after the
spectra was processed by the ClinProTools software with a 0.1% maximum peak
shift tolerance and a beginning m/z cut-off of 800. The box denotes where the
intensities of the majority of samples lie and the whiskers of the box plot
demonstrate range of intensities of all samples that are not deemed outliers. All
outliers are shown as individual points. The mean is depicted as a dotted line and
the median is depicted as a solid line. For m/z 1216, the mean was 7.69 for PCa
and 10.15 for BPH, while the median was 7.24 for PCa and 9.75 for BPH. Using
a student t-test, the P-value for this peak was determined to be 0.0042.
Significance is < 0.05.
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opportunities in biomarker protein discovery and analysis of complex biological
proteomes. In particular, analysis of serum and plasma will always be a challenge both
because of the inherent dynamic characteristics of the fluid and the persistent clinical
variables that affect the quality of the starting material. Any proteomic study using
clinically obtained samples will be influenced by issues involving sample collection,
processing and storage, the level of epidemiological input and study design biases. The
different sample processing workflows described in this Aim demonstrate the feasibility
of sequential chromatographic fractionation and trypsinization protocols to elucidate
proteomic differences in complex samples like serum and the peptides generated are ideal
for direct MALDI-TOF/TOF sequence determinations.
The technique described in this method paper is complementary to the mining of
the low molecular weight (LMW) proteome in that it allows for the examination of
peptides that may have been previously outside the m/z range of the mass spectrometer.
In addition, the high-efficiency of the immobilized trypsin may allow for the release of
less abundant proteins from carrier molecules or protein complexes. These newly
created, low abundant peptides may be enriched by using various up-front fractionation
methods. For example, many biological processes are influenced and identified through
altered glycosylation events on proteins and may be targeted by using specific lectins, as
will be demonstrated in Aim III, to capture specific carbohydrate moiety carrying
proteins. Many other post-translational modifications and truncations are also possible.
Thus, inclusion of the trypsinization step can facilitate detection of these modifications or
truncations due to the altered spectra of the affected peptides.
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The majority of the proteins identified in our cataloguing analysis have been
reported previously in the serum after the use of techniques that enrich for LMW proteins
(64). Many of the proteins we identified are found in the median concentration ranges of
serum and plasma proteins. For example, the protein Platelet-basic protein(PBP)/betathromboglobulin/NAP-2 belongs to a family of CXC cytokines and is reportedly found in
serum as multiple isoforms in the ug/mL concentration range (135). Additionally, the
differential protein Bcl-9 from the SOF study is a ubiquitously expressed, but lowabundant, nuclear protein. It is unlikely that the WCX fractionation alone could account
for the enrichment of some of these low-abundant proteins. However, as previously
mentioned, it is possible that these proteins are enriched on carrier proteins or bound to
other larger protein complexes become released during the efficient trypsinization
process. Specifically, the aforementioned PBP/beta-thromboglulin/NAP-2 protein has
previously been reported as albumin-associated (136).
The trypsinization step which we have integrated after fractionation of serum is an
effective means to profile serum and acquire identifications of peaks of interest given that
the LIFT- MALDI-TOF/TOF is effective at the < 4,000 m/z range (19). Traditional insolution protein digestions can be tedious, require long incubation times, and the amount
of trypsin included is limiting to minimize interfering auto-digestion peaks. The method
we describe takes advantage of the fact that immobilizing enzymes can yield reactions
that are faster, more efficient and have high-throughput (31, 32). This is due in part to
the increased stability of the immobilized enzyme and also to the ability of using higher
enzyme-to-substrate ratios. There have been other approaches to immobilize trypsin onto
solid supports to increase its catalytic ability, thus minimizing the time needed for
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digestion and streamlining the trypsinization process. Innovative approaches such as
trypsin adsorbed directly onto a metal MALDI plate (33, 34), linked to copolymer
MALDI sample array chips (35) or immobilized onto different monolithic HPLC
columns (32, 36) have been described. Currently, trypsin is also commercially available
bound to agarose beads or immobilized as individual spin columns. However, in terms of
profiling studies, the method we describe is advantageous in that it allows for the total
automation of the trypsin digest protocol, in a timely, efficient manner. Additionally, it
may be effectively combined with various robotic fractionation techniques in tandem,
creating workflows that allow for the effective chromatographic separation of large
sample sets with minimal operator error for the purpose of exploring complex proteomes
in greater detail. This robotic workflow will also be examined further in Aim III.
Currently, we are using both the WCX/trypsin beads/Cl 8 scheme and the
WAX/trypsinbeads/C18 scheme to profile different sample sets. A challenge when
peptide profiling using the MALDI-TOF/TOF is that the spectrum is crowded in the
<4000 Da mass range. Thus, there are peaks that are much more difficult to identify
using LIFT due to other peptides over-shadowing their signal or fragmenting along with
the peak of interest. Thus, one way to determine the identity of a peptide that is
presenting in this manner is to employ an LC-MALDI-TOF/TOF to reduce the
complexity of individual spots on the target plate, while retaining all the information in
the increased number of elutions of a specific sample.
Fortunately, in both our clinical cohort examples we were able to identify all
major peaks of interest. In the SOF study, processed with the WCX
fractionation/immobilized-trypsin bead workflow, the most compelling peptide in terms
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of reproducibility and intensity was the m/z 2017 peptide from the alpha-2HSglycoprotein. This protein was elevated in individuals that will develop breast cancer in
the future. The true biological role of alpha-2HS-glycoprotein is unknown, but it has
been implicated as a negative acute-phase protein. It is highly expressed in developing
fetal tissue, but is dramatically decreased in adults. Additionally, it has been found that
normal circulating levels in adults (300-600 ug/ml) fall significantly during injury and
infection (137). Interestingly, one group of researchers, using Lewis lung carcinoma cells
as a cancer model, reported finding that the lack of the mouse form of alpha-2HSglycoprotein (fetuin-A) significantly protects those mice from developing tumors in vivo.
Furthermore, according to the authors, fetuin-A is capable of promoting the growth of
more aggressive tumor cells, but not benign and normal cells in vitro (138). Hence it
would be plausible that the elevation of this protein, which is thought to act in the
neutralization of inflammatory components, may yield a permissive microenvironment
for breast cancer to develop without the intervention of the immune system.
Another peptide that was elevated in women that develop breast cancer was m/z
2383, a peptide from the Bcl-9 protein. The Bcl-9 protein, whose overexpression is
associated with B-cell malignancies, is a coactivator (and also a nuclear shuttle protein)
that binds unphosphorylated beta-catenin thereby aiding in the activation of Wnt target
genes (139, 140). This Wnt signaling pathway is pathologically activated in many
different types of human cancers and research has shown that resulting WNT proteins are
overexpressed in different tumors (141,142). Interestingly, components of the Wnt/j8catenin pathway have also been found activated in up to 60% of breast carcinomas (143,
144).
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As for the BPH/PCa cohort, the most striking differential protein was ApoAIV.
Two peptides from this protein, m/z 1216 and 1353, were increased in patients diagnosed
with BPH as compared to patients diagnosed with PCa for samples processed with the
WCX fractionation/immobilized-trypsin bead workflow. Additionally, the ApoAIV m/z
1216 peptide was also increased in the BPH patients as compared to PCa patients as seen
by the WAX fractionation/immobilized-trypsin bead method. ApoAIV is a plasma
protein that circulates freely in solution or associates with chylomicrons and high-density
lipoprotein (HDL) (145, 146). This apolipoprotein does not have a known function
though it is thought to have a role in lipid absorption, transport and metabolism, and may
act as a satiety signal. It has also been suggested that higher levels of ApoAIV leads to
an increase of chylomicron formation, which is then responsible for a more efficient
absorption and amplified lymphatic output of the cartenoid, lycopene (147). Lycopene is
a powerful antioxidant that has been shown to scavenge oxygen free radicals and also to
interact with reactive oxygen species thereby protecting cells from oxidative damage.
Oxidative damage caused by free radicals to cellular proteins, lipids and DNA has been
implicated as a possible mechanism for the propagation of cancer, including PCa (148).
Additionally, lycopene has been implicated in the prevention of PCa by affecting various
signaling pathways (i.e. insulin-like growth factor) (149). However, the extent of
lycopene's ability in thwarting PCa is still very controversial with conflicting reports
coming out regularly (150).
One study recently found that plasma lycopene concentrations are decreased in
subjects with localized and metastatic prostate cancer as compared to normal and BPH
diagnosed subjects (151, 152). This is also validated by the finding that malodialdehyde
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levels (which are used as an indicator of lipid oxidation) were increased in PCa patients
as compared to BPH and normal individuals (152). Interestingly, ApoAIV has also been
shown to be a potent inhibitor of lipid oxidation (153). Thus, a decrease of ApoAIV may
lead to an elevated risk of PCa owing to the increase in lipid oxidation caused by the
diminishment of antioxidant activity through lycopene and/or ApoAIV itself.
In both serum cohorts that we examined, the protein kininogen-1 (represented by
m/z 1031) was elevated in women that were going to develop breast cancer and also men
that were diagnosed with PCa. It is interesting that kininogen-1 is increased in patients
that have or will develop cancer. Kininogen-1, also known as alpha-2-thiol proteinase
inhibitor, is a blood protein involved in the kallikrein-kinin system, which is involved in
blood clotting. There are two types of kininogen, high molecular weight (HMW) and low
molecular weight (LMW), which are both composed of a heavy chain and a light chain.
HMW-kininogen (HK) and LMW-kininogen (LK) have an identical heavy chain
sequence, but a differing light chain sequence. HK binds to endothelial cells where it can
be cleaved by plasma kallikrein to release bradykinin (BK). The remaining portion of
this protein is termed cleaved high-molecular-weight kininogen (HKa) (154). Recent
studies have found that HKa is anti-angiogenic, while HK, BK and LK are proangiogenic (155). The HKa anti-angiogenic properties, which include inhibition of
endothelial cell migration and proliferation, have all been allocated to the D5 domain
(located in the light chain). Whether HKa or HK are further proteolyzed in vivo to
release D5 is unknown, but current in vitro data support this possibility (154). The
peptide we found to be increased in patients that will develop or currently have cancer
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could be a component of HK, LK or HKa (but is not part of D5 or BK), since it is located
in the heavy chain region.
In adults the vasculature is quiescent and tightly regulated by a balance of pro- and
anti-angiogenic factors (156). Thus, it could be possible that in individuals at risk for
cancer, or who have cancer, this system could be deregulated. For example, there may be
an over-abundance of pro-angiogenic factors (HK, BK and LK), while the antiangiogenic factor, HKa, may be misfolded (hiding the D5 domain) or may be degraded or
subjected to missed cleavage by proteases, rendering it incapacitated. Alternatively,
since angiogenesis is a complicated process involving many factors, the kininogen
protein may be elevated, but there may be contact or signaling problems downstream in
the anti-angiogenic pathway, thus making the pro-angiogenic pathway dominant.
However, a problem with analyzing the true importance of this protein in clinical sample
studies is that HK (but not LK), as mentioned above, is part of the clotting cascade and
thus must be looked at with caution, since improper sample handling and storage may
affect its presence.
These cohort studies demonstrate that it is unlikely that there will be one sole
biomarker that will effectively (with perfect sensitivity and specificity) be used in the
early detection of cancer, be it breast cancer or prostate cancer. As discussed in the
introduction of this thesis, cancer is a very complicated state, with many elements
working together and against each other to create a favorable tumor microenvironment.
Thus, it is more reasonable that a panel of biomarkers, along with specialized algorithms,
will assess an individual's risk of developing a certain type of cancer (or detect that
cancer early in its development).
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CHAPTER V
AIM III: DEVELOPMENT OF INTEGRATED FRACTIONATION PROTOCOLS
FOR IN-DEPTH AND AUTOMATED MALDI-TOF/TOF ANALYSIS

5.1 Introduction
In general serum expression profiling is reproducible and portable across multiple
laboratories, especially when rigorous study design and sample handling are combined
with carefully controlled instrument calibration, automated sample preparation, and
supervised bioinformatic data analysis (47, 50, 62, 126). Furthermore, the recent
development of TOF/TOF technology has brought with it the capability of protein
identification (m/z 4000 or less) through the generation of fragment ions and homology
searching. As discussed in Chapter IV, this has alleviated one common problem in
expression profiling: the intricacy of determining protein identities of potential biomarker
peaks. However, another difficulty that still remains in expression profiling, particularly
for serum and plasma studies, is the issue of protein dynamic range and complexity,
highlighting the need for new strategies to increase the utility of these techniques for
clinical biomarker assay development (43, 47, 71, 125).
The majority of the proteins that are seen as peptides by the WCX and WAX
workflows described in Chapter IV are all high-abundant proteins, whose abundance may
not necessarily be reflective of disease state in relation to cancer. These proteins are
considered acute phase proteins, or host response proteins, that are mainly synthesized in
the liver and reflective of the host immune response (157). Additionally, many criticize
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the use of these host response proteins as biomarkers, since some are altered by the
clinical processing of samples (especially serum samples) (57, 65).
This issue may be addressed by using a targeted fractionation method, which
involves using immobilized lectins to separate glycosylated proteins from nonglycosylated proteins and even separate differentially glycosylated proteins. This is
comparatively a more biologically relevant fractionation method since glycans participate
in many biological processes such as cell adhesion, molecular trafficking and clearance,
cell recognition and the immune response (124). Notably, it has been shown that
glycosylation profiles in the cell change significantly during oncogenesis and that altered
glycoforms may lead to cancer progression. Since, the blood is enriched for secreted and
shed cell surface glycoproteins, it therefore contains many potential biomarkers that may
reflect disease specific glycan differences (157). One example of a secreted glycoprotein
is the aforementioned PSA, of which multiple glycoforms have been described (71,158,
159).
The "bottom-up" expression profiling approaches, described in Chapter IV and
further elaborated on in this Chapter, typically utilize magnetic bead surfaces and are thus
are designed to be compatible with automated robotic sample processing. Automation,
using the ClinProt robot and the MALDI-TOF/TOF instrument from Bruker, would be
advantageous because it is high-throughput, reproducible, limits operator error and
consumes small amounts of the patient's sample (62, 71, 72). This leads not only to more
significant results due to the increase in sample numbers, but may also provide an ideal
technique that translates effectively into clinical, diagnostic laboratories.

In this Chapter we revisit the immobilized-trypsin bead technique, developed in
Chapter IV, and adapt it into two different approaches with the goal of a more
comprehensive look at the serum profile. We began by first examining tandem bead
approaches for the purpose of sample preservation and also to determine if more
information may be garnished from an already fractionated sample through fractionation
with another chemical-affinity bead type. We next explore lectin capture strategies with
our established immobilized-trypsin bead workflow. All of these approaches are
designed with the goal of automation since, as discussed previously, the benefit to robotic
automation is that it allows for the opportunity of analysis of large numbers of samples
comprising many clinical cohorts with limited operator variation. Thus, we end this Aim
with a look at the automation of the WCX workflow that was performed manually in
Chapter IV. Challenges of this automated workflow are discussed, with a final robotic
schematic design presented.

5.2 Materials and Methods
Serum Samples
A pooled human serum sample collected from over 360 donors (50) was used for
method development procedures.

Tandem-bead workflows
Initial fractionation of serum was done with either MB-WCX (weak cationic
exchange) or MB-WAX (weak anionic exchange) paramagnetic beads essentially as
described by the manufacturer's protocols (Bruker Daltonics, Bremen, Germany).
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Briefly, 20 uL of serum was mixed with 40 uL of binding solution (the WAX protocol
utilized the pH 5 binding solution) supplied with the beads and 20 uL MB-WCX or MBWAX beads (note that the WAX beads were equilibrated with activation solution prior to
this step) for 15 minutes (mixing every 5 minutes). A magnetic bead separator was used
to concentrate the beads and for the wash/rinse processes. Unbound serum proteins were
removed for processing with the opposite bead-type (if on WCX then added to WAX and
vice versa) and the bound serum proteins (after washing) were eluted with 10 uL of MBWCX or MB-WAX elution solution supplied by the manufacturer. Eight microliters of
HPLC water and 1 \xL of MB-WCX stabilization solution were added to the WCX eluate,
and 11 uL of MB-WCX elution was added to the WAX eluate, to give a final sample pH
of 7.5-8.5. Finally, the unbound serum proteins were processed with the opposite bead
type using the same workflow as described above. The pH was adjusted according to
their secondary fractionation bead type.

Magnetic bead-bound lectin workflows
Magnetic bead (MB)-ConA (concavalin A) and MB-WGA (wheat germ
agglutinin), from Bruker Daltonics, were used to initially fractionate the serum according
to the manufacturer's protocol (20 uL serum to 20 \xL lectin beads). These lectin beads
were used either separately or together in a mixture, where the solutions (binding and
wash) utilized were from the MB-ConA kit.
Three separate schemes (discussed in Results) were tested to yield the best MS
pattern: 1) Elution using acidic elution solution provided by manufacturer, 2) elution with
competitive sugars, and 3) a tandem-bead approach after elution off of lectin beads. Ten
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microliters of elution solution provided with the Bruker lectin kit was utilized to elute the
bound glycoproteins. To make the pH fall into the ideal range for reduction, alkylation
and trypsinization (pH 7-9), 10 uL of WCX elution solution was added to the lectin
elution. Alternatively, between 1.5 and 2 uL of 1M NaOH was added to the 10 uL of
lectin elution. Two competitive sugar elutions were also tested using MB-ConA as an
example lectin (10 uL of 200 mM or 400 mM mannose was used to elute off of the ConA
magnetic beads). For the tandem bead approach, each of the lectin bead types were
eluted with 10 uL of Bruker elution solution, brought up to 20 uL with 25 mM
Ammonium bicarbonate (pH 7.8), and then added directly to a MB-WCX reaction (20 uL
sample, 40 uL binding solution and 20 uL beads). Additionally, 2 MB-WGA elutions
were pooled into one sample, concentrated under reduced pressure, and reconstituted in
their original volume with 25 mM Ammonium bicarbonate (pH 7.8). The entire lectin
fractionated sample was then manually processed through the WCX fractionation
protocol.

Agarose bead-bound lectin workflow
Serum was first depleted using ProteoPrep ImmunoAffmity Albumin and IgG
Depletion Kit (Sigma, Saint Louis, MO). Three-hundered microliters of ConA/WGA
agarose-bound lectins (E.Y. Labs, San Mateo, CA) were washed with binding buffer (25
mM Tris, 150mM NaCl, ImM MnCL. and 1 mM CaCl2). The depleted serum was then
incubated overnight at 4°C with the washed lectin beads in a total volume of 200 uL (the
volume was adjusted using the binding buffer). The sample was eluted with 100 uL of
the competitive sugar. This glycoprotein elution was subsequently acetone precipitated

and the resulting pellet was reconstituted in 80 uL of 25 mM Ammonium bicarbonate
(pH 7.8). Twenty-two microliters of sample was added into the reduction and alkylation
reaction described below.

Automated MB-WCX workflow utilizing the ClinProt robot
The automated workflow for the MB-WCX beads was performed very similarly
to the manual method described in Chapter IV. Briefly, 20 \iL of serum was mixed with
40 uL of binding solution supplied with the beads and 20 uL MB-WCX (in the first
automated run 10 |LIL of beads were added). A magnetic bead separator was used to
concentrate the beads and for the wash/rinse processes. Unbound serum proteins were
removed and the beads were washed 3 times with the MB-WCX wash solution. Bound
serum proteins were eluted with 10 uL of MB-WCX elution solution supplied by the
manufacturer. The final addition of the stabilization solution supplied with the bead kit
was replaced with an addition of 8 uL of water.

Manual and automated reduction, alkylation and digestion using immobilizedtrypsin beads
For reduction and alkylation, ~ 8 )j,g of the fractionated samples were reduced
with 8 mM DTT in 25 mM ammonium bicarbonate (pH 7.8) at 56 °C for one hour (24 JIL
total volume). For the automated run, 8 ng was estimated as 10 p.L of the final WCX
eluate. Also, apart from the agarose-bound lectin eluate, the rest of the lectin eluates had
very low protein concentrations and therefore 10 uL of each of these eluates was added to
their respective reduction reaction (as this was the maximum volume recommended).
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The reduced samples were then alkylated with 17 mM iodoacetamide in 20 mM
ammonium bicarbonate total solution (29 uL total volume).
The resulting tryptic peptides were re-captured and concentrated with HIC-C18
paramagnetic beads (Bruker Daltonics, Bremen, Germany) as follows. Twenty
microliters of the tryptic digest was incubated with 10 uL HIC-C18 beads and 40 uL
HIC-C18 binding buffer. Bound peptides were washed with the manufacturer's wash
solution and eluted in 10 uL of 50% ACN as per the manufacturer's specifications. It
should be noted that for the lectin capture studies we also attempted a C8 clean-up,
however the results were similar to those seen for the WCX trypsinization workflow in
Chapter IV, in that the CI8 bead type produced more robust spectra. Thus, MB-C18 was
retained as the preferential bead-type for clean-up and concentration of peptides for
analysis on the MALDI-TOF instrument.

MALDI-TOF analysis
The tryptic peptide samples (for the WCX and WAX tandem bead workflow and
the automated WCX workflow) after HIC-C18 clean-up were mixed in a 1:3 dilution (for
manual method of spotting) or 1:5 dilution (for automatic method of spotting) with
CHCA matrix solution (4 mL ethanol, 2 mL acetone, 0.008 g CHCA, and 0.1 % TFA) and
1 uL of the mixture was manually spotted (or robotically spotted by the ClinProt robot
where indicated) onto an AnchorChip plate using a dried droplet spotting technique. The
lectins were spotted using a reverse-thin layer spotting technique described in the
Materials and Methods of Chapter IV.
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The UltraFlex III MALDI-TOF/TOF instrument (Bruker Daltonics, Bremen,
Germany) was used to analyze peptides in reflectron mode and the resulting spectra were
processed using FlexAnalysis 2.0 or ClinProTools 2.0 (Bruker Daltonics, Bremen,
Germany). Peaks of interest were further analyzed on a separate platform using the LIFT
function of a MALDI-TOF/TOF Ultraflex III instrument. The BioTools software and the
MASCOT search engine (www.matrixscience.com) were used to compare the TOF/TOF
spectra against primary sequence databases (SwissProt) to determine peptide sequence
identities (unless otherwise noted the search criteria is as follows: carbamidomethyl and
oxidation modifications; 100 ppm mass tolerance MS; 0.5 Da MS/MS tolerance).

5.3 Results
Tandem-bead workflows
We first investigated whether the workflows discussed in Chapter IV would be
compatible if performed in tandem and if so would these types of new workflows yield
any new protein observations. Figure 29 illustrates the workflows from Chapter IV and
the tandem workflows that are described in this section.
We first analyzed a tandem workflow that involved an initial WAX fractionation,
with the unbound fraction going directly into a WCX fractionation reaction. After the
WCX fractionation, the eluate was reduced, alkylated, trypsinized using immobilizedtrypsin beads, and the peptides were captured onto a CI 8 bead type. Unfortunately, the
resulting spectra, compared to a WCX alone workflow, seemed to be enriched in serum
albumin and only 1 peptide, alpha-lB-glycoprotein (peptide m/z 2295.98,
R.TPGAAANLELIFVGPQHAGNYR.C, from protein P04217, with expect value of
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Figure 29. Single bead and tandem bead workflows. A) Workflow depicting the use of
one bead type (i.e. WCX or WAX) prior to trypsin digestion (as was described in Chapter
IV). B) Workflows depicting utilization of tandem bead types where the unbound serum
fraction from one bead type is introduced into another bead type workflow.

4.2e-05) was able to be identified as a peptide that was not seen in the WCX or WAX
alone schemes (Figure 30).
We next tested another workflow that involved an initial WCX fractionation, with
the unbound sample being directly WAX fractionated. After the WAX fractionation, the
eluate was reduced, alkylated, trypsinized using immobilized-trypsin beads, and the
peptides were captured onto a CI 8 bead type. This tandem bead workflow also did not
yield more information as compared to the WAX single bead type workflow. In fact the
sample appeared to be more enriched with Ig alpha-1 C chain region, with 3 of the most
robust peptides originating from this protein. However, one peptide was represented in
this WCX/WAX workflow that was not prominent in the WAX (or WCX alone)
fractionation scheme and this was alpha-1-acid glycoprotein (Figure 31).
In light of these results, we are not interested in further pursuing these tandem
bead approaches for MALDI-TOF profiling. The resulting spectra did not yield enough
novel peptides, as compared to the single front-end fractionation described in Chapter IV,
to be deemed useful. In fact, both of these tandem workflow methods seemed to be
enriched with proteins that are typically thought of as the most abundant in serum i.e.
serum albumin and Ig-alpha. However, we have demonstrated that the buffers are
compatible between the two fractionation methods; thus, this method may be utilized for
samples that are limited in quantity (and thus two separate bead type runs are not an
option). Using this approach one may pick the primary bead type of interest, generate
spectra from that initial fractionation step, and then still be able to utilize the unbound
sample for further analysis with another bead type.
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Figure 30. Comparison of spectra from a tandem fractionation scheme and a single
fractionation scheme of serum. The top panel illustrates a spectrum of the unbound from a
MB-WAX fractionation scheme that was later subjected to MB-WCX/trypsin bead
workflow. The bottom panel is a single fractionation of serum with MB-WCX followed by
subsequent digestion with immobilized-trypsin beads. All samples were cleaned-up and
concentrated with MB-C18 and spotted onto an AnchorChip plate. The samples were then
analyzed by the MALDI-TOF/TOF UltraFlex III in reflectron mode and processed by the
FlexAnalysis 2.0 software. The arrows denote serum albumin peaks, with the solid arrows
indicating peaks that are not shared between the two spectra and the dashed arrows
indicating peaks that are shared between the two spectra.

Figure 31. Spectrum of a tandem fractionation scheme. Shown is a spectrum generated
from the unbound of a MB-WCX fractionation scheme that was later subjected to MBWAX/trypsin bead workflow. The tryptic peptides were captured and concentrated
using MB-C18 and spotted onto an AnchorChip plate. The samples were then analyzed
by the MALDI-TOF/TOF UltraFlex IE in reflectron mode and processed by the
FlexAnalysis 2.0 software.. The arrows indicate the 3 peaks, 1213.80, 1470.97, and
1836.29, which were found to be from the protein Ig alpha-1 C region. Peaks 1213.8
and 1470.97 are typically not seen in a WAX alone fractionation and digestion scheme.
However, 1836.29 is seen in both the tandem fraction and single fractionation scheme.
The star designates a peptide that is not prominent in a WAX alone fractionation and
digestion scheme: alpha-1-acid glycoprotein 1 (expect value: 1.6e-05 and peptide
R.YVGGQEHFAHLLILR.D).

Targeted capture using immobilized-lectins
Because tandem bead workflows using chemical affinity beads did not give us a
more in-depth profile of the serum samples, we decided to take a targeted capture
approach and interrogate the serum proteome profile with a lectin bead type. We first
began with a magnetic bead approach that could be easily adapted to the ClinProt robot.
To this end, Bruker lectin beads, MB-ConA and MB-WGA, were utilized individually or
together. Unfortunately, it was discovered that the eluted samples had very low protein
concentration. Given that the quantity and the type of proteins in solution play an
important role in the ability to alter the pH of that solution; we encountered a problem of
effectively being able to bring the eluted sample into the correct pH range for
reduction/alkylation/trypsinization. Adding a dilute, but high pH base (i.e. WCX elution
buffer) made the concentration of the eluted sample very low (i.e. -0.3 ptg/nL, compared
to ~ 1.3 jttg/^L for WCX or WAX fractionation schemes after pH adjustment) and yielded
spectra with very minimal peaks that were seen in the WCX or WAX scheme (Figure
32). As a reference, the MB-WCX workflow utilized in Chapter IV yielded spectra with
an average of 85 peaks in the m/z range ideal for TOF/TOF analysis. Conversely, the
peak numbers seen after the lectin workflows were 22, 14, and 8 for ConA/WGA, ConA
and WGA respectively. On the other hand utilizing a concentrated, high pH base yielded
variable results with a danger of precipitating the proteins from solution. Thus, this was
not an acceptable result since this step would not be able to be standardized.
We next attempted to perform a competitive sugar elution off of the lectin Bruker
beads (in lieu of the acidic elution solution). Using MB-ConA as an example lectin we
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Figure 32. Spectra comparison of serum fractionated with MB-ConA/WGA, MBConA, and MB-WGA and eluted with Bruker elution buffer. Samples were processed
using either a mixture of ConA and WGA magnetic beads from Bruker or with a single
bead type of ConA or WGA. The samples were eluted with the buffer provided by the
manufacturer and the pH was adjusted for optimal trypsinization. The samples were
then reduced, alkylated and digested with immobilized trypsin beads. The tryptic
peptides were captured using MB-C18 and the resulting elutions were spotted using a
reverse thin-layer spotting technique. The tryptic eluates were analyzed in reflectron
mode using the MALDI-TOF UltraFlex III and spectra were processed using
FlexAnalysis 2.0. The top panel shows a spectrum from a ConA/WGA fractionation
scheme, the middle panel shows a spectrum from a ConA alone scheme and the bottom
panel shows a spectrum from a WGA alone scheme.
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found that 400 mM mannose slightly improved the amount of protein eluted and the
robustness of the spectra. However, the resulting eluate again had a very similar minimal
protein concentration. Thus after reduction/alkylation/trypsinization there was very little
complexity (i.e peak number of 10) to the resulting spectra (Figure 33). An additional
consideration with this approach is that the competitive sugars used to elute the
glycoproteins are more than likely still in the trypsinized sample after MB-C18 clean-up.
These carbohydrates bind the CI8 bead type and thus when eluted with the peptides may
interfere with the generation of the spectra. We utilized a C8 bead type in hopes that a
smaller amount of carbons may decrease the binding abilities of the elution sugars.
However, using the C8 bead type did not improve the spectra and in fact resulted in
reduced abundance of peaks (as it did for the WCX workflow in Chapter IV).
Our final try at using the lectin-immobilized magnetic beads was to utilize a
tandem workflow to nullify the elution solution pH concern (since WCX binding buffer
has a pH ~ 4). This workflow used an initial lectin bead to capture glycoproteins from
the serum and the subsequent elution was added to a MB-WCX fractionation reaction.
This approach was moderately successful, but still produced rather sparse spectra. A
comparison of the Bruker elution spectra (14 peaks recognized in spectra) and the tandem
workflow spectra (20 peaks recognized in spectra) is shown in Figure 34 (using a MBConA approach as an example).
In order to demonstrate that these less-than-ideal spectra results are mainly due to
low concentration of proteins eluted off of the lectin bead we dried down the 2 lectin
elutions (using WGA eluted sample as an example since it yielded the weakest spectra
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Figure 33. Spectra comparison of serum fractionated with MB-ConA and eluted either
with Broker elution buffer or with a competitive sugar. Samples were processed using
ConA magnetic beads from Broker. The samples were eluted with either the buffer
provided by the manufacturer, in which case the pH was adjusted for optimal
trypsinization, or with a mannose competitive sugar elution. The samples were then
reduced, alkylated and digested with immobilized trypsin beads. The tryptic peptides
were captured using MB-C18 and the resulting elutions were spotted using a reverse
thin-layer spotting technique. The tryptic eluates were analyzed in reflectron mode using
the MALDI-TOF UltraFlex III and spectra were processed using FlexAnalysis 2.0. The
top panel shows a spectrum from a sample eluted with the manufacturer's elution buffer
and the bottom panel shows a spectrum from a sample eluted with 400 mM of mannose.
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Figure 34. Spectra comparison of serum fractionated with MB-ConA or MBConA/WCX. Samples were first processed using ConA magnetic beads from Bruker.
The samples were eluted with the buffer provided by the manufacturer and the pH was
either adjusted for optimal trypsinization or the entire eluted sample was subjected to
MB-WCX fractionation. The samples were then reduced, alkylated and digested with
immobilized trypsin beads and the tryptic peptides were captured using MB-C18. The
resulting elutions were spotted using a reverse thin-layer spotting technique and
analyzed in reflectron mode using the MALDI-TOF UltraFlex III. The generated
spectra were processed using FlexAnalysis 2.0. The top panel showcases a spectrum
from a ConA alone scheme, while the bottom panel showcases a spectrum from a
tandem ConA/WCX fractionation approach.
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results) and reconstituted the eluted glycoproteins in 25 mM Ammonium bicarbonate (to
yield the acceptable WCX binding pH). The entire glycoprotein solution was then added
to a WCX fractionation reaction. Figure 35 shows the resulting WGA/WCX spectra,
which has 45 peaks identified by the FlexAnalysis software, compared to the WGA alone
scheme, which only had 8 peaks identified by FlexAnalysis. However, we discarded this
approach for use with clinical samples because the drying down of samples during an
automated procedure would not be very feasible. Additionally, this type of step
performed with many samples would add unwanted variation into the protocol, seeing as
reconstituting each sample reproducibly may pose a logistics problem.
Since there is not enough material being eluted off of the Bruker magnetic lectin
beads (for visualization by MALDI-TOF after trypsinization) and increasing bead volume
to capture more glycoproteins would not be cost-effective and also beyond the volume
capabilities of the liquid handling robot, we opted to use agarose bound lectins to capture
glycoproteins in higher quantities. Our lab has previously worked out the protocol for
agarose-bound lectin capture, which includes an initial serum albumin depletion step
(71). Additionally, the most abundant elution comes from a combination capture using a
mixture of ConA and WGA bead types. Figure 36 shows the spectra generated from the
immobilized-trypsin digestion of the ConA/WGA lectin capture. This compares to the
WCX workflow method optimized in Chapter IV (i.e. 88 peaks for the agarose-bound
ConA/WGA scheme and 85 peaks for the MB-WCX scheme). Table 12 lists the
identities of the top 10 peaks from these spectra. Although, the initial capture of these
glycoproteins is not compatible with an automated system, the subsequent steps
(reduction/alkylation, digestion with immobilized trypsin, MB-C18 clean-up and sample
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Figure 35. Spectra comparison of serum fractionated with MB-WGA or MBWGA/WCX. Samples were first processed using WGA magnetic beads from Bruker.
The samples were eluted with the buffer provided by the manufacturer. One eluted
sample had its pH adjusted for optimal trypsinization, while two of the eluted samples
were pooled, dried down, resuspended with 25 mM ammonium bicarbonate and then the
entire pooled elution was subjected to MB-WCX fractionation. All the samples were
then reduced, alkylated and digested with immobilized trypsin beads and the tryptic
peptides were captured using MB-C18. The resulting elutions were spotted using a
reverse thin-layer spotting technique and analyzed in reflectron mode using the
MALDI-TOF UltraFlex III. The generated spectra were processed using FlexAnalysis
2.0. The top panel showcases a spectrum from a WGA alone scheme, while the bottom
panel showcases a spectrum from a tandem WGA/WCX fractionation approach (using
double the WGA fractionation sample for the subsequent WCX fractionation scheme).
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Figure 36. Spectra of serum fractionated with ConA/WGA agarose immobilized lectins.
Serum was first albumin and IgG depleted using Sigma immunocapture depletion
columns. The depleted serum was incubated overnight with a mixture of agarose-bound,
ConA and WGA beads. The sample was eluted with a competitive sugar, acetone
precipitated and reconstituted in 25 mM Ammonium bicarbonate. Eight micrograms of
the glycoprotein elute was then reduced, alkylated, and digested with immobilized trypsin
beads. The tryptic peptides were captured on MB-C18 beads and after elution were
diluted with CHCA matrix in a 1:3 ratio and spotted on an AnchorChip plate using a
dried-droplet technique. Spectra were generated using the reflectron mode of the
MALDI-TOF UltraFlex III. This spectrum had 88 peaks as recognized by the
FlexAnalysis 2.0 software.
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Table 12. Top 10 peptides seen in the immobilized-trypsin digestion of ConA/WGA
fractionationated serum after serum albumin and IgG depletion.
Mass

Accession
#

980.50

P00738

1117.66

P01876

1160.61

P02763

1642.95

P04217

1753.01

P02763

1825.00

P00739

1834.98

P00738

2016.12

P02765

2097.19

P02763

2109.11

P00738

Peptide
Identity
Haptoglobin
Ig alpha-1
chain C region
Alpha-1-acid
glycoprotein 1
Alpha-IBglycoprotein
Alpha-1-acid
glycoprotein 1
Haptoglobinrelated protein
Haptoglobin
Alpha-2-HSglycoprotein
Alpha-1-acid
glycoprotein 1
Haptoglobin

58

Expect
value
6.10E-05

R.VGYVSGWGR.N

47

0.00083

R.GFSPKDVLVR.W

62

3e-05

K.WFYIASAFR.N

Score

Peptide

48

0.00038 R.ATWSGAVLAGRDAVLR.C

46

0.00057

58

4.4e-05

59
87
31
132

R.YVGGQEHFAHLLILR.D

R.ILGGHLDAKGSFPWQAK.
M
R.VMPICLPSKDYAEVGR.V
4e-05
R.TWQPSVGAAAGPVVPPC
4.2e-08
PGR.I
R.YVGGQEHFAHLLILRDTK.
0.016
T
R.TEGDGVYTLNNEKQWIN
1.6e-12
K.A

spotting on a target plate) are all designed to be able to be processed by the ClinProt
robot.
Automation of the immobilized-trypsin bead protocol
Because the majority of the workflows described in this thesis were designed with
automation in mind, we next decided to write parameters for the ClinProt robot (robotic
sample handling system equipped with magnetic separation capabilities) to determine if
the MB-immobilized-trypsin bead workflow could be reproducibly automated. The robot
was first utilized to process aliquots of the same serum sample using the MB-WCX
workflow. Since at this point we were only looking at the reproducibility of the
immobilized-trypsin beads, we pooled the WCX fractionated serum and introduced 4
aliquots into the trypsin-bead workflow as processed by the ClinProt robot. As with the
manual method, the robot first reduced, alkylated and then added the reduced/alkylated
samples to the trypsin beads (after first washing the trypsin beads to neutralize their pH).
These 4 digested samples were then independently subjected to the robotic MB-C18
workflow and spotted in duplicate. Figure 37, shows the reproducibility of this method
visually and Table 13 lists the CVs of 12 representative peaks (these are the same 12
peaks that were used to assess the reproducibility of the manual method in Table 8 of
Chapter IV).
Given that the immobilized-trypsin workflow can reproducibly digest the WCX
fractionated sample using an automated workflow, we next attempted to completely
automate the entire MB-WCX/immobilized-trypsin beads/MB-C18 workflow. Fifteen
samples were processed as described in Materials and Methods and spotted in duplicate
on an AnchorChip plate by the ClinProt robot. Figure 38 shows the resulting spectra in
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Figure 37. Reproducibility of automated immobilized-trypsin/MB-C 18 workflow.
Four aliquots of the same serum pool were processed with the MB-WCX workflow by
the ClinProt robot. The eluates were pooled together and re-aliquoted into 4 separate
samples and then reduced, alkylated and trypsin digested by the ClinProt robot. The
robot next processed the tryptic peptides through a MB-C18 workflow and spotted the
samples in duplicate on an AnchorChip plate. The samples were analyzed on the
MALDI-TOF UltraFlex III instrument and the resulting spectra were analyzed by the
ClinProTools 2.0 software. The top panel showcases a heatmap of the spectra and the
bottom panel shows the individual spectra.
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Table 13. Reproducibility of automated immobilized trypsin bead method as seen by
the coefficient of variance (CV) of twelve representative peaks.
Automatic run
Mass

Intensity

CV (%)

1124.81

2.28

6.84

1585.99

7.46

7.30

1667.97

6.09

12.30

1670.92

20.99

7.04

1694.93

13.92

8.74

1717.04

23.90

9.07

1885.02

29.19

10.28

1932.26

10.15

6.38

2017.31

211.19

10.30

2383.24

49.79

3.71

2425.80

96.94

6.69

2636.63

18.10

6.03

Figure 38. Reproducibility of the automated MB-WCX/immobilized-trypsin/MB-C18
workflow. Fifteen aliquots of the same serum pool were processed with the MB-WCX
workflow by the ClinProt robot. The eluates were then individually reduced, alkylated
and trypsin digested by the ClinProt robot. The robot next processed the tryptic
peptides through a MB-C18 workflow and spotted the samples in duplicate on an
AnchorChip plate. The samples were analyzed on the MALDI-TOF UltraFlex III
instrument and the resulting spectra were analyzed by the ClinProTools 2.0 software.
The top panel showcases a heatmap of the spectra and the bottom panel shows the
individual spectra.
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Table 14. Reproducibility of immobilized trypsin bead method determined by the
coefficient of variance (CV) of twelve representative peaks (with and without
outliers).

Mass
1124.87
1586.21
1667.24
1671.14
1695.17
1717.21
1885.26
1933.40
2017.47
2383.50
2426.20
2637.72

15 samples
CV (%)
20.21
27.91
18.57
26.52
16.28
21.79
37.15
21.28
36.92
35.68
36.89
32.57

10 samples
CV (%)
15.54
13.97
16.36
24.57
12.28
16.95
32.67
16.84
32.15
31.30
32.08
29.19
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heatmap and individual spectra form. Additionally, Table 14 lists the CVs of the same 12
representative peaks that were highlighted in Table 8 and Table 12. The CVs were
improved on average by 5% if 5 sample "outliers" were removed, leaving 20 samples (10
samples with duplicates) for CV determination (Table 14). Unlike the first automated run
(where the WCX fractionated sample was initially pooled giving the digestion reaction a
similar starting point) or the manual method described in Chapter IV (where protein
concentrations were first determined before adding a set amount of protein into the
reduction/alkylation/trypsinization reaction), this automated workflow was not as
reproducible. This was mainly due to the ClinProt robot occasionally removing beads
from the reactions and mishandling buffers, so that the eluted WCX fractionated samples
had variable protein concentrations.

5.4 Discussion
The goal of most proteomic research is to extensively investigate the proteome of
the system under investigation in a reproducible and high-throughput manner. Serum
expression profiling is a valuable technique as one may compare up to 192 samples on
one MALDI plate using the same settings, thus greatly reducing sample to sample
variability. However, one drawback to this is that the each sample spot on the MALDI
plate is dense with peptides/proteins and thus typically only highly abundant proteins are
seen. There is much controversy as to whether these abundant proteins, which are
considered acute phase proteins, are truly specific to the disease being profiled, especially
when considering how dilute tumor-generated biomarkers are in the blood. Additionally,
these acute phase proteins may be influenced by sample collection, processing, and

storage and are therefore analyzed with caution. One way of overcoming this obstacle is
to look beyond the abundant proteins through aggressive fractionation protocols.
Another method is to use a targeted capture approach, such as a differential capture of
glycan groups on proteins. In this manner the focus is not on the actual abundance of the
protein, but on its carbohydrate decorations. As mentioned earlier, several disease,
including cancer, have been associated with alterations in glycan moieties.
In this Aim we have seen that tandem bead workflows may be performed as long
as buffer compatibility is kept in mind and as long as the final protein yield is at least 5
fig in a 10 /JLL volume (though 8 ptg is ideal). Although the tandem bead workflows
described here did not give us a more encompassing look into the serum proteome, we
did conclude that this is a good sample sparing technique (critical if your sample set is
minimal and precious), in that one may generate both a WCX and a WAX profile from
one sample aliquot.
Additionally, a depletion step (of some of the abundant proteins) may be
introduced into the tandem fractionation workflow in order to look at lower abundant
proteins. This approach, however, is accompanied by many caveats. Firstly, most
depletion kits commercially available target serum albumin and/or IgG (such as the
Sigma kits used in the lectin workflow). Since serum albumin and IgG make up about
50% of the blood proteome they are wise targets. However, once serum albumin is taken
out of the picture some of the lower abundant proteins, such as beta-thomboglobulin
(NAP2), which is a cytokine seen in our WCX workflow, would more than likely not be
seen. As discussed in Chapter IV, serum albumin is a carrier protein, which when
isolated has been shown to be rich of cellular peptides, cytokines and other lower
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abundant proteins that typically would not be seen in the blood proteome (64, 136).
Additionally, there are several other abundant proteins, which together with serum
albumin make-up about 99% of the blood proteome. Thus, by removing serum albumin
and IgG, we are simply making room for the other abundant proteins. A remedy to this
would be to use a depletion step that removes the top (i.e. 20) most abundant proteins.
However, most of these depletion kits are in single column form and therefore are not
adaptable to a high-throughput workflow. Additionally, there may be an issue of sample
cross-contamination if trying to process many samples in tandem through one column.
The other goal of this Aim was to adapt our tryptic peptide profiling workflow to
incorporate a targeted capture of glycoproteins, thereby turning the focus on glycan
moiety differences, instead of strictly protein abundance differences. To this end we first
investigated the feasibility of using lectins immobilized to magnetic beads, which would
be amenable to a complete automated workflow. However, of these only a ConA/WGA
lectin mix proved to be passably satisfactory. We demonstrated that the reason we were
seeing weak spectra was mainly due to the low protein concentration of glycoproteins
eluted off of the lectin beads. Unfortunately one remedy to this, pooling two eluates and
concentrating them into one eluate, would be very low-throughput and highly susceptible
to variation as discussed in the Results section. The other solution of increasing the lectin
magnetic beads is impractical, as the robot can only handle a certain volume and also at a
certain point this would no longer be a cost-effective experiment. A more highthroughput solution involves using agarose-bound lectins. Thus, the front-end
fractionation step would be manual, but the reduction, alkylation, trypsinization, MB-C18
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clean-up and sample spotting on a MALDI plate could be performed on an automated
platform.
Finally, as the goal of all these workflows was to make this tryptic peptide
workflow automated, we designed protocols that could be operated by the ClinProt robot.
Using a front-end WCX fractionation for the method design, we examined the
reproducibility of an automatic workflow starting from the reduction step and terminating
with the robot spotting on a MALDI target plate after MB-C18 capture of tryptic
peptides. Additionally, we also investigated performing a complete automatic workflow
starting with the MB-WCX fractionation and ending with the MB-C18 protocol and
spotting of peptides on a MALDI target plate.
We found that the automated trypsin digestion/MB-C18 protocol was highly
reproducible, given that the CVs for 12 representative peptides were under 13% (these
were the same peptides analyzed for the reproducibility of the manual workflow).
However, the robot had a very difficult time reproducibly processing the MB-WCX
workflow, resulting in WCX fractionated elutions with varying concentrations. This led
to the generation of spectra that were far less reproducible than the manual workflow
described in Chapter IV and the automated trypsin bead/MB-C18 workflow described in
this Aim (both of these protocols added a constant amount of WCX fractionated serum
into the reduction reaction). The same peaks that were found to have CVs of 13% or less
in both the manual workflow (Table 8) and the automatic trypsin bead/MB-Cl 8
workflow (Table 13) had CVs ranging from 16% to 37% in the completely automated
MB-WCX/tryspin bead digestion/MB-C18 workflow (without 5 sample "outliers" the
CVs ranged from 12% to 33%). We therefore recommend (taking into account the high
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reproducibility of this method performed both manually and robotically from the
reduction step) that serum samples may be initially fractionated manually and then
depending on the cohort size may be either further processed manually (if a small cohort)
or robotically (if a large cohort).
The importance of creating a workflow that is entirely automated is without
question as it will allow for the processing of large numbers of samples that will satisfy
statistical requirements of experimental data and will also limit operator interference, thus
making the protocols less susceptible to variation between laboratories. However, we
conclude that the ClinProt robot is not optimal the platform for automation of the
workflows designed in this thesis. Our main concern with this platform is its habit of
removing beads from samples during wash steps. This is a haphazard occurrence and
therefore produces variation between the samples. Currently, our front-end fractionation
methods performed manually produce much more consistent and reproducible results.
We will discuss further alternatives to, and adaptations of, the ClinProt platform in the
main Conclusions and Future Directions section.

CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Aim I (Chapter III): Development of Precious Sample Sparing Techniques for
Mass Spectrometry Analysis.
A. The results indicated that there was no significant difference in quality of data
between scraping a frozen serum sample and thawing the whole sample. Therefore, since
our SOF cohort was a compelling, yet limited sample set, we decided to utilize the scrape
technique for the processing of all SOF samples and thus preserve the samples for future
use without the addition of unnecessary freeze-thaw cycles.

B. SELDI-TOF MS analysis using MAC fractionation of 42 cases and 42 controls
yielded 11 peaks that were predictor variables used in the generation of the classification
and regression trees. A tree containing 4 terminal nodes, with 3 peaks used as splitting
factors (m/z 7850.989, 9303.888, and 9190.488), was deemed optimal and possessed a
recognition capability of 85.7% of cases and 78.6% of controls of the test set. Crossvalidation of the generated tree yielded correct classification of 31 of the 42 cases (74%
cases correctly classified) and 30 of the 42 controls (71% of controls correctly classified).
Unfortunately, this model did not prove successful in validating samples at an
independent institution.

C. The best MALDI-TOF MS genetic algorithm model generated using the WCX
fractionation scheme with the initial 84 sample set yielded an overall 71.1% recognition
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capability between groups. However, this 7 peak genetic algorithm model proved to be
over-fitted for the 84 sample set and produced very low external validation sensitivity
and specificity (overall recognition capability was below 50%). A 5 peak genetic
algorithm model yielded the highest sensitivity and specificity comparatively during
external validation of 112 samples, with an overall recognition capability of 61.2%
between cases and controls. However, this model performed poorly when used again to
identify case and control status of 96 blinded samples (overall recognition capability of
52.1%).

6.2 Future directions of Aim I
The main success of this Aim is the knowledge that serum samples may be
scraped without being thawed and will still produce comparable spectra to samples that
were completely thawed. In this way the integrity of the serum proteome is conserved,
while still retaining the convenience of retaining the samples in their original storage
vials. Unfortunately, the classification success of the SELDI-TOF MS and MALDI-TOF
MS analyses of the SOF sample set processed with the scrape technique left much to be
desired. A very complex question was addressed in this sample set: Can serum protein
profiles predict whether women will develop breast cancer in the future based on their
serum profiles. This is a very difficult question to pose to two MS platforms that are
limited in their ability to penetrate the immense concentration range of the serum
proteome, especially for the SELDI-TOF MS due to its flat chip surface fractionation.
However, MALDI-TOF MS would be amenable to several front-end fractionations
performed in tandem or targeted capture (i.e. lectin capture of glycoproteins) for a more
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encompassing examination of the serum proteome of these women. Additionally, as
demonstrated in Chapter IV this cohort is being investigated on a small scale with pooled
samples subjected to such bottom-up approaches as the immobilized-trypsin bead
workflow and quantitative iTRAQ analysis. This will continue with the inclusion of
more samples and fractionation techniques. In the future it would also be interesting to
see what the albuminome of these patients holds in terms of predictive peptides/proteins
for breast cancer risk.
Another consideration in the interrogation of this sample set is that many of these
women may not even have tumor development at the time of blood draw. Thus, there
may not be tumor-specific biomarkers present in the blood. As mentioned several times
in this dissertation, breast cancer is a very heterogeneous disease with many factors (i.e.
ER and HER-2 receptor status) playing a role in influencing prognosis and response.
Additionally, many genetic and environmental variables have been implicated as factors
influencing breast cancer risk. Two such variables, race and hormone-replacement
therapy, have been eliminated from the study. However, many other risk factors remain
that may be used to stratify the samples. Certain factors such as ER status are beyond the
scope of the current sample set, since the original goal of the SOF study was osteoporosis
and not breast cancer risk evaluation. However, stratifying patients based on their serum
levels of known breast cancer prognosis markers, such as HER-2 and MUC-1, is still an
interesting possibility. Although, these biomarkers are typically assayed to determine
breast cancer aggressiveness, progression and drug response it would still be interesting
to determine if these biomarkers are altered pre-cancer diagnosis and thus underlying
genetic factors in breast cancer risk. It may also prove useful to look into BRCA-1 and
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BRCA-2 genetic status as a possible stratification factor (though BRCA mutations
typically affect a small percentage of the breast cancer population) since mutations of
these proteins leads to a high risk of developing breast cancer. Furthermore, depending
on the information collected along with the original patient consent, we may be able to
classify patients based on factors used to evaluate breast cancer risk in the Gail model.
These would include age at menarche and age at first live birth, which may be known
since these incidents also correlate to osteoporosis risk. Another factor that increases
breast cancer risk is obesity and thus BMI (body mass index) may be an additional factor
used to stratify the samples. However, this stratification may not be as relevant in 1980s,
when this sample set was collected, as it would be today given the steady rise of obesity
in the United States. According to the Centers for Disease Control and Prevention, in the
1970s and early 1980s only 15% of the adult population was obese. However, by 2004
33% of the adult population in the United States was considered obese and this situation
is worsening with each passing year.
By using these different variables to put patients into more specific groups we
may begin to focus on biomarkers related to breast cancer risk, rather than to biological
variation between patients that are as complex as the disease itself. These stratifications,
along with novel MALDI-TOF technology and aggressive fractionation techniques
discussed above, may allow for the discovery of predicative biomarkers for breast cancer.
These biomarkers may be incorporated with current breast cancer disease progression
biomarkers and risk models in order to design a more sensitive and specific diagnostic
tool for physicians to predict an individual woman's breast cancer risk.
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6.3 Aim II (Chapter IV). Increasing the Effectiveness of the MALDI-TOF/TOF for
Analysis of Large Molecular Weight Proteins.
A. The immobilized-trypsin beads are very efficient at digesting proteins in short
incubation times (30 minutes compared to 4 hrs to overnight with traditional soluble
trypsin protocols) and digestion efficiency is increased when proteins are reduced and
alkylated. Adjusting the pH of the fractionated serum eluates to ~ pH 8 prior to reduction
and alkylation also improves the digestion efficiency of the bead. We furthermore
determined that for robust and reproducible spectra 8 |a.g is the ideal starting protein
content for reduction and alkylation, with ~ 5 fxg of reduced/alkylated sample being
digested with 25 uL trypsin beads. Additionally, since the trypsin is attached to
paramagnetic beads it can be removed from the reaction by placing the reaction tube
against a magnet, thereby not contaminating the spectra with autocatalytic trypsin
peptides, a common draw-back to soluble trypsin digests.

B. To create more uniform peptide/matrix spots, and make the peptide spectra more
robust, a clean-up step using reverse-phase chromatography beads is necessary. Either
ZipTipsCl 8 or MB-C18 may be used; however the latter is more adaptable to an
automated platform. Additionally, it was found that MB-C18 produced more intense and
full spectra as compared to MB-C8.

C. A final immobilized-trypsin bead workflow was established that may be applied
regardless of the front-end fractionation type: (1) Fractionate serum and adjust pH of
eluate to ~8, add 8 jag of the eluate into a reduction reaction, (2) follow with an alkylation

step (29 |iL total volume), (3) add 20 uL of the reduced/alkylated sample to 25 uL of
washed immobilized-trypsin beads, (4) incubate together at 37 °C for 30 minutes and
remove the digested sample, (5) add the 20 uL digest into a MB-C18 workflow, (6) elute
the captured peptides off of the CI 8 beads and spot on an AnchorChip plate (1:3) with
CHCA matrix using the dried droplet technique.

D. This final immobilized-trypsin bead workflow was found to be reproducible with
minimal intra-spectra variation of samples processed individually, but originating from
the same pooled serum sample.

E. Both MB-WCX and MB-WAX front-end fractionation workflows were incorporated
successfully with the immobilized-trypsin bead scheme and using LIFT-MS/MS peptide
identities were able to be determined for most of the top peaks in the respective spectra.
We also demonstrated the minimal amount of information garnished in terms of
visualized and identified peptides from undigested MB-WCX and MB-WAX workflows.

F. The immobilized-trypsin workflow followed by ClinProTools analysis and peptide
identification by LIFT-MALDI-TOF/TOF proved to be an effective and reproducible
scheme for profiling clinical samples and directly identifying differential peptides.
F.l. Pools of the SOF samples (described in Chapter III) were processed with this
workflow and 3 peaks were found to be differential: m/z 1031 (kininogen-1), m/z 2017
(alpha-2HS-glycoprotein), and m/z 2383 (Bcl9 protein). The forced peak genetic
algorithm model that was generated using these three peaks had a 100% recognition

capability of the test set and a cross-validation of 87.23% correctly classified cases and
77.36% of correctly classified controls. These samples were re-processed months later
and the same 3 peaks were used to generate a forced peak genetic algorithm model. This
model once again had 100% recognition of the test set and cross-validation yielding
70.83% for both sensitivity and specificity. Additionally, this model was used to
externally validate the 1st data set and the result was 17/24 correctly classified cases
(70.83% sensitivity) and 20/24 correctly classified controls (83.3% specificity).
F.2. Pools of a BPH vs. PCa sample set were processed using the WCX/trypsin bead
workflow and three peaks were determined to be differential between the two groups: m/z
1031 (kininogen-1), m/z 1216 (apolipoprotein AIV) and m/z 1353 (apolipoprotein AIV).
The forced peak genetic algorithm that was created using these 3 peaks had 100%
recognition of the test set and a cross-validation that correctly classified 84.11 % of PCa
and 75% of BPH. The samples were re-processed in a blinded manner and then this
model was used to classify the blinded samples into their respective groups. The genetic
algorithm model was able to correctly classify 10/12 PCa cases correctly and 10/12 BPH
controls correctly. This outcome demonstrates the reproducibility of the immobilizedtrypsin bead method with clinical samples.

6.4 Aim III (Chapter V). Development of Integrated Fractionation Protocols for InDepth and Automated MALDI-TOF/TOF Analysis.
A. Tandem bead workflows (i.e. MB-WCX unbound fraction processed by MB-WAX
and vice versa and subjected to immobilized-trypsin bead digestion) are a good way to
maximize information generated from one sample aliquot. This is therefore a

recommended process if the samples being interrogated are of limited quantity.
However, this tandem workflow does not yield more revealing spectra results for peptide
profiling than single bead front-end fractionation methods. In actuality, the tandem bead
workflow tended to have a profile skewed slightly towards the two most abundant
proteins, serum albumin and Ig alpha, as compared to single bead workflows.

B. Bruker lectins were found to be successfully integrated into the immobilized-trypsin
bead workflow if the eluates were concentrated (i.e. using a dry down method of pooled
samples), followed by a MB-WCX fractionation workflow, or two lectin magnetic bead
types were used simultaneously to capture glycoproteins (i.e ConA/WGA). All of these
methods increased the eluted concentration of glycoproteins for further processing by the
immobilized-trypsin beads. However, the most ideal glycoprotein output was generated
with ConA/WGA lectins immobilized on agarose beads following albumin and IgG
depletion. This lectin workflow generated tryptic peptides of the same quality and
intensity as the WCX and WAX workflow results in Chapter IV.

C. Because all of the workflows described in this thesis dissertation are either amenable
to partial or complete automation, we assessed the reproducibility and feasibility of using
the ClinProt robot for processing these workflows (using the MB-WCX scheme as a
representative workflow. We found that the partial automation (starting at the reduction
step and terminating at the MB-C18 and sample spotting step) is very reproducible as
demonstrated by low coefficient of variance values. However, the complete automation
(starting at the MB-WCX step and going through to the MB-C18 and sample spotting

step) was not as reproducible, since the ClinProt robot generated initial WCX eluates
with variable protein concentrations, which negatively impacted the rest of the protocol.
This was mainly due to the robots tendency towards removing trace amounts of magnetic
beads during wash steps and other manipulations leading to the elution. Therefore, we
conclude that the ClinProt robot may be used for partial automation, but that it may not
be the ideal platform for the automation of these workflows.

6.5 Future Directions of Aim II and Aim III
The immobilized-trypsin bead technique described in these Aims is effective at
generating peptides that ionize in the ideal m/z peak range for most effective utilization
of LIFT-MALDI-TOF/TOF for direct identification of differential peaks. Since the
trypsin is immobilized onto paramagenetic beads, this scheme may be adapted to a
robotic front-end processing system and allow for a relatively high-throughput, rapid and
reproducible method for peptide profiling. This immobilized-trypsin technique may
essentially be modified to suite any strategy that would normally utilize in-solution
trypsin digestions. For example, we are currently looking into streamlining this method
with comparative isotopic mass tagged quantitative approaches (160-162). Additionally,
if one adheres to the basic scheme designed in this dissertation then this trypsin bead
method may be made compatible with many fractionation workflows still to be
envisioned. One such method may involve designing a depletion/capture strategy that is
more amenable to high-throughput processing than current commercially available
depletion kits. For example, antibodies to human serum albumin may be immobilized on
magnetic beads and thus utilized to remove the serum albumin and by the same token
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capture it for further analysis. Consequently, from one sample aliquot two separate
fractions will be generated: 1) a depleted serum sample that may be further processed
with other fractionation schemes to look at peptides and proteins that may have been
overshadowed by the bulk of serum albumin, and 2) a serum albumin fraction, which
may be used to profile the differences between sample groups based on peptides/proteins
that are carried by this molecule.
One obstacle that may be encountered when using this peptide profiling technique
is that certain peaks of interest may not be able to be identified by LIFT. This may occur
for a number of reasons, one being that a peak of interest may be embedded in a dense
peak cluster, thus when the parent ion is fragmented the other contaminating peaks may
be fragmented along side it. Another common reason for a peak of interest's inability to
be identified by LIFT-MS/MS is that surrounding dominant peaks in the spectra may be
suppressing the signal of the protein of interest. A possible solution to both of these
problems is the use of LC-MALDI-TOF/TOF to fractionate the sample into many spots
onto a MALDI AnchorChip plate based on the peptides chemical affinity properties. In
this way the fractionated sample results in the deconvolution of the original tryptic
peptide spectra that was crowded into a single spot on the MALDI plate. Thus, we are
currently working on adapting the immobilized-trypsin beads for compatibility with the
LC-MALDI-TOF/TOF platform.
In our two cohorts investigated in Chapter IV, we discovered several potential
biomarkers. It will be necessary to process larger samples sets with our workflow to
assess the viability of these biomarkers and the genetic algorithm models using these
biomarkers for classification. If these biomarkers hold true for the larger sample set, then

we will be ready to independently validate the results. Therefore, another consideration
that will be further investigated is the validation of discovered biomarkers. One approach
would be to use commercially available Enzyme-Linked Immunosorbent Assays
(ELISAs) to measure protein levels of the identified proteins in many serum samples.
However, when a peptide is identified as differential between two sample sets, as in our
workflow, it is not known if the entire protein expression level is elevated or if the
increase is due to the elevation of an isoform, glycoform, or post-translational modified
version of this protein. Initial validation of biomarkers using an ELISA would only look
at the global change of the identified protein, thus all variations on that protein (if the
epitope is present for detection by the antibody) would be incorporated in the expression
levels without distinction. However, doing individual western blots for each sample
would be tedious and labor-intensive. A remedy to this would be to use an immunocapture strategy with specific antibodies for the protein of interest immobilized on
magnetic beads (43, 46). The captured proteins would be eluted, digested and analyzed
by MALDI-TOF MS to determine if there are specific peptides generated that are
elevated, while the other peptides from this molecule are comparable between groups.
The identity of the differential peptide may then be identified using LIFT-MS/MS.
However, if the post-translational modification is too complex or more specific
information needs to be gleaned from the peptide, such as the site and composition of a
glycosylation, multiple-reaction monitoring (MRM) may be utilized (163). A triplequadrupole linear ion trap instrument is available to our lab for performing such analysis
if deemed necessary. Once the reason behind the protein level increase is elucidated, a
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more specific ELISA may be designed and processed with many samples for true
validation.
Finally, we have demonstrated that by using the Bruker ClinProt instrument with
the immobilized-trypsin bead workflow at least partial automation may be attained. The
ClinProt robot's main problem is the premature, random removal of magnetic beads with
bound protein. Thus, for the full automation capability of the developed workflows
described in this thesis dissertation we would need to either evaluate other robotic
platforms or look for ways to improve the ClinProt platform. There are other liquid
handling robotic systems available, such as the Tecan Freedom Evo, which may be
evaluated for their performance with our workflows. However, after observing the
ClinProt robot we believe that a single modification in plastic ware may improve its
performance. We will therefore evaluate the use of alternative 96-well work-plates than
are currently used with this platform. The current work-plates end in a sharp point at the
bottom of each well and overall the wells are very narrow. Both of these qualities allow
the needles of the ClinProt robot to agitate the magnetic beads during the handling of the
buffers, thus permitting beads to be aspirated along with the liquid. Additionally, a
rounded 96 well plate may make for easier mixing of the samples, which currently tend to
result in the uneven distribution of the magnetic beads throughout the solution due to the
clumping of the beads (this especially true for the trypsin beads). Changing the velocity
of mixing performed by the robot does not improve this issue. Unfortunately, changing
the work-plates is easier said than done, given that the module which holds the plate in
place is specifically tailored to this type of plate shape. However, it would be more cost-
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efficient to replace this component rather than the entire robot if it was indeed discovered
that the work-plate shape influences the performance of the robot.

6.6 Concluding Remarks
SELDI and MALDI are reproducible and portable methods, however as
demonstrated by McLerran et al (119), great care has to be put into standardizing sample
collection, processing and storage of samples as each of these factors may add sample
bias and lead to inaccurate conclusions. One main drawback to SELDI-TOF MS is that it
does not possess the capability of identifying peaks found to be differentially expressed.
Also, the chip-surface area utilized in SELDI-TOF MS analysis may not lead to efficient
fractionation, which is needed for the simplification of the large dynamic range of serum
proteome. Since MALDI-TOF MS is not limited by on-chip fractionation protocols it
may allow for more extensive fractionation. These front-end fractionation techniques
typically employ paramagnetic beads, which not only have more surface area than a flat
surface chip, but also allow for in-tandem use of these bead types in an automated
manner.
Serum expression profiling typically occurs in the linear range, which is more
sensitive in terms of peptide detection. However, it is the mass precision of the reflectron
mode that is needed for MS/MS identification of peptide sequences. We have shown that
common fractionation schemes such as WCX and WAX do not yield robust spectra
necessary for endogenous peptide sequencing. Additionally, the peptides present are
difficult to identify since the enzyme that generated each peptide is not known. Overall
endogenous peptide profiling with MALDI-TOF is a step above SELDI-TOF MS

profiling since some peptide identity information may be garnered from the spectra
analyzed by the MALDI platform compared to no possibility for direct peptide
sequencing by the SELDI platform. However, it is necessary to design a scheme that
may be used as a companion to endogenous peptide profiling; one that will allow for the
visualization of many peptides in the mass range of the reflectron mode and thus permit
relatively easy identification by LIFT-MS/MS.
Based on this necessity we tailored a workflow that utilizes immobilized-trypsin
beads. We found that this technique is highly reproducible and may be adapted to many
different front-end fractionation schemes performed individually or in tandem to reduce
the complexity of the serum. Since this workflow utilizes paramagnetic beads it may be
either partly or completely automated, though current robotic technology is only capable
of reproducible and consistent partial automation. Using these workflows we were able
to identify several promising biomarkers in two serum cohorts that are pending future
analysis and validation. However, the most important discovery is that these workflows
produce consistent results on clinical samples, yielding similar results and conclusions on
independent runs. There are many exciting applications for these workflows, as
described in the future directions section, and the fractionation schemes described herein
are only the start of many different possibilities. We expect that work outlined in this
dissertation may serve as a guide for all future analysis.
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